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PREFACE  
Five years ago I embarked on this project. A project that would enrich me as a researcher but also as a 
community pharmacist. After this project, I am convinced – even more than I ever was – that 
community pharmacists play an essential role in the current healthcare system. The wide-spread 
presence of community pharmacists in Belgium should be seen as an enormous strength that we 
should exploit to make healthcare even more accessible and effective.  
 
At first instance, I hope this thesis will give a boost to community pharmacists, so they would take up 
their role in patient counselling with more persuasion and courage. On the other hand, I wish to 
convince other healthcare workers and policy makers that community pharmacists are an essential 
link in the healthcare system. It is therefore with great joy that I introduce my doctoral thesis, a plea 
for community pharmacists and their value in the current healthcare setting.  
 
Eline Tommelein, Ghent, April 3rd 2016 
 
VOORWOORD 
Vijf jaar geleden ging ik van start met dit project. Een project dat me zoveel zou verrijken, zowel als 
onderzoeker maar ook als apotheker. Nu ben ik er meer dan ooit van overtuigd dat officina-apothekers 
een essentiële rol spelen in de hedendaagse gezondheidszorg. De wijdverspreidheid van apotheken in 
België moet gezien worden als een sterkte en moeten aangewend worden om de gezondheidszorg nog 
toegankelijker en effectiever te maken dan ze momenteel is.  
 
Ik hoop in eerste instantie dat deze thesis officina-apothekers een duwtje in de rug geeft, opdat ze met 
meer overtuiging en durf hun rol in de patiëntbegeleiding zouden opnemen. Daarnaast hoop ik andere 
zorgberoepen en beleidsmakers te laten inzien dat de officina-apotheker een onmisbare schakel is in 
de gezondheidszorg. Het is dan ook met veel plezier dat ik mijn doctoraatsthesis voorstel. Een pleidooi 
voor de officina-apotheker en zijn waarde in de gezondheidszorg van vandaag. 
 
Eline Tommelein, Gent, 3 April 2016 
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1. THE EVOLVING ROLE OF THE COMMUNITY PHARMACIST 
1.1. Professional activities of the community pharmacist 
In 1994, the World Health Organization (WHO) presented a position paper1 about the role of the 
pharmacist in the healthcare system. Until then, the professional activities of the community 
pharmacist had mainly been limited to the oversight of the supply of medicines, both prescription and 
non-prescription. In addition, community pharmacists manufactured medicines on a small-scale, often 
through extemporaneous preparations.  
The complexity of medication use, as well as the risk for Drug Related Problems (DRP), has however 
increased during the last decades. Accordingly, the role of the community pharmacist has become 
broader, resulting in more care-related activities. For example, the community pharmacist’s role now 
often includes counselling of patients at the time of dispensing prescription and non-prescription 
medication, next to the provision of drug-related information to patients, the general public or other 
healthcare professionals. Additionally, the community pharmacist carries out a range of other 
professional activities (Table 1.1).  
 
Table 1.1: Current main professional activities of the community pharmacist (adopted and adapted from 1 ) 
Essential activities of the community pharmacist 
Processing of prescription The pharmacist verifies the legality, safety and appropriateness of the prescription order, checks 
the patient medication record, ensures that the quantities of medication are accurate and 
decides whether the medication should be handed to the patient, with appropriate counselling.  
Care of patients or clinical pharmacy The pharmacist collects and integrates information about the patient’s drug history, clarifies the 
patient’s understanding of the intended dosage regimen and method of administration and 
advises the patient of drug-related precautions. Additionally, the pharmacist monitors and 
evaluates the therapeutic response.  
Monitoring of drug utilization The pharmacist participates in monitoring drugs utilizations, through for example, research 
projects and the tracking of adverse drug reactions.  
Responding to symptoms of minor 
ailments 
Pharmacists respond to requests from patients for advice on a variety of symptoms and, when 
appropriate, refers the inquiries to a medical practitioner. If the symptoms relate to a self-
limiting minor ailment, the pharmacist can supply a non-prescription medicine, together with 
advice. Alternatively, the pharmacist may give advice without supplying medicines.  
Health promotion The pharmacist takes part in health promotion campaigns, both locally and nationally, on a wide 
range of health-related topics and particularly, on drug-related topics.  
Extemporaneous preparation and 
small-scale manufacture of medicines 
 
Pharmacists prepare medicines, enabling them to adapt the formulation of a medicine to the 
needs of an individual patient.  
Optional activities of the community pharmacist 
Traditional and alternative medicines Pharmacists can be authorized to dispense traditional medicines as well as homeopathic 
prescriptions.  
Domiciliary services The pharmacist can provide both an advisory and a supply service to residential homes for older 
patients and other long-term patients.  
Informing healthcare professionals 
and the public 
The pharmacist can compile and maintain information on all medicines, and – particularly on 
newly-introduced medicines – provide this information as necessary to other healthcare 
professionals and to patients. They also can provide consulting services regarding the rational 
use of drugs, to physicians and members of the public.  
Agricultural and veterinary practice Pharmacists can supply animal medicines and medicated animal feeds 
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1.2. Pharmaceutical care 
In the early nineties of the 20th century, a large part of the pharmacists’ professional tasks, besides 
the mere administrative ones, were merged under the term “pharmaceutical care”2. Later, in 2012 the 
European Directorate for the Quality of Medicines & HealthCare (EDQM) published a document 
“Pharmaceutical Care – Policies and Practices for a Safer, More Responsible and cost-effective Health 
System”3, outlining a European definition for pharmaceutical care: 
 
“Pharmaceutical care involves the process through which a pharmacist co-operates with a patient 
and other professionals in designing, implementing and monitoring a therapeutic plan that will 
produce specific therapeutic outcomes for the patient.3” 
 
The delivery of pharmaceutical care therefore includes the identification, resolving and prevention 
of both potential and actual DRPs. DRPs include all events or circumstances that interfere with the 
patient experiencing the optimal outcome of medical care2. For example, a DRP might include 
inappropriate prescribing of medication (e.g. inappropriate dosing), but might also include 
inappropriate delivery (e.g. dispensing errors) or inappropriate patient behaviour (e.g. nonadherence) 
(Table 1.2). In summary, providing pharmaceutical care contributes to the optimisation of outcomes 
from medicines and to the prevention of harm from their inappropriate use3.  
 
Table 1.2: Overview of different types of drug related problems (Based on 4 5 ) 
Inappropriate prescribing 
Overuse 
Therapy for an indication which is no (longer) present 
Combination therapy where monotherapy is sufficient 
Pharmacotherapy for treatment of side effects of other drugs (‘prescribing cascade’) 
Underuse 
Not treating present medical condition  
Omission of prophylactic therapy 
Misuse 
Wrong choice of drug (formulation)  
- Drug with better effectiveness or with lower risk available 
- Functional capacity of the patient does not allow use of the drug  
- Suboptimal formulation  
Dosing problem 
- Dose too high or too low 
- Suboptimal dosing scheme 
Presence of or higher risk for adverse drug events  
- Adverse drug events (type 1 or 2) 
- Contra-indicated drug (‘Drug-Disease Interaction’ (DDisI)) 
- Interaction with other drug (‘Drug-Drug Interaction’ (DDI)) 
- Interaction with food 
Inappropriate dispensing 
Wrong drug dispensed 
Insufficient or inadequate information provided during drug dispensing 
Overlooking of practical problems (opening package, swallowing problems, etc.)  
Inappropriate patient behaviour  
Not following user instructions 
Medication nonadherence 
Inappropriate monitoring and reporting  
Insufficient or no follow-up of medication adherence 
Insufficient or no follow-up of lab values or clinical effect after start of some drugs  
Not discussing or reporting side-effect with/to the treating physician.  
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1.3. Pharmaceutical care in Belgium 
In 2009, the Belgian government voted a new Royal Decree, which legally outlines sound 
pharmaceutical practices for Belgian community pharmacists6. Pharmaceutical care became a major 
topic in the task description of the community pharmacist and was subdivided into ‘basic 
pharmaceutical care’ and ‘advanced pharmaceutical care’6.  
Basic pharmaceutical care starts with the validation of each patient question. This includes ensuring 
sufficient information is obtained to assess a health-related problem. Consequently, a product is 
dispensed, advice is given or the dispensing of a product is refused. In any case, the community 
pharmacist stays within the boundaries of the profession and refers to a physician when needed. 
Second, the community pharmacist provides oral or written information and advice, appropriate to 
the patient’s need. The information can be self-contained, e.g. self-management strategies, or linked 
to the dispensing of a product, e.g. dosing regimen. The goal is to increase the quality of life of the 
patient and to provide him or her with sufficient material to make an informed decision. Third, a 
patient record is set up at the pharmacy. At a minimum, this record contains contact data of the patient 
and his or her general practitioner, supplemented with all dispensing data. Optionally, details about 
delivered pharmaceutical care or personal data can be registered, as long as such details are useful in 
the light of the pharmacist’s job function. Finally, the community pharmacist provides a general 
medication counselling, or when appropriate, he or she may propose advanced pharmaceutical care.  
According to the Royal Decree, counselling in basic pharmaceutical care is therefore more general 
and medication-centred. Advanced pharmaceutical care counselling on the other hand, is individually-
adapted and patient-centred. It is meant for patients with special pathologies, multi-morbidity or poor 
medication adherence. The reason to proceed to advanced pharmaceutical care should be well-
motivated and thoroughly documented in the patient’s record. Additionally, the patient has to give his 
consent to this level of counselling. This is needed as advanced pharmaceutical care includes a 
significant role for the patient, requiring frequent visits to the pharmacy for the purpose of monitoring 
his or her expectations as well as participation in the development of a feasible treatment plan. When 
necessary, advanced pharmaceutical care can be expanded with robotic unit dose-dispensing based 
on a weekly validated medication chart. Advanced pharmaceutical care services are often referred to 
as cognitive pharmacy services. 
For both basic and advanced pharmaceutical care, but especially for the latter, there are two 
essential requirements: (1) co-operation with the patient and (2) co-operation with other healthcare 
professions. The first emphasizes the importance of involving the patient in his therapy – currently 
referred to as ‘patient-centred care’ – and the second, underlining the role of multidisciplinary 
healthcare teams.   
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1.4. Patient-centred care 
Putting the patient in the centre of his or her health care 
management, is what patient-centred care is all about7 8. In 
practice, this concept seeks to focus all medical attention on the 
individual patient’s needs and concerns, rather than on the 
aspects related to the healthcare provider or the diagnosis. 
Patient-centred care requires that all healthcare providers 
enhance the patient’s participation and cooperation to ensure 
the best possible outcomes3.  
Another catchall term for treatment plans that encompass patient-level characteristics, is 
personalized medicine9. This holistic approach has often been applied on an ad-hoc basis. More 
recently, however, algorithmic approaches are being developed. Such approaches are called adaptive 
treatment strategies or dynamic treatment regimens9 and denote that the treatment is adapted to 
evolving patient characteristics. 
With respect to the community pharmacist as a healthcare provider, a fundamental prerequisite 
for effective delivery of pharmaceutical care in this patient-centred context must be the pharmacist’s 
mutually-beneficial relationship with the patient. In such a relationship, the patient grants authority to 
the community pharmacist, who in turn provides professional competences and commitment1. The 
community pharmacist can consequently actively involve the patient in his or her pharmacotherapy. 
This involvement could positively impact the patient’s motivation, his or her medication adherence, 
and thus, the long-term effectiveness of his or her pharmacotherapy10.  
 
1.5. The community pharmacist as part of a multidisciplinary healthcare team 
With the patient at the centre of his or her care, all involved healthcare providers should ideally co-
operate as a multidisciplinary team to provide the safest and most effective pharmacotherapy for the 
patient. A number of different professions may participate in such a healthcare team, e.g. pharmacists, 
physicians, physiologists, dieticians, nurses, etc. It is essential that all these healthcare professions 
meet as equals to bring different knowledge, needs and concerns together, while none asserting a 
position of superiority7. In this way, healthcare teams can establish common approaches to the choice 
of treatment plan and increase the quality of the delivered healthcare7 11 12.  
Any healthcare team must be concerned with the use of medicines, and thus should include a 
pharmacist1. A community pharmacist is ideally placed to take part in the primary healthcare team, as 
he sees the patients on a regular basis and maintains communication with various healthcare workers. 
The community pharmacist can be consulted for typical, more practical medication-related questions, 
such as drug modalities and dosing regimens, as well as pharmacotherapeutic issues. 
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1.6. The community pharmacist makes a difference 
During the last decades, the community pharmacy field has initiated extensive research on a wide 
range of subjects. This research shows that the involvement of a community pharmacist in patient care 
can make a difference. Considering cognitive pharmacy services in general, multiple programs can be 
identified across Canada, the United States, Europe and Australia13. Such programs range in complexity 
from emergency contraception counselling and vaccination programmes to minor ailment schemes 
and full clinical medication review13 14.  
A determination of the effectiveness and cost-effectiveness of advanced pharmaceutical care is 
challenging because of variations in healthcare settings, the populations studied and the outcome data 
measured15-17. Furthermore, performed interventions are often inadequately described or vary widely. 
Nevertheless, there is some consistency in concluding that falls and hospitalizations might be reduced 
with modest cost savings15 18 19. Also, significant results favouring pharmacist interventions were found 
for specific health outcomes such as blood pressure, blood glucose control, etc19. No studies reported 
a benefit in terms of mortality, mental capacity or activities of daily living15 18.  
It can be concluded that cognitive pharmacy services are probably of value and may be cost-
effective, with estimated returns on investment ranging from $1.30 to $26 per dollar spent13 16 20. 
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2. OPTIMIZATION OF PHARMACEUTICAL CARE FOR SPECIFIC PATIENT POPULATIONS AS THE MAIN GOAL OF THIS THESIS 
Optimizing pharmaceutical care, especially for chronic care patients and patients with difficult 
medication schemata, has a great potential to improve their treatments and overall cost savings. These 
groups consume a disproportionate share of health care expenditures, including pharmaceuticals. 
Their pharmacological needs require access to a broad range of medications and an individualized 
approach to care. The ultimate goal is to ensure that these people derive maximum benefits from their 
drug therapy21.  
As the number of chronic care patients and patients with difficult medication schemata is 
increasing, it would be unfortunate that the added value of a community pharmacist’s clinical input is 
not maximally utilized. These patients require surely a patient-centred and multidisciplinary care 
approach. Therefore, in this thesis we report on the possibilities for and effectiveness of community 
pharmacist interventions for two specific patient groups; (1) older patients with polypharmacy and (2) 
patients with Chronic Obstructive Pulmonary Disease (COPD) as an example of chronic disease. The 
choice for both groups was deliberate as they are both increasingly present in the ambulatory setting 
and place a significant burden on the healthcare system. Additionally, this way, we can validate these 
new role of the community pharmacist. 
 
2.1. Medication review for older patients with polypharmacy 
2.1.1. The population 
Over the past years, the proportion of the European and Belgian population aged 65 years and over 
has been increasing22. Recent numbers of the European Commission Eurostat group show that almost 
20% of the total population is 65 years or older22, representing about 2,200,000 people in Belgium. 
When prescribing medication for older patients, we have to take into account age-related changes in 
pharmacokinetics and pharmacodynamics. Additionally, because of co-morbidities they are often 
prescribed multiple drugs (with polypharmacy defined as 5 or more different drugs). Both older age 
and polypharmacy increase the risk for Adverse Drug Events1 (ADEs) significantly23. On its turn, this 
leads to increased morbidity and mortality, hereby putting a high (financial) burden on the healthcare 
system23-26.  
A recent systematic review reported an ADE prevalence up to 23% with preventability rates up to 
53% for older adults in ambulatory care23. Many factors contribute to the presence of ADEs, such as 
number of drugs and impaired renal function27. As well, Potentially Inappropriate Prescribing (PIP) has 
shown to be a main contributor28, and is thus a potential, though indirect, cause for increased social 
and economic burden29 30.  
                                                          
1 An ADE is defined by the World Health Organization as a “medical occurrence, temporally associated with the use of a medicinal product,  
but not necessarily causally related” 
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In 2012 Opondo et al. published a systematic review on PIP in the primary care setting31. An overall 
median PIP rate of 19.1% (range: 2.9% – 38.5%), i.e. the percentage of older patients with at least one 
PIP, was described. This high prevalence represents an important opportunity to improve the 
prescribing quality in the primary care setting. The community pharmacist is ideally placed to engage 
in this process because of his medication-specific knowledge and because of the availability of an 
electronic dispensing record in the pharmacy, including dispensed over-the-counter (OTC) medication.  
The complexity of the matter however, makes it unlikely that a single intervention at one point in 
the medication management process will be sufficient to tackle this issue. Literature showed that 
multidisciplinary interventions including education and based on a systematic screening method are 
the most efficient for resolving and preventing all types of PIP32-34.  
 
2.1.2. Medication Review 
Reviewing a patient’s medication use can reveal potential DRPs (Table 1.2). These can be rather 
practical (e.g. difficulties with splitting tablets), or mainly therapeutic (e.g. dosing error). Medication 
reviews can be performed by any healthcare worker sufficiently trained in pharmacotherapy; however, 
most often, they are initiated by a (community) pharmacist. The pharmacist can review the medication 
use during the time of dispensing or on a regular basis, irrespective of the drug dispensing4 31.  
 
2.1.2.1. Medication review during dispensing  
Reviewing a patient’s medication at the time of dispensing has the advantage that it is quick and 
performed together with every medication dispensing or medication change. The limited amount of 
time available on the other hand implies that the review is restricted to a number of (automatized) 
checks, such as for interactions and contra-indications. These automatized checks are placed under 
the term Computerized Decision Support Systems (CDSS). CDSS appears to reduce a range of 
medication errors, most of them safety-related35 36.  
A systematic review evaluating the impact of pharmacy CDSS on prescribing, clinical and patient 
outcomes concluded that two-thirds of included Randomized Controlled Trials (RCT) showed 
statistically significant results in favour of CDSS on the majority of outcomes36. This systematic review 
included both RCTs that evaluated the quality of the medicines use (e.g. checking secondary prevention 
medication) and RCTs that evaluated drug safety and monitoring (e.g. interactions).  
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More recently, the PINCER-trial showed that a pharmacist-led information technology intervention, 
composed of feedback and educational outreach, decreased the number of patients that had at least 
one prescription problem or at least one monitoring problem, both after 6 and 12 months of follow-
up35. Another RCT, recently performed in general practitioners’ offices, additionally showed that CDSS 
led to significant improvement in appropriate medication adjustments for patients with impaired renal 
function, a pharmacovigilance task as well perfectly suitable for the community pharmacist37.  
 
2.1.2.2. Medication review on a regular basis, irrespective of dispensing  
Another possibility for the community pharmacist is to screen a patient’s medication on a regular 
basis, irrespective of dispensing. The main goal of this process is to detect DRPs, mainly focusing on 
PIP, including overuse, underuse and misuse of medicines (see above, Table 1.2). Detection of PIP can 
be very specific, for example focused on the discontinuation of benzodiazepines38, or be very general, 
incorporating all aspects of PIP39. Three types of medication review exist: simple, intermediate or 
advanced (Table 1.3)40. 
 
Table 1.3: Types of Medication Review40 
 Type 1: Simple Type 2a: Intermediate Type 2b: Intermediate Type 3: Advanced 
Data collection 
Medication history V V V V 
Patient - V - V 
Patient’s medical records  - - V V 
The review  
Drug-Drug Interactions V V V V 
Duplication V V V V 
Drug-Disease interactions Partly Partly V V 
Dosage Check Partly Partly V V 
Adherence evaluation Partly V Partly V 
Type of screening tool that can be used to support the medication review 
Explicit screening tool V V V V 
Implicit screening tool - Partly Partly V 
  
To support the medication review, two types of screening tools can be used: implicit or explicit 
tools. Implicit tools such as the (adapted) Medication Appropriateness Index (MAI – Appendix 1.1) 
judge the appropriateness of therapy using clinical information of an individual patient and patient 
preferences 39 41. They have the advantage to be holistic, taking all patient factors into account. On the 
other hand, they are very time-consuming and require the availability of all clinical patient data. Explicit 
tools, such as the STOPP/START-criteria21 (Appendix 1.2) or the Beers-criteria22 (Appendix 1.3), involve 
lists of drugs to be avoided or describe appropriate prescribing indicators. These instruments are most 
often used by general practitioners, specialists or hospital pharmacists. They are straightforward, quick 
to apply and can be fully automatized. On the other hand, they do not take into account all patient 
factors in evaluating the pharmacotherapy, e.g. diagnoses, patient preferences or earlier attempts to 
tackle PIP. An overview of existing explicit, implicit and combined methods is given in Appendix 1.4.  
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Two recent systematic reviews evaluated the effectiveness of pharmacist-led medication reviews19 
33. The first, by Meid et al33, showed that medication review can significantly reduce the number of 
omitted drugs per patient. Another meta-analysis on medication review performed by pharmacists19 
showed that clinical medication review positively influenced clinical outcomes (e.g. blood pressure) 
and additionally significantly reduced hospitalization. 
 
2.2.  Counselling chronic diseases in the community pharmacy, an example for COPD 
2.2.1. The Population 
As with older patients, the proportion of patients with COPD is increasing. In Belgium and in the 
Netherlands, the prevalence of COPD is currently estimated to be about 2 to 3%, which increased since 
the early nineties42 43. A systematic review published in 2012, reported that the prevalence of COPD 
ranged from 0.2%–37%, but prevalence varied widely across countries, populations, COPD diagnosis 
and classification methods44. Equal to the prevalence, the incidence of COPD is dependent on age and 
gender. Based on data of the Rotterdam Study45, the incidence of COPD is estimated to be about 
9.2/1000 person-years (PY), with a higher incidence for men (14/1000 PY) compared to women 
(6/1000 PY) in a cohort of patients ≥55 year.  
COPD is a disease with high mortality rates. Chapman and colleagues46 projected that from 1990 to 
2020, COPD would move from the sixth- to the third-most-common cause of death worldwide, with a 
mortality rate from 3–111 deaths per 100,000 population44, confirmed by WHO data of 201247. 
Additionally, they projected a rise from fourth to third place in terms of morbidity46.  
Although COPD can be managed well with both non-pharmacological and pharmacological 
options48, adherence to therapy is often suboptimal49. Adherence rates reported in asthma and COPD 
studies vary largely with rates between 22% and 78%, depending on the population assessed and the 
methods of measure50. Considering solely COPD, adherence rates are mainly estimated to be about 
50%49. An observational study performed in Belgian community pharmacies detected underadherence 
in 48% of patients and overadherence in 5% of patients51. Suboptimal adherence has been associated 
with higher morbidity and healthcare use (i.e., general practitioner (GP) visits, emergency room visits 
and hospitalizations) due to more frequent episodes of worsening of symptoms – exacerbations – in 
nonadherent patients52-54. Similarly, an association with increased mortality has been reported52 54. 
Consequently, treatment of COPD and its exacerbations contribute substantially to overall healthcare 
costs. In the European Union the costs approximately count for 6% of the total European healthcare 
budget48.  
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Additionally, as COPD is a respiratory disease, a great deal of the medication is administered locally, 
through inhalation therapy. This specific administration route leads to other, more practical issues. 
The correct handling of inhalation devices seems to be problematic for many patients with COPD. 
Mehuys et al reported that 21% of patients with COPD made major inhalation errors, such as failing to 
remove the inhaler cap and/or failing to shake the inhaler51. However, research showed that inhaler 
mishandling remains common and is associated with reduced disease control55. Studies, researching 
the optimization of inhalation technique suggest that repeated training is necessary as positive effects 
disappear over time56. This would require long-term and continuous monitoring of patients with COPD.  
Community pharmacists are well-placed to engage in COPD monitoring programs due to their 
frequent patient contacts upon prescription refill, and their specific medication-related expertise. 
Furthermore, research showed that mere self-management programs are insufficient to reduce severe 
exacerbations57. Consequently, monitoring and optimizing COPD maintenance therapy in the 
community pharmacy setting could be a good balance between unsupervised self-management and 
extensive hospital monitoring 58 59.  
 
2.2.2. Chronic Disease Counselling 
Medication or disease counselling can ensure that people derive maximum benefits from drug 
therapy by individualizing care plans, optimizing the communication between professionals, disease 
knowledge and self-care21. This counselling can take place, either at the time of diagnosis and start-up 
of chronic therapy or, later on, evaluating the effectiveness of and adherence to the chronic therapy.  
 
2.2.2.1. Counselling start-up of chronic therapy 
Starting new medication is a particularly vulnerable moment for patients who are faced with a 
possible new diagnosis, a new treatment plan, potential side effects, and the need to incorporate the 
dosing schedule into their daily routine. A study, initiated in pharmacies, showed that face-to-face 
counselling at start of statin therapy lead to greater medication adherence and persistence than in a 
comparison group (Figure 1.1)60. Another study, evaluating a pharmacy service consisting of a 15-min 
face-to-face interview and a 10-min telephone follow-up interview for patients that are initiating any 
type of chronic therapy, showed that patients were satisfied with the pharmacy service and reported 
that it helped them getting a good start with the new medication61.  Finally, a large RCT, performed in 
the United Kingdom, showed that 10 weeks after receiving a new medicine counselling from the 
community pharmacists, patients were more likely to be taking their medicine, compared with those 
who received the normal service from their pharmacist62. 
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Figure 1.1: Adherence to statin therapy, from initiation to 12-month follow-up (Adopted from Taitel et al60) 
MPR: Medication Possession Ratio 
 
2.2.2.2. Long-term counselling of chronic therapy 
After starting new medication, long-term counselling of the patient is necessary. Not only to 
optimize adherence (see Figure 1.1), but also to detect ADEs (e.g. falls or dizziness), to assess risk 
factors (e.g. functional status) or evaluate risk/benefit ratios (e.g. potassium sparing diuretic in heart 
failure).  
This counselling can partially be executed by a community pharmacist. Several trials have evaluated 
the effectiveness of community pharmacists’ interventions for chronic diseases. For example, an RCT 
by Wu et al63 showed that in patients receiving polypharmacy, periodic telephone counselling by a 
pharmacist improved adherence and reduced mortality63. This conversation included the pharmacist 
asking about the patient’s treatment regimens, clarified any misconceptions, explained the nature of 
any side effects, reminded patients of their next clinic appointment, and reinforced the importance of 
compliance with treatment and relevant aspects of self-care, such as diet, exercise, and self-
monitoring63. A systematic review specifically researching community pharmacists’ interventions on 
adherence to chronic medication concluded more ambivalently17. Despite the fact that the majority of 
the included studies showed significant adherence improvement at one or more time points17, there 
was still a need for well-designed and well-conducted studies on the topic.  
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APPENDIX 1.1: THE MEDICATION APPROPRIATENESS INDEX 
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APPENDIX 1.2: THE STOPP AND START-CRITERIA 
SCREENING TOOL OF OLDER PERSONS’ PRESCRIPTIONS (STOPP) VERSION 2. 
Section A: Indication of medication 
1. Any drug prescribed without an evidence-based clinical indication. 
2. Any drug prescribed beyond the recommended duration, where treatment duration is well defined. 
3. Any duplicate drug class prescription e.g. two concurrent NSAIDs, SSRIs, loop diuretics, ACE inhibitors, 
anticoagulants (optimisation of monotherapy within a single drug class should be observed prior to considering a 
new agent). 
Section B: Cardiovascular System 
1. Digoxin for heart failure with normal systolic ventricular function (no clear evidence of benefit) 
2. Verapamil or diltiazem with NYHA Class III or IV heart failure (may worsen heart failure). 
3. Beta-blocker in combination with verapamil or diltiazem (risk of heart block). 
4. Beta blocker with bradycardia (< 50/min), type II heart block or complete heart block (risk of complete heart block, 
asystole). 
5. Amiodarone as first-line antiarrhythmic therapy in supraventricular tachyarrhythmias (higher risk of side-effects 
than beta-blockers, digoxin, verapamil or diltiazem) 
6. Loop diuretic as first-line treatment for hypertension (safer, more effective alternatives available). 
7. Loop diuretic for dependent ankle oedema without clinical, biochemical evidence or radiological evidence of heart 
failure, liver failure, nephrotic syndrome or renal failure (leg elevation and /or compression hosiery usually more 
appropriate). 
8. Thiazide diuretic with current significant hypokalaemia (i.e. serum K+ < 3.0 mmol/l), hyponatraemia (i.e. serum Na+ 
< 130 mmol/l) hypercalcaemia (i.e. corrected serum calcium > 2.65 mmol/l) or with a history of gout (hypokalaemia, 
hyponatraemia, hypercalcaemia and gout can be precipitated by thiazide diuretic) 
9. Loop diuretic for treatment of hypertension with concurrent urinary incontinence (may exacerbate incontinence). 
10. Centrally-acting antihypertensives (e.g. methyldopa, clonidine, moxonidine, rilmenidine, guanfacine), unless clear 
intolerance of, or lack of efficacy with, other classes of antihypertensives (centrally-active antihypertensives are 
generally less well tolerated by older people than younger people) 
11. ACE inhibitors or Angiotensin Receptor Blockers in patients with hyperkalaemia. 
12. Aldosterone antagonists (e.g. spironolactone, eplerenone) with concurrent potassium- conserving drugs (e.g. 
ACEI’s, ARB’s, amiloride, triamterene) without monitoring of serum potassium (risk of dangerous hyperkalaemia 
i.e. > 6.0 mmol/l – serum K should be monitored regularly, i.e. at least every 6 months). 
13. Phosphodiesterase type-5 inhibitors (e.g. sildenafil, tadalafil, vardenafil) in severe heart failure characterised by 
hypotension i.e. systolic BP < 90 mmHg, or concurrent nitrate therapy for angina (risk of cardiovascular collapse) 
Section C: Antiplatelet/Anticoagulant Drugs 
1. Long-term aspirin at doses greater than 160mg per day (increased risk of bleeding, no evidence for increased 
efficacy). 
2. Aspirin with a past history of peptic ulcer disease without concomitant PPI (risk of recurrent peptic ulcer ). 
3. Aspirin, clopidogrel, dipyridamole, vitamin K antagonists, direct thrombin inhibitors or factor Xa inhibitors with 
concurrent significant bleeding risk, i.e. uncontrolled severe hypertension, bleeding diathesis, recent non-trivial 
spontaneous bleeding) (high risk of bleeding). 
4. Aspirin plus clopidogrel as secondary stroke prevention, unless the patient has a coronary stent(s) inserted in the 
previous 12 months or concurrent acute coronary syndrome or has a high grade symptomatic carotid arterial 
stenosis (no evidence of added benefit over clopidogrel monotherapy) 
5. Aspirin in combination with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in patients with 
chronic atrial fibrillation (no added benefit from aspirin) 
6. Antiplatelet agents with vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in patients with stable 
coronary, cerebrovascular or peripheral arterial disease (No added benefit from dual therapy). 
7. Ticlopidine in any circumstances (clopidogrel and prasugrel have similar efficacy, stronger evidence and fewer side-
effects). 
8. Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors for first deep venous thrombosis without 
continuing provoking risk factors (e.g. thrombophilia) for > 6 months, (no proven added benefit). 
9. Vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors for first pulmonary embolus without 
continuing provoking risk factors (e.g. thrombophilia) for > 12 months (no proven added benefit). 
10. NSAID and vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in combination (risk of major 
gastrointestinal bleeding). 
11. NSAID with concurrent antiplatelet agent(s) without PPI prophylaxis (increased risk of peptic ulcer disease) 
Section D: Central Nervous System and Psychotropic Drugs 
1. TriCyclic Antidepressants (TCAs) with dementia, narrow angle glaucoma, cardiac conduction abnormalities, 
prostatism, or prior history of urinary retention (risk of worsening these conditions). 
2. Initiation of TriCyclic Antidepressants (TCAs) as first-line antidepressant treatment (higher risk of adverse drug 
reactions with TCAs than with SSRIs or SNRIs). 
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3. Neuroleptics with moderate-marked antimuscarinic/anticholinergic effects (chlorpromazine, clozapine, 
flupenthixol, fluphenzine, pipothiazine, promazine, zuclopenthixol) with a history of prostatism or previous urinary 
retention (high risk of urinary retention). 
4. Selective serotonin re-uptake inhibitors (SSRI’s) with current or recent significant hyponatraemia i.e. serum Na+ < 
130 mmol/l (risk of exacerbating or precipitating hyponatraemia). 
5. Benzodiazepines for ≥ 4 weeks (no indication for longer treatment; risk of prolonged sedation, confusion, impaired 
balance, falls, road traffic accidents; all benzodiazepines should be withdrawn gradually if taken for more than 4 
weeks as there is a risk of causing a benzodiazepine withdrawal syndrome if stopped abruptly). 
6. Antipsychotics (i.e. other than quetiapine or clozapine) in those with parkinsonism or Lewy Body Disease (risk of 
severe extra-pyramidal symptoms) 
7. Anticholinergics/antimuscarinics to treat extra-pyramidal side-effects of neuroleptic medications (risk of 
anticholinergic toxicity), 
8. Anticholinergics/antimuscarinics in patients with delirium or dementia (risk of exacerbation of cognitive 
impairment). 
9. Neuroleptic antipsychotic in patients with behavioural and psychological symptoms of dementia (BPSD) unless 
symptoms are severe and other non-pharmacological treatments have failed (increased risk of stroke). 
10. Neuroleptics as hypnotics, unless sleep disorder is due to psychosis or dementia (risk of confusion, hypotension, 
extra-pyramidal side effects, falls). 
11. Acetylcholinesterase inhibitors with a known history of persistent bradycardia (< 60 beats/min.), heart block or 
recurrent unexplained syncope or concurrent treatment with drugs that reduce heart rate such as beta-blockers, 
digoxin, diltiazem, verapamil (risk of cardiac conduction failure, syncope and injury). 
12. Phenothiazines as first-line treatment, since safer and more efficacious alternatives exist (phenothiazines are 
sedative, have significant anti-muscarinic toxicity in older people, with the exception of prochlorperazine for 
nausea/vomiting/vertigo, chlorpromazine for relief of persistent hiccoughs and levomepromazine as an anti-emetic 
in palliative care ). 
13. Levodopa or dopamine agonists for benign essential tremor (no evidence of efficacy) 
14. First-generation antihistamines (safer, less toxic antihistamines now widely available). 
Section E: Renal System. The following drugs are potentially inappropriate in older people with acute or chronic kidney 
disease with renal function below particular levels of eGFR (refer to summary of product characteristics datasheets and 
local formulary guidelines) 
1. Digoxin at a long-term dose greater than 125µg/day if eGFR < 30 ml/min/1.73m2 (risk of digoxin toxicity if plasma 
levels not measured). 
2. Direct thrombin inhibitors (e.g. dabigatran) if eGFR < 30 ml/min/1.73m2 (risk of bleeding) 
3. Factor Xa inhibitors (e.g. rivaroxaban, apixaban) if eGFR < 15 ml/min/1.73m2 (risk of bleeding) 
4. NSAID’s if eGFR < 50 ml/min/1.73m2 (risk of deterioration in renal function). 
5. Colchicine if eGFR < 10 ml/min/1.73m2 (risk of colchicine toxicity) 
6. Metformin if eGFR < 30 ml/min/1.73m2 (risk of lactic acidosis). 
 Section F: Gastrointestinal System 
1. Prochlorperazine or metoclopramide with Parkinsonism (risk of exacerbating Parkinsonian symptoms). 
2. PPI for uncomplicated peptic ulcer disease or erosive peptic oesophagitis at full therapeutic dosage for > 8 weeks 
(dose reduction or earlier discontinuation indicated). 
3. Drugs likely to cause constipation (e.g. antimuscarinic/anticholinergic drugs, oral iron, opioids, verapamil, 
aluminium antacids) in patients with chronic constipation where non- constipating alternatives are available (risk 
of exacerbation of constipation). 
4. Oral elemental iron doses greater than 200 mg daily (e.g. ferrous fumarate> 600 mg/day, ferrous sulphate > 600 
mg/day, ferrous gluconate> 1800 mg/day; no evidence of enhanced iron absorption above these doses). 
Section G: Respiratory System 
1. Theophylline as monotherapy for COPD (safer, more effective alternative; risk of adverse effects due to narrow 
therapeutic index). 
2. Systemic corticosteroids instead of inhaled corticosteroids for maintenance therapy in moderate-severe COPD 
(unnecessary exposure to long-term side-effects of systemic corticosteroids and effective inhaled therapies are 
available). 
3. Anti-muscarinic bronchodilators (e.g. ipratropium, tiotropium) with a history of narrow angle glaucoma (may 
exacerbate glaucoma) or bladder outflow obstruction (may cause urinary retention). 
4. Non-selective beta-blocker (whether oral or topical for glaucoma) with a history of asthma requiring treatment (risk 
of increased bronchospasm). 
5. Benzodiazepines with acute or chronic respiratory failure i.e. pO2 < 8.0 kPa ± pCO2 > 6.5 kPa (risk of exacerbation 
of respiratory failure). 
Section H: Musculoskeletal System 
1. Non-steroidal anti-inflammatory drug (NSAID) other than COX-2 selective agents with history of peptic ulcer disease 
or gastrointestinal bleeding, unless with concurrent PPI or H2 antagonist (risk of peptic ulcer relapse). 
2. NSAID with severe hypertension (risk of exacerbation of hypertension) or severe heart failure (risk of exacerbation 
of heart failure). 
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3. Long-term use of NSAID (>3 months) for symptom relief of osteoarthritis pain where paracetamol has not been 
tried (simple analgesics preferable and usually as effective for pain relief) 
4. Long-term corticosteroids (>3 months) as monotherapy for rheumatoid arthrtitis (risk of systemic corticosteroid 
side-effects). 
5. Corticosteroids (other than periodic intra-articular injections for mono-articular pain) for osteoarthritis (risk of 
systemic corticosteroid side-effects). 
6. Long-term NSAID or colchicine (>3 months) for chronic treatment of gout where there is no contraindication to a 
xanthine-oxidase inhibitor (e.g. allopurinol, febuxostat) (xanthine- oxidase inhibitors are first choice prophylactic 
drugs in gout). 
7. COX-2 selective NSAIDs with concurrent cardiovascular disease (increased risk of myocardial infarction and stroke) 
8. NSAID with concurrent corticosteroids without PPI prophylaxis (increased risk of peptic ulcer disease) 
9. Oral bisphosphonates in patients with a current or recent history of upper gastrointestinal disease i.e. dysphagia, 
oesophagitis, gastritis, duodenitis, or peptic ulcer disease, or upper gastrointestinal bleeding (risk of 
relapse/exacerbation of oesophagitis, oesophageal ulcer, oesophageal stricture) 
Section I: Urogenital System 
1. Antimuscarinic drugs with dementia, or chronic cognitive impairment (risk of increased confusion, agitation) or 
narrow-angle glaucoma (risk of acute exacerbation of glaucoma), or chronic prostatism (risk of urinary retention). 
2. Selective alpha-1 selective alpha blockers in those with symptomatic orthostatic hypotension or micturition 
syncope (risk of precipitating recurrent syncope) 
Section J. Endocrine System 
1. Sulphonylureas with a long duration of action (e.g. glibenclamide, chlorpropamide, glimepiride) with type 2 
diabetes mellitus (risk of prolonged hypoglycaemia). 
2. Thiazolidenediones (e.g. rosiglitazone, pioglitazone) in patients with heart failure (risk of exacerbation of heart 
failure) 
3. Beta-blockers in diabetes mellitus with frequent hypoglycaemic episodes (risk of suppressing hypoglycaemic 
symptoms). 
4. Oestrogens with a history of breast cancer or venous thromboembolism (increased risk of recurrence). 
5. Oral oestrogens without progestogen in patients with intact uterus (risk of endometrial cancer). 
6. Androgens (male sex hormones) in the absence of primary or secondary hypogonadism (risk of androgen toxicity; 
no proven benefit outside of the hypogonadism indication). 
Section K: Drugs that predictably increase the risk of falls in older people 
1. Benzodiazepines (sedative, may cause reduced sensorium, impair balance). 
2. Neuroleptic drugs (may cause gait dyspraxia, Parkinsonism). 
3. Vasodilator drugs (e.g. alpha-1 receptor blockers, calcium channel blockers, long-acting nitrates, ACE inhibitors, 
angiotensin I receptor blockers, ) with persistent postural hypotension i.e. recurrent drop in systolic blood pressure 
≥ 20mmHg (risk of syncope, falls). 
4. Hypnotic Z-drugs e.g. zopiclone, zolpidem, zaleplon (may cause protracted daytime sedation, ataxia). 
Section L: Analgesic Drugs 
1. Use of oral or transdermal strong opioids (morphine, oxycodone, fentanyl, buprenorphine, diamorphine, 
methadone, tramadol, pethidine, pentazocine) as first line therapy for mild pain (WHO analgesic ladder not 
observed). 
2. Use of regular (as distinct from PRN) opioids without concomitant laxative (risk of severe constipation). 
3. Long-acting opioids without short-acting opioids for break-through pain (risk of persistence of severe pain) 
Section N: Antimuscarinic/Anticholinergic Drug Burden 
1. Concomitant use of two or more drugs with antimuscarinic/anticholinergic properties (e.g. bladder antispasmodics, 
intestinal antispasmodics, tricyclic antidepressants, first generation antihistamines) (risk of increased 
antimuscarinic/anticholinergic toxicity) 
  
SCREENING TOOL TO ALERT TO RIGHT TREATMENT (START), VERSION 2. 
Section A: Cardiovascular System 
1. Vitamin K antagonists or direct thrombin inhibitors or factor Xa inhibitors in the presence of chronic atrial 
fibrillation. 
2. Aspirin (75 mg – 160 mg once daily) in the presence of chronic atrial fibrillation, where Vitamin K antagonists or 
direct thrombin inhibitors or factor Xa inhibitors are contraindicated. 
3. Antiplatelet therapy (aspirin or clopidogrel or prasugrel or ticagrelor) with a documented history of coronary, 
cerebral or peripheral vascular disease. 
4. Antihypertensive therapy where systolic blood pressure consistently > 160 mmHg and/or diastolic blood pressure 
consistently >90 mmHg; if systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg, if 
diabetic. 
5. Statin therapy with a documented history of coronary, cerebral or peripheral vascular disease, unless the patient’s 
status is end-of-life or age is > 85 years. 
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6. Angiotensin Converting Enzyme (ACE) inhibitor with systolic heart failure and/or documented coronary artery 
disease. 
7. Beta-blocker with ischaemic heart disease. 
8. Appropriate beta-blocker (bisoprolol, nebivolol, metoprolol or carvedilol) with stable systolic heart failure. 
Section B: Respiratory System 
1. Regular inhaled 2 agonist or antimuscarinic bronchodilator (e.g. ipratropium, tiotropium) for mild to moderate 
asthma or COPD. 
2. Regular inhaled corticosteroid for moderate-severe asthma or COPD, where FEV1 <50% of predicted value and 
repeated exacerbations requiring treatment with oral corticosteroids. 
3. Home continuous oxygen with documented chronic hypoxaemia (i.e. pO2 < 8.0 kPa or 60 mmHg or SaO2 < 89%) 
Section C: Central Nervous System& Eyes 
1. L-DOPA or a dopamine agonist in idiopathic Parkinson’s disease with functional impairment and resultant disability. 
2. Non-TCA antidepressant drug in the presence of persistent major depressive symptoms. 
3. Acetylcholinesterase inhibitor (e.g. donepezil, rivastigmine, galantamine) for mild- moderate Alzheimer’s dementia 
or Lewy Body dementia (rivastigmine). 
4. Topical prostaglandin, prostamide or beta-blocker for primary open-angle glaucoma. 
5. Selective serotonin reuptake inhibitor (or SNRI or pregabalin if SSRI contraindicated) for persistent severe anxiety 
that interferes with independent functioning. 
6. Dopamine agonist (ropinirole or pramipexole or rotigotine) for Restless Legs Syndrome, once iron deficiency and 
severe renal failure have been excluded. 
Section D: Gastrointestinal System 
1. Proton Pump Inhibitor with severe gastro-oesophageal reflux disease or peptic stricture requiring dilatation. 
2. Fibre supplements (e.g. bran, ispaghula, methylcellulose, sterculia) for diverticulosis with a history of constipation. 
Section E: Musculoskeletal System 
1. Disease-modifying anti-rheumatic drug (DMARD) with active, disabling rheumatoid disease. 
2. Bisphosphonates and vitamin D and calcium in patients taking long-term systemic corticosteroid therapy. 
3. Vitamin D and calcium supplement in patients with known osteoporosis and/or previous fragility fracture(s) and/or 
(Bone Mineral Density T-scores more than -2.5 in multiple sites). 
4. Bone anti-resorptive or anabolic therapy (e.g. bisphosphonate, strontium ranelate, teriparatide, denosumab) in 
patients with documented osteoporosis, where no pharmacological or clinical status contraindication exists (Bone 
Mineral Density T-scores -> 2.5 in multiple sites) and/or previous history of fragility fracture(s). 
5. Vitamin D supplement in older people who are housebound or experiencing falls or with osteopenia (Bone Mineral 
Density T-score is > -1.0 but < -2.5 in multiple sites). 
6. Xanthine-oxidase inhibitors (e.g. allopurinol, febuxostat) with a history of recurrent episodes of gout. 
7. Folic acid supplement in patients taking methotexate. 
Section F: Endocrine System 
1. ACE inhibitor or Angiotensin Receptor Blocker (if intolerant of ACE inhibitor) in diabetes with evidence of renal 
disease i.e. dipstick proteinuria or microalbuminuria (>30mg/24 hours) with or without serum biochemical renal 
impairment. 
Section G: Urogenital System 
1. Alpha-1 receptor blocker with symptomatic prostatism, where prostatectomy is not considered necessary. 
2. 5-alpha reductase inhibitor with symptomatic prostatism, where prostatectomy is not considered necessary. 
3. Topical vaginal oestrogen or vaginal oestrogen pessary for symptomatic atrophic vaginitis. 
Section H: Analgesics 
1. High-potency opioids in moderate-severe pain, where paracetamol, NSAIDs or low- potency opioids are not 
appropriate to the pain severity or have been ineffective. 
2. Laxatives in patients receiving opioids regularly. 
Section I: Vaccines 
1. Seasonal trivalent influenza vaccine annually 
2. Pneumococcal vaccine at least once after age 65 according to national guidelines 
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APPENDIX 1.3: FIRST PAGE EXAMPLE OF THE BEERS-CRITERIA 2012 
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APPENDIX 1.4: OVERVIEW OF EXISTING IMPLICIT, EXPLICIT AND COMBINED CRITERIA 
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Chapter 1 – Outline and aims of the thesis 
 
The main goal of this thesis is to develop, optimize and evaluate advanced pharmaceutical care 
interventions in chronic care. We focused on older patients with polypharmacy and on patients with 
COPD as an example of chronic disease. The choice for both groups is deliberate as they are both 
increasingly present and are burdensome for both the patient and the healthcare system.  
 
In Chapter 2 we developed and validated a strategy to optimize pharmaceutical care for older 
patients with polypharmacy. This strategy included the development and validation of a new screening 
tool to perform a medication review originating from the community pharmacy. This way, community 
pharmacists can initiate this process and use the outcomes to improve interdisciplinary 
communication. Additionally, we assessed the prevalence of Potentially Inappropriate Prescribing (PIP) 
according to this screening tool in the ambulatory and nursing home setting and evaluated usability 
and feasibility. The specific aims are as follows:   
 
Aim 1: To get an insight in the overall prevalence of PIP in Europe, the drugs and drug groups that 
are mainly involved in PIP and the most important risk factors associated with PIP. 
To this end, we performed a systematic literature review of 52 observational studies on PIP in 
community-dwelling older patients in Europe, described in Part 1.  
 
Aim 2: To develop an explicit screening tool to detect PIP with high clinical relevance, usable in a 
typical community pharmacy practice and specifically adapted to the European market 
In Part 2, the developmental process of a new screening tool is elaborately described. The process 
was completed using the RAND/UCLA method. An additional round on feasibility for the 
contemporary community pharmacy setting resulted in the Ghent Older People’s Prescriptions 
community Pharmacy Screening (GheOP³S-)tool, a list of 83 PIP-items. 
 
Aim 3: To validate the newly developed GheOP³S-tool 
In Part 3 we describe the validation of the GheOP³S-tool, using the results of an observational study, 
performed on acutely hospitalized older patients with polypharmacy. For each PIP-item detected 
with the GheOP³S-tool, the clinical relevance, the relevance of the proposed alternative treatment 
plan and the subsequent acceptance by the geriatrician was evaluated. Additionally, we assessed 
the contribution to the admission and preventability. Lastly, we evaluated the completeness of a 
PIP-screening with the GheOP³S-tool through comparison with the adapted Medication 
Appropriateness Index (aMAI). 
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Aim 4: To determine the prevalence of PIP in Belgian older adults with polypharmacy 
To this end, two observational studies, using the GheOP³S-tool to determine PIP-prevalence, were 
performed. The first was executed in 204 Belgian community pharmacies and included 1016 
ambulatory older patients (≥ 70 years) with polypharmacy (≥ 5 drugs) (see Part 4). Analogously, a 
second observational study, was performed in 10 nursing homes in Flanders, all supplied by one 
community pharmacy chain. From each nursing home, 40 residents aged 70 years or older and using 
5 or more chronic drugs were included (Part 5). Besides determining PIP-prevalence, the feasibility 
of applying the GheOP³S-tool in daily community pharmacy practice was as well evaluated (Part 4). 
 
Consequently, in Chapter 3, we shifted our focus to patients with COPD as an example of chronic 
disease. To document the extent of the issues experienced by patients with COPD, we elaborately 
introduce COPD by reviewing the pathology, pathophysiology, epidemiology and burden of disease in 
Part 1. Additionally, we elaborate on pharmacotherapeutical optimisation possibilities, with regard to 
inhalation technique and medication adherence. Subsequently, from Part 2 on, we evaluated a 
counselling strategy, provided by the community pharmacist in the management of the disease. The 
specific aims are as follows:   
 
Aim 1: To evaluate the effectiveness of a pharmaceutical care intervention, focusing on inhalation 
technique and medication adherence, executed in the community pharmacy. 
Part 2, describes the results of the PHARMAceutical care in COPD-trial (PHARMACOP-trial). This was 
a single-blind 3-month randomized controlled trial, conducted in 170 community pharmacies in 
Belgium, including 734 patients. Patients were allocated to the intervention group, receiving 
protocol-defined pharmacist care, or control group, receiving usual pharmacist care. The primary 
outcomes were inhalation technique and medication adherence, however, also secondary 
outcomes such as exacerbation rate were evaluated.  
 
Aim 2: To assess the current implementation level of the items included in the PHARMACOP-
protocol in Flemish community pharmacies and perspectives on future implementation. 
To this end, Part 3 describes the results of a cross-sectional study, conducted in randomly selected 
community pharmacies in Flanders. Pharmacists were questioned using structured interviews. 
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Aim 3: To assess the accuracy of a self-report measure of adherence for identifying nonadherent 
users of inhalation medication among patients with COPD 
As medication adherence seemed to be problematic in patients with COPD, the availability of an 
accurate method to measure adherence appeared to be essential. Therefore, in Part 4, we used the 
results of the PHARMACOP-trial to determine the accuracy of the Medication Adherence Report 
Scale (MARS-5) to identify nonadherent users of inhalation medication among patients with COPD. 
This was accomplished through comparison with the medication refill adherence (MRA) as a 
reference. 
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ABSTRACT 
 
Background. Potentially Inappropriate Prescribing (PIP) is one of the main risk factors for adverse drug 
events (ADEs) in older people.  
 
Purpose. This systematic literature review aims to determine prevalence and type of PIP in community 
dwelling older people across Europe, as well as identifying risk factors for PIP.  
 
Methods. The PubMed and Web of Science database were searched systematically for relevant 
manuscripts (January 1, 2000 - December 31, 2014). Manuscripts were included if the study design was 
observational, the study participants were community-dwelling older patients in Europe, and if a 
published screening method for PIP was used. Studies that focused on specific pathologies or that 
focused on merely one inappropriate prescribing issue were excluded. Data analysis was performed 
using R statistics. 
 
Results. Fifty-two manuscripts were included, describing 82 different sample screenings with an 
estimated overall PIP prevalence of 22.6% (CI: 19.2– 26.7%; Range: 0.0 – 98.0%). Ten of the sample 
screenings were based on the Beers 1997 criteria, 19 on the Beers 2003 criteria, 14 on STOPP-criteria 
(2008 version), 8 on START-criteria (2008 version) and 7 on the PRISCUS-list. The 24 remaining sample 
screenings were carried out using compilations of screening methods or used country specific lists such 
as the Laroche-criteria. It appears that only PIP prevalence calculated from insurance data significantly 
differs from the other data collection method categories. Furthermore, risk factors most often 
positively associated with PIP prevalence were polypharmacy, poor functional status and depression. 
Drug groups most often involved in PIP were anxiolytics (ATC-code: N05B), antidepressants (N06A) and 
non-steroidal anti-inflammatory and anti-rheumatic products (M01A).  
 
Conclusion. PIP prevalence in European community-dwelling older adults is high and depends partially 
on the data collection method used. Polypharmacy, poor functional status and depression were 
identified as most common risk factors for PIP.  
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INTRODUCTION 
Over the past years, the proportion of the European population aged 65 years and over has been 
increasing1. Aging is often associated with a growing number of chronic diseases and hence 
polypharmacy, which increases the risk for adverse drug events (ADEs)2 3, drug-related hospitalizations 
and related costs2 4. A recent systematic review reported an ADE prevalence up to 23% for older adults 
in ambulatory care with preventability rates up to 53%3.  
Previous studies have identified Potentially Inappropriate Prescribing (PIP) as one of the main risk 
factors for ADEs in older adults5-9. PIP is defined as the prescribing of medication that could introduce 
a significant risk of an ADE, in particular when there is an equally or more effective alternative with 
lower risk available10 11. PIP encompasses three main categories: over-, under- and misprescribing (e.g. 
inappropriate dose or duration)12. Both explicit (criteria-based) and implicit (judgement-based) 
screening methods were developed and used to detect PIP13-16. Studies using these tools clearly 
demonstrated that PIP prevalence is high and that an early detection may indeed prevent 
hospitalizations and improve health outcomes10 17-19. Research to detect and reduce PIP was initially 
mainly situated in hospital and nursing home settings as one of the strategies to prevent and lower the 
prevalence of ADEs20-22. Over the past decade however, PIP-screening in primary care received 
increasing attention among health care workers because detecting and tackling PIP at that point in the 
health care system could be more (cost-)effective10 19.  
In 2012 Opondo et al. published the first systematic review on PIP in the primary care setting10. 
Eight of the 19 included studies were carried out in Europe, describing an overall median PIP rate of 
19.1% (range: 2.9% – 38.5%). However, this review only included studies that reported on 
‘unconditionally inappropriate medication prescriptions’. Studies investigating drug-drug interactions 
drug-disease interactions, or other types of PIP were excluded. In addition, risk factors for PIP have not 
yet been reviewed. This information is however needed to enable the design of well-defined targeted 
interventions to improve the quality of prescribing for older adults. Furthermore, since the publication 
of the systematic review of Opondo et al.10, several new studies in the European ambulatory setting 
have emerged, which have contributed to a better characterization of the contemporary field23-26.   
In order to improve quality of care for community-dwelling older adults, it is necessary to determine 
the magnitude, nature and relevance of PIP in Europe. Only then, straightforward and targeted 
management plans for patient groups at risk can be developed to tackle the most problematic PIPs in 
primary care. The aim of this systematic review is (1) to synthesize observational research on PIP 
prevalence in community-dwelling older adults in Europe, (2) to present an overview of the risk factors 
mostly described in association with PIP and (3) to summarize the drugs or drug groups most often 
involved in PIP.  
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METHODS 
Searches 
We searched the PubMed and Thomson Reuters Web of ScienceTM database for relevant 
manuscripts from January 1, 2000 to December 31, 2014. The search strategy contained terms and 
combinations related to older patients, medications, (in)appropriateness, ambulatory care, outpatient 
care or community-dwelling patients, including the MeSH terms “Aged” and “Inappropriate 
prescribing” as shown in Appendix 2.1.1. The final literature search was performed on the 31st 
December 2014. The database search was completed with a manual search of the reference lists of 
included articles (i.e. “snowballing”). The quality of the systematic review was supported by the use of 
the PRISMA guidelines27 . 
 
Eligibility criteria 
Manuscripts were eligible for inclusion if they met the following criteria: (1) study design was 
observational, (2) study participants were community-dwelling older patients (65 years and older) in 
Europe and (3) a published screening method, either implicit or explicit for PIP was used. Manuscripts 
could be published in English, French, Dutch, German or Spanish. Studies that focused on specific 
pathologies (e.g. patients with dementia) or that focused on merely one inappropriate prescribing 
issue (e.g. benzodiazepine use) were excluded in addition to manuscripts that not specifically 
mentioned a focus on the primary care setting or the older age group.  
 
Study selection  
Duplicate manuscripts were removed after exporting search results to Endnote (Thomson Reuters, 
Times Square, New York, NY, USA). Subsequently, two reviewers (ET & EM) independently screened 
the title, abstract and full-text of the retrieved manuscripts for eligibility. Each manuscript showing 
uncertainty regarding inclusion criteria was discussed until consensus about inclusion in the following 
selection round was reached.  
 
Data collection, synthesis & analysis 
Data concerning country, study period, inclusion criteria, used data collection method and used 
screening method were collected from the selected manuscripts. Additional extracted data included 
sample size, mean (SD) age of the screened population, mean (SD) or median (IQR) number of drugs 
taken (as presented in the original manuscript and therefore sometimes including OTC-drugs), and PIP 
prevalence (reported as the percentage of patients or prescriptions with at least one PIP). When 
repeated measurements were reported, we included only the most recent rate of PIP.  
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When data could not be retrieved from the published manuscript, we contacted the corresponding 
author to request for additional information. If the corresponding author did not reply, a reminder e-
mail was sent one month later. The study quality (“risk of bias”) of the included studies was evaluated 
by using a slightly adapted quality assessment scale from the Cochrane Collaboration group, including 
the following domains: study participation, data collection, screening method used, outcome 
measurement and statistical analysis. All studies were judged having a low or moderate risk of bias.  
We estimated an overall prevalence with its 95% confidence interval (CI), using a random effects 
model with random intercepts. Prevalence data were modelled on a logit scale using sample size as a 
weighting factor. Likewise, a conditional prevalence with its 95% CI was estimated for the most used 
PIP screening methods (Beers, STOPP, START and PRISCUS), each method of data collection ((1) face-
to-face interview, (2) prescribing, dispensing or primary health database, (3) insurance data, (4) 
questionnaire, (5) medical record or (6) combinations) and their interactions, using a (saturated) 
random effects model with fixed effects. For this analysis, all Beers analyses and combinations of data 
collection methods were collapsed into single categories. Analyses were carried out using R® (R 
Foundation for Statistical Computing, Vienna, Austria).  
Subsequently, we selected those manuscripts that assessed risk factors associated with PIP and 
extracted the results as mentioned in the original manuscript. For the factor ‘polypharmacy’, different 
groups used other definitions (varying from the use of ≥4 up to ≥7 drugs), which were merged for 
reasons of comparability. Finally, we selected those manuscripts that provided detailed information 
about PIP prevalence for specific drugs or drug groups and summarized the information. The 10 drugs 
or drug groups most frequently associated with PIP were extracted as originally mentioned in the 
included manuscript and classified according to the Anatomical Therapeutic Chemical (ATC) 
classification system (3rd level) (e.g. ‘M01AB05 - diclofenac’ was classified as ‘M01A – anti-
inflammatory and antirheumatic products, non-steroids’, or ‘B01AC - platelet aggregation inhibitors’ 
as ‘B01A – antithrombotic agents’)28. Due to the heterogeneity of the methodologies applied in the 
included studies, the overview of risk factors and drugs or drug groups most frequently associated with 
PIP are merely reported in a descriptive way. 
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RESULTS 
We identified 1375 manuscripts and screened 1138 titles and 154 abstracts for eligibility after 
duplicate removal. We screened the full text of 62 manuscripts and excluded 23. Thirteen manuscripts 
were added via manual search of the references. Our final sample comprised 52 manuscripts reporting 
on 82 sample screenings of PIP in community-dwelling older adults in Europe (Figure 2.1.1). These 
studies were performed in 23 different European countries. The eventual list of included manuscripts 
is presented in Table 2.1.1, arranged by country and year of publication.  
 
 
Figure 2.1.1: Flowchart of the literature search 
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PIP Prevalence  
The overall estimated weighted PIP prevalence was 22.6% (CI: 19.5-26.7%). PIP prevalence ranged 
from 0.0 % to 98.0%, with sample sizes varying from 50 to 1,019,491 patients. A large heterogeneity 
and inconsistency in study design (data collection methods) and outcome measures (screening 
methods used) was however observed. 
Eighteen of the 52 included manuscripts used more than one screening method to assess PIP 
prevalence, resulting in 82 different sample screenings. Nineteen of the sample screenings were based 
on Beers 2003 criteria11, 10 on the Beers 1997 criteria31, 14 on STOPP-criteria (2008 version) 55, 8 on 
START-criteria (2008 version)55 and 7 on the PRISCUS-list16. Twenty-two sample screenings were 
carried out using compilations of the previously mentioned lists or used country specific lists such as 
the Laroche-criteria42, the improving prescribing in the elderly tool (IPET)53 or NORGEP-criteria64. Only 
two sample screenings used the Medication Appropriateness Index (MAI) but accounted however for 
the two highest mentioned prevalence rates (84% and 98%)34 80. In only 14 of the 82 sample screenings 
(17%) the complete original screening method was maintained. In all other sample screenings (n = 68), 
the screening method was adapted.  
Accordingly, large differences were seen in the method of data collection. Of the 52 included 
manuscripts, 16 collected data via patient interviews (30 sample screenings). Eleven studies used 
insurance data (16 sample screenings) while 11 manuscripts used another specific type of database 
(dispensing, prescribing or primary care database – 13 sample screenings). Four studies used medical 
records (9 sample screenings), 4 used a questionnaire, either filled in by a general practitioner or 
patient (5 sample screenings) and 6 used a combination of data sources (9 sample screenings).  
To estimate an overall conditional prevalence for different methods of data collection, different 
screening methods and possible interactions, fifty-nine sample screenings were included in the 
random effects model (parameter estimates from the model are presented in Appendix 2.1.2). Only 
the data collection method proved to be a significant predictor in the model and in addition, it appears 
that only PIP prevalence calculated from insurance data significantly differs from the other data 
collection method categories (p<.05).  
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Factors associated with PIP 
Twenty-seven of the 52 included manuscripts evaluated factors associated with overuse and misuse 
without taking underuse into consideration. Seventeen used multivariate logistic regression analyses, 
8 a bivariate logistic regression and 2 a univariate logistic regression. The studies evaluated a total of 
24 different risk factors. All risk factors, evaluated in at least 3 studies, are presented in Table 2.1.2. 
Polypharmacy, advanced age and female gender were most often taken into account, however only 
polypharmacy showed a consistent positive association with PIP. Factors that were less often taken 
into account but showed a repeated positive association in multiple studies with PIP were presence of 
depression, moderate self-rated health quality, a low functional status or a poor economic status. 
Only 2 manuscripts reviewed factors associated with underuse of medication, taking into account 
polypharmacy, advanced age and female gender in the analyses. One study found a positive 
association between underuse of medication and polypharmacy and the other between underuse and 
advanced age. One study found a negative association between underuse of medication and female 
gender23 24.  
 
Table 2.1.2: Summary of factors associated with PIP (overuse and misuse) (n = 27) 
Risk factor  No. of studies 
evaluating this risk 
factor (%) 
No. of studies 
detecting positive 
association with PIP 
(%) 
No. of studies 
detecting negative 
association with PIP 
(%) 
No. of studies 
detecting no 
association with PIP 
(%) 
Polypharmacy 27 27 (100) 0 (0) 0 (0) 
Advanced age 25 12 (48) 2 (8) 11 (44) 
Female  gender 25 10 (40) 2 (8) 13 (52) 
Comorbidity score / 
presence of comorbidities 
10 6 (60) 1 (10) 3 (30) 
Depressive feelings / 
depression 
7 5 (71) 0 (0) 2 (29) 
Reduced cognition 7 4 (57) 0 (0) 3 (43) 
Advanced education 7 1 (14) 0 (0) 6 (86) 
Moderate SRHQ 6 4 (67) 0 (0) 2 (33) 
Poor economic situation / 
low household income 
6 4 (67) 0 (0) 2 (33) 
Living alone 6 3 (50) 0 (0) 3 (50) 
Low functional status 
(using ADL-score) 
3 3 (100) 0 (0) 0 (0) 
Increasing BMI 3 1 (33) 0 (0)  2 (67) 
Recent hospital stay  3 1 (33) 0 (0) 2 (67)  
ADL: Activities of Daily Living; BMI: Body Mass Index; SRHQ: Self-Rated Health Quality 
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Drugs most frequently involved in PIP 
Forty of the 52 included manuscripts mentioned detailed drug information on 53 sample screenings 
(Appendix 2.1.3).  
Forty-seven of those 53 sample screenings used a screening method to detect overuse or misuse. 
The most frequently overused or misused drugs were: (1) anxiolytics (N05B), (2) antidepressants 
(N06A) and (3) non-steroidal anti-inflammatory and anti-rheumatic products (M01A). PIP dependent 
on an underlying diagnosis is part of misuse of drug. However, only 15 of the 47 sample screenings 
used a screening method that – additional to PIPs independent of underlying diagnosis – also included 
PIP dependent on confirmed diagnosis (e.g. different STOPP criteria, the second part of the Beers list). 
Therefore, no PIPs dependent on underlying diagnoses are mentioned in Appendix 2.1.3. We believe 
however that this information is of importance and therefore, we performed a subanalysis to detect 
these PIPs and reported them separately in a subsection of Appendix 2.1.3. Eleven of the 15 sample 
screenings taking into account underlying diagnoses used the STOPP-criteria and 4 the second part of 
the Beers list. Most frequent were (1) the long-term use of NSAIDs (>3 months) in mild osteoarthritis, 
(2) the use of calcium channel blockers in chronic constipation and (3) the use of noncardioselective β-
blockers in patients with COPD. 
The 6 remaining sample screenings used a tool to detect underuse of medication, and all made use 
of START-criteria. When considering the 10 most prevalent items of each screening, a total of 17 
different START-criteria were detected. The START-criterion most often mentioned by the included 
sample screenings was the omission of antiplatelet therapy in diabetes mellitus with co-existing major 
cardiovascular risk factors. This criterion was detected in all of the 6 sample screenings. An overview 
of the other most prevalent underused drugs detected by START-criteria is given in Appendix 2.1.3. 
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DISCUSSION 
In this systematic literature review, we evaluated the prevalence of PIP in community-dwelling 
older adults across Europe. Our review included studies evaluating all types of PIP (overuse, misuse 
and underuse) and included all studies irrespective of the fact that they presented detailed information 
on the specific PIP-items, or used a specific type of data collection. Fifty-two manuscripts were 
selected, describing 82 different sample screenings with an estimated weighted overall PIP prevalence 
of 22.6% (CI: 19.5-26.7%).  
 
PIP prevalence 
Consistent with the reviews performed by Aparasu et al.21 and Opondo et al.10 (both mainly USA 
based), our review found that about one in five older patients in Europe is exposed to PIP. This suggests 
that the possible inappropriateness of prescribing in Europe and the USA is comparable. To obtain a 
contemporary image of the problem, we only included manuscripts published after 2000. It seems 
though that the overall PIP rate hasn’t substantially decreased since the previous reviews despite 
considerable attention in the scientific literature and increasing research on this topic (22 manuscripts 
published between 2000 and 2009 compared to 30 between 2010 and 2014). Three other reviews, by 
Shade et al.18, Hill-Taylor et al.17 and Guaraldo et al87 didn’t calculate an overall PIP prevalence. Our 
estimated mean falls however within the ranges observed in these studies (22.7-74%17, 21.4-79%17 and 
11.5-62.5%87). 
The wide range in observed PIP prevalence probably relates to the wide diversity of screening 
methods used and the sometimes extensive adaptations to these screening methods. In 83% of the 
sample screenings the original screening method was adapted; either because it was not compatible 
with the applied data collection method (e.g. STOPP/START on insurance data with no clinical data 
detected significantly lower prevalence of 6% compared to 30% when used on medical record – 
Appendix 2.1.2) or because it didn’t fully match the European setting (e.g. Beers criteria). Using such 
adapted screening methods seems contra-intuitive, hampers interpretation of the data, and probably 
leads to an underestimation of the true PIP prevalence. If limited clinical data are available, the use of 
the GheOP³S-tool88 or the Matanovic criteria33 may offer a better approach, since they both present a 
comprehensive protocol that screens for overuse, misuse and underuse, are adapted to the European 
setting and do not require clinical data or confirmed diagnoses. 
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Moreover, as underuse, overuse and misuse are all types of PIP12, it is surprising that in multiple 
research, PIP prevalence is separately given for START and STOPP criteria23 69 72. Presenting the 
prevalence as the proportion of patients with at least one START or STOPP criterion might represent a 
more accurate image of PIP. Additionally, different data collection methods, differences in quality of 
prescribing across geographical regions or the status of medication review practices in the European 
countries could furthermore also have contributed to the reported wide range89 90.  
Despite the impossibility of comparing the individual sample screenings, the information presented 
in the sample screenings did give an interesting insight in the way data collection methods or used 
screening methods influence PIP prevalence (see Appendix 2.1.2). Although not significant, there is a 
trend that the combination of data collection methods leads to higher prevalence. As well, the two 
screenings that used an implicit screening method – the MAI –, showed the highest PIP prevalence. It 
will be interesting to see whether the new version of STOPP/START91, where some implicit criteria were 
added, will follow this trend and lead to higher prevalence rates.  
 
Factors associated with PIP 
Many research showed that advanced age and polypharmacy are important and independent risk 
factors for the presence of PIPs and ADEs17 87. It was however unclear whether other factors are also 
of significance and could help to further target patient groups at risk for PIPs and ADEs. The present 
evaluation of risk factors showed that polypharmacy, a low functional status, depression, a moderate 
self-rated health quality, poor economic situation, a high comorbidity score and reduced cognition are 
most often positively associated with a higher risk for PIP. It was however remarkable that from those 
studies that evaluated the association between PIP and advanced age, only in about half a positive 
association was found17 87.  
 
Drugs most frequently involved in PIP 
In concordance with previous findings10, we observed that the use of anxiolytics, hypnotics and 
sedatives are most often involved in PIP. In addition, antidepressants (such as amitriptyline and 
doxepin), NSAIDs and antithrombotic agents (such as ticlopidine and dipyridamole) are also often 
involved in PIP. One drug group that was not mentioned in previous systematic research as 
substantially associated with PIP but highly present in this review, is the “antihistamines for systemic 
use”-group.  
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In our review, we additionally focused on PIPs depending on a confirmed diagnosis and underuse 
because until now, only little systematic research on these types of PIP has been performed. It appears 
that NSAIDs are most often interfering with underlying diseases such as peptic ulcer and moderate or 
severe hypertension. In contrast to other research92-94, interactions with chronic heart failure, 
dementia and renal impairment are not often detected in our review. This discrepancy could be 
explained by the fact that many of the research included in the current review used data collection 
methods without confirmed diagnoses as 3 were solely dispensing databases, 5 were based on patient 
interviews and 7 (partially) on medical records.  
Considering underuse, the results of our review are in line with a previous review performed by 
Hill-Taylor et al., reviewing studies that used START-criteria17. Besides the underuse of calcium/vitamin 
D supplements and statin therapy, we observed that antiplatelet therapy and metformin are often 
omitted in diabetes mellitus as well as β-blockers in chronic stable angina.  
 
Strengths and limitations 
In order to obtain as much available research as possible, more than one electronic database was 
used and literature was supplemented by manually checking reference lists of all included manuscripts. 
Compared to previously published reviews10 87, this systematic review gives a larger overview of PIP, 
including underuse, drug-disease interactions and drug groups most often associated with PIP. In 
addition, the review specifically focuses on the European setting which was not the focus of any other 
previous research10 17 18 21 87. Furthermore, this is the first review summarizing all research regarding 
risk factors for PIP. By limiting the time period and including all European studies, we attempted to 
provide a contemporary and country-specific overview of PIP, offering a point of reference for 
countries in which PIP is still poorly characterized. Nevertheless, several limitations remain when 
interpreting the findings of this systematic review. Comparing results from the included manuscripts 
was difficult due to use of different inclusion criteria, different screening methods and inconsistent 
adaptations of these tools. Additionally, differences in health-care settings and countries may also 
have impacted PIP prevalence.  
 
  
 
 
 
Medication screening in the community pharmacy setting – Chapter 2  
49 
Conclusion 
This systematic review shows that PIP prevalence in community-dwelling older adults in Europe 
remains high and depends partially on the screening method used. Additionally, the review gives an 
insight in the risk factors most commonly associated with PIP and the drug groups most commonly 
involved in PIP. The results can contribute to outlining cross-border and country-specific action plans 
to reduce PIP in primary care as they represent an important opportunity to improve the prescribing 
quality in the primary care setting. There is a need for randomized controlled trials evaluating 
interventions that resolve PIP in the most cost-effective way to improve patient related outcomes such 
as quality of life and to prevent drug related problems leading to hospitalizations. A formal and 
straightforward screening method can be a great support in the evaluation of the patient’s 
pharmacotherapy, but should always be embedded in a global patient assessment by a 
multidisciplinary care team. Only then, positive effects on patients’ health outcomes can be shown95. 
Moreover, the complexity of the matter makes it unlikely that a single intervention at one point in the 
medication management process will be sufficient to tackle PIP. It had been demonstrated that 
multidisciplinary interventions including education and a systematic screening method are the most 
efficient for resolving and preventing all types of PIP96-98. 
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APPENDIX 2.1.1: DETAILED SEARCH STRATEGY OF THE SYSTEMATIC REVIEW 
A. Define text words & synonyms for the text words 
1. (elder* or senior* or geriatr* or (old* and adult*)).af. 
2. (medication and error*).af. 
3. (prescr* and error*).af. 
4. (medication and safety).af. 
5. (prescr* and safety).af. 
6. (inappropriate* and prescr*).af. 
7. (inappropriate* and medication).af. 
8. 2 or 3 or 4 or 5 or 6 or 7 
9. ((primary and care) or (office and practice) or (ambulat* and care) or (general and practice) or 
(outpatient* and care)).af 
 
B. Perform test searches – I 
10. 1 AND 8 AND 9  
11. Limit to following languages: German, Dutch, English, French & Spanish 
12. 10 AND 11 AND 2000/01/01 to present.date  
 
C. Identify “controlled vocabulary” (keywords) used for the indexing of databases (MeSH) 
12. Inappropriate prescribing (Mesh)  
13. Aged (Mesh) 
 
D. Perform test searches – II 
14. 12 AND 13  
15. Limit to following languages: German, Dutch, English, French & Spanish 
16. 14 AND 15 AND 2000/01/01 to present.date  
 
E. Remove duplicates  
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APPENDIX 2.1.2: PREVALENCE OF PIP BASED ON THE MAIN DIFFERENT SCREENING METHODS AND METHODS OF DATA 
COLLECTION 
Appendix Table 2.1.2: Prevalence of PIP based on the main different screening methods and methods of data collection 
→ Screening method used 
↓Method of Data collection  
 Beers PRISCUS START STOPP 
n = 59 – 21.06% [18.2 – 24.2]  18.6%  
[15.1 – 22.7; 30] 
21.9% 
[13.7 – 33.1; 7] 
23.6% 
[14.8 – 35.4; 8] 
25.2% 
[17.8 – 34.4; 14] 
Insurance Data 13.6% 
[9.9 – 18.2; 13] 
12.5% 
[7.8 – 19.3; 6] 
19.0%  
[11.8 – 29.2; 5] 
7.9%  
[2.3 – 23.8; 1] 
5.8% 
[1.7 - 18.5; 1] 
Prescribing, Dispensing or 
Primary health Database 
20.4% 
[12.9 – 30.7; 9] 
17.4% 
[11.5 – 25.3; 7] 
- - 34.7% 
[17.4 – 55.7; 2] 
FTF interview 23.7%  
[16.2 – 33.4; 17] 
22.9% 
[16.8 – 30.4; 11] 
25.0% 
[8.6 – 54.2; 1] 
27.9% 
[10.7 – 55.7; 2] 
24.9% 
[13.6 – 41.0; 3] 
Questionnaire 23.0%  
[13.2 – 36.8; 5] 
19.3 % 
[8.9 – 36.9; 2] 
37.3% 
[13.9 – 68.7; 1] 
25.9% 
[10.6 – 59.7; 1] 
14.6% 
[4.6 – 37.8; 1] 
Medical Record 25.2%  
[15.9 – 37.4; 8] 
15.5% 
[6.9 – 31.2; 2] 
- 27.5% 
[15.2 – 44.5; 3] 
31.1% 
[17.6 – 48.8; 3] 
Combination methods 28.3% 
[17.6 – 42.0; 7] 
27.7% 
[13.0 – 49.6; 2] 
- 28.0% 
[8.7 – 61.3; 1] 
28.6% 
[17.3 – 43.3; 4] 
All data are presented as: estimated prevalence (%) [confidence interval; number of studies used for the estimation] 
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APPENDIX 2.1.3: SUMMARY OF THE MOST PREVALENT PIPS 
Appendix Table 2.1.3: Summary of the most prevalent PIPs 
1. Overuse or misuse of drugs for older patients (47 sample screenings) 
Mentioned drug or drug group  ATC-category No. of screenings having this 
drug or drug group in top 10 of 
most prevalent PIPs (n=47) 
% of studies 
reporting this 
item in their 
top ten 
Anxiolytics 
Benzodiazepine derivatives 
Diazepam  
N05B 
N05BA 
N05BA01 
38 
 26 
 15 
81 
Antidepressants 
Amitriptyline  
Doxepin 
N06A 
N06AA09 
N06AA12 
29 
 25 
 8 
62 
Anti-inflammatory and anti-rheumatic products, non-steroids 
Indomethacin  
M01A 
M01AB01 
21 
 14 
45 
Hypnotics and sedatives 
Benzodiazepine derivatives 
N05C 
N05CD 
20 
 16 
43 
Antithrombotic agents 
Ticlopidine 
Dipyridamole 
B01A 
B01AC05 
B01AC07 
20 
 9 
 9 
43 
Antihistamines for systemic use R06A 20 43 
Antiadrenergic agents, peripherally acting 
Doxazosin 
C02C 
C02CA04 
14 
 11 
30 
Cardiac glycosides 
Digoxin 
C01A 
C01AA05 
13 
 8 
28 
Antiarrhythmics, class I and III 
Amiodarone 
C01B 
C01BC01 
13 
 10 
28 
1bis. Subanalysis: PIPs for older adults, dependent on an underlying diagnosis (15 of 47 sample screenings) 
Mentioned Drug Disease Interaction Diagnosis  No. of screenings having this 
item in top 10 of most 
prevalent PIPs (n=15) 
% 
Long-term use of NSAIDs (>3 months) Mild osteoarthritis 7 47 
Calcium Channel Blocker Chronic constipation 7 47 
Noncardioselective β-blocker COPD 5 33 
NSAID Peptic Ulcer 4 27 
Thiazide diuretic Gout 4 27 
NSAID Moderate-severe 
hypertension 
4 27 
Benzodiazepines Fallers  4 27 
2. Underuse of drugs, indicated for older patients (6 sample screenings) 
START-criterion  No. of screenings having this 
START-criterion in top 10 of 
most prevalent PIPs (n=6) 
% 
Antiplatelet therapy in DM with co-existing major cardiovascular risk factors 6 100 
Ca and VitD supplement in patients with known osteoporosis 5 83 
Statin therapy in DM if coexisting major cardiovascular risk factors present 5 83 
Metformin with DMII ± metabolic syndrome 5 83 
Statin therapy with a documented history of coronary, cerebral or peripheral vascular 
disease, where the patient’s functional status remains independent for activities of daily 
living and life expectancy is >5years 
5 83 
β-blockers with chronic stable angina 5 83 
ACE inhibitor with chronic heart failure 4 67 
Aspirin or clopidogrel with a documented history of atherosclerotic coronary, cerebral 
or peripheral vascular disease in patients with sinus rhythm 
4 67 
ACE inhibitor or AIIA in diabetes with nephropathy, i.e. overt urinalysis proteinuria or 
microalbuminuria (>30mg/24h) ± serum biochemical renal impairment 
3 50 
ACE inhibitor following acute myocardial infarction 3 50 
Regular inhaled β2 agonist or anticholinergic agent for mild to moderate asthma or 
COPD 
3 50 
ACE: Angiotensin Converting Enzyme; AIIA: Angiotensin II antagonist; Ca: Calcium; COPD: Chronic Obstructive Pulmonary Disease; DM: 
Diabetes Mellitus; NSAID: Non Steroidal Anti Inflammatory Drugs; VitD: Vitamine D 
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ABSTRACT 
 
Background. Aging of the population often leads to polypharmacy. Consequently, Potentially 
Inappropriate Prescribing (PIP) becomes more frequent. Systematic screening for PIP in older patients 
in primary care could yield a large improvement in health outcomes, possibly an important task for 
community pharmacists. In this manuscript, we develop an explicit screening tool to detect relevant 
PIP that can be used in the typical community pharmacy practice, adapted to the European market.  
 
Methods.  Eleven panellists participated in a two-round RAND/UCLA (Research and Development/ 
University of California, Los Angeles) process, including a round zero meeting, a literature review, a 
first written evaluation round, a second face-to-face evaluation round, and finally, a selection of those 
items that are applicable in the contemporary community pharmacy. 
 
Results. Eighteen published lists of PIP for older patients were retrieved from the literature, 
mentioning 398 different items. After the two-round RAND/UCLA process, 99 clinically relevant items 
were considered suitable to screen for in a community pharmacy practice. A panel of seven community 
pharmacists selected 83 items, feasible in the contemporary community pharmacy practice, defining 
the final GheOP³S-tool.  
 
Conclusion. A novel explicit screening tool (GheOP³S) was developed to be used for PIP-screening in 
the typical community pharmacy practice.  
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INTRODUCTION 
The population of older patients is increasing in most European countries1. Because of co-
morbidities and polypharmacy, in addition to age-related changes in pharmacokinetics and 
pharmacodynamics, older patients are more at risk for adverse drug events (ADEs), leading to 
increased morbidity, mortality and financial costs2 3. ADE prevalence has been shown to be associated 
with Potentially Inappropriate Prescribing (PIP)4. PIP comprises overuse, underuse and misuse of 
drugs5 and is thus a potential, though indirect, cause for increased social and economic burden1 6. 
Despite increasing awareness of PIP in older patients and its consequences, PIP prevalence remains 
high7 8.  
Several interventions aiming to reduce PIP in older patients have been proposed and evaluated9. 
Most of these interventions apply an approach that involves a (clinical) pharmacist who initiates a 
screening process using a specifically developed screening tool9. However, most of these screening 
tools have been designed and validated solely in hospitals or nursing home settings10-23, and often 
require clinical and laboratory information, usually unavailable to the community pharmacist. 
Therefore, studies that investigate PIP in primary care need to either modify or can only use portions 
of existing screening criteria24-27. Furthermore, some screening tools lack scientific evidence, are not 
yet validated in clinical practice, do not offer alternative therapeutic options or are not adapted to the 
European market10-12 22. Yet, it seems reasonable that systematic screening for PIP in older patients in 
primary care could yield a large improvement in health outcomes28.  
The community pharmacist may be ideally placed to engage in this process because of his 
medication-specific knowledge and because of the availability of an electronic dispensing record in the 
pharmacy. However, this engagement would require an evidence-based and feasible screening tool 
specifically suitable for use in the typical community pharmacy practice. Such a tool, to the best of our 
knowledge, has not yet been developed. In this manuscript, we therefore present the development of 
the GheOP³S-tool: the Ghent Older People’s Prescriptions community Pharmacy Screening tool.   
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METHODS  
Design summary 
The GheOP³S-tool was developed in five steps, based on the RAND/UCLA (Research and 
Development/University of California Los Angeles) method29. It included (i) a round zero meeting, (ii) 
a literature review, (iii) a first written Delphi round, (iv) a second face-to-face Delphi round based on 
the first round evaluation, and (v) finally, a selection of those items considered applicable in the 
contemporary community pharmacy practice.  
 
Round zero meeting 
In the round zero meeting the research team (ET, MP, AS, EM, KB) reached consensus on the 
working procedures, and on a 5-part structure for the GheOP³S-tool: Part 1: Potentially inappropriate 
drugs, independent of diagnosis, Part 2: Potentially inappropriate drugs, dependent on diagnosis, Part 
3: Potential Prescribing Omissions (PPOs), Part 4: Drug-Drug Interactions (DDIs) of specific relevance 
and Part 5: General care-related items to be addressed in the community pharmacy (Table 2.2.1). This 
structure was deliberately chosen to make community pharmacists familiar with the existence of 
different types of PIP (underuse, overuse and misuse). Furthermore, this structure offers the 
opportunity of a stepwise implementation of the tool.  
 
Literature review  
To identify previously developed screening tools for the detection of PIP in older adults, a literature 
search was performed within the PubMed database, using following terms and/or combinations: 
“elderly”, “older age”, “Aged”, “inappropriate prescribing”, “inappropriate medication”, “protocol”, 
”criteria” and “screening tool”. All articles published between January 1990 and December 2012 were 
eligible if they contained explicit criteria addressing inappropriate prescribing in older patients. For 
lists that were updated (such as Beers List), only the most recent version was included. References of 
included articles were manually searched for completeness.  
A total of 18 explicit lists were retrieved 10-23 30-33 and summarized. All mentioned items were 
classified into the 5-part-structure of the GheOP³S-tool. Criteria to withhold items for evaluation by 
the Delphi-panel were determined for each part of the tool (See Appendix 2.2.1). This way, a literature-
based list of potential items for the tool was created. Furthermore, the literature review was extended 
with an up-to-date summary of the best available scientific evidence regarding all withheld items. 
Where evidence from randomized controlled trials was missing, the review also included lower quality 
of evidence. Additionally, for each PIP item, an alternative therapeutic option was offered, relying on 
existing evidence.   
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Table 2.2.2: Drugs with high risk for anticholinergic (side-)effects (Adapted from Duran et al. 47) 
High-potency anticholinergics Low-potency anticholinergics 
Acepromazine Hydroxyzine Alimemazine Fluoxetine Prochlorperazine 
Amitriptyline Hyoscyamine Amantadine Fluvoxamine Promazine 
Atropine Imipramine Baclofen Haloperidol Quetiapine 
Belladonna Alkaloids Levomepromazine Bromocriptine Hydrocodone Ranitidine 
Brompheniramine Meclozine Carbamazepine Ketorolac Risperidone 
Chlorphenamine Nortriptyline Cetirizine Lithium Temazepam 
Chlorpromazine Orphenadrine Chlordiazepoxide Loperamide Theophylline 
Clemastine Oxybutynin Cimetidine Loratadine Tramadol 
Clomipramine Procyclidine Citalopram Loxapine Trazodone 
Clozapine Promethazine Clonazepam Meperidine 
(=Pethidine) 
Triazolam 
Cyproheptadine Propantheline Codeine Methadone  
Darifenacin Pyrilamine Cyclobenzaprine Methocarbamol   
Dexchlorpheniramine Scopolamine Diazepam Mirtazapine  
Dicyclomine Thioridazine Digitoxin Morphine   
Dimenhydrinate Tizanidine Disopyramide Olanzapine  
Diphenhydramine Tolterodine Domperidone Oxcarbazepine  
Doxepin  Trihexyphenidyl Dosulepin Oxycodone  
Flavoxate Trimipramine Entacapone Paroxetine  
Fluphenazine Tropatepine Fentanyl Phenelzine  
Homatropine  Fexofenadine Pimozide  
Remark: Tiotropium and ipratropium not included because of low risk for systemic side-effects after inhalation.  
 
First Delphi round: written individual evaluation 
The research team invited a 12-person multidisciplinary Delphi panel encompassing all decision-
making disciplines involved in geriatric care, including 4 clinical pharmacists, 2 geriatricians, 2 general 
practitioners, 2 academics, one community pharmacist, and an emergency physician. Eleven panellists 
from various European countries agreed to participate. The main selection criteria for panellists were 
acknowledged leadership in the panel member’s specialty, absence of conflicts of interest, geographic 
diversity and diversity of practice setting.  
In February 2013, all participating panellists were provided with the literature review and a scoring 
form. For each item, panellists were asked to reply to the following questions considering scientific 
evidence from the literature review and using their best clinical judgement: “How do you rate the 
added clinical value of a check on this item for an older patient by the community pharmacist?” and 
“How do you rate the proposed alternative?”. Prescribing and sales data of the proposed items were 
available to the panellists upon request. Practical aspects considering the organization of community 
pharmacies in the panellist’s country and cost implications were on the other hand specifically 
instructed to be excluded in making this judgement (e.g., access to patients’ clinical records at the 
community pharmacy had not be taken into account). All items were scored on a scale, ranging from 
1 to 9, with 1 indicating that checking for this item in the community pharmacy has no added clinical 
value or the proposed alternative was not appropriate. A score of 9 indicated that checking for this 
item in the community pharmacy has a high added clinical value or that the proposed alternative is 
highly appropriate. 
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After summarizing all panellists’ individual ratings, a preliminary list of clinically relevant items for 
the tool was created, consisting of all items with a median score in the 7-9 range and all items rated 
“with disagreement”. To define “disagreement” we used the previously developed “D9R” definition: 
“considering all ratings, at least one falls in the lowest 3-point region and at least one falls in the 
highest”. We controlled results with the IPRAS method described in the RAND/UCLA user manual, 
however no discrepancies were detected29. The panellists were also offered the possibility to add items 
and to suggest alternative treatments, which, to their judgement, would form a positive contribution 
to the screening tool. A summary of these items was made and the evidence supporting the suggested 
items was collected. These suggestions were also added to the preliminary list. Panellists were 
provided with the complete preliminary list of clinically relevant items for the tool two weeks prior to 
the second Delphi round. Only items scored with disagreement and suggested items or alternative 
treatments were to be discussed in the second Delphi round. 
 
Second Delphi round: face-to-face meeting 
During the second Delphi round in May 2013, all participating panellists were provided with their 
individual ratings and the ratings of the other group members. One general practitioner, one clinical 
pharmacist and one emergency physician could not attend, resulting in an 8-member panel. The 
moderator specifically focused the discussion on newly suggested items and on items for which there 
was “disagreement” among the panellists, as described in the RAND/UCLA manual29. After discussing 
each part of the preliminary list of clinically relevant items for the GheOP³S-tool, panellists were asked 
to re-rate the items. No attempt was made to force panellists to consensus.  
The same summarizing method was used as in the first Delphi round, with the exception that all 
items rated “with disagreement” at this stage were deleted from the list. This resulted in a final list of 
clinically relevant items for the tool, which was sent out to all panellists for final approval. 
 
Retaining items applicable in contemporary community pharmacy practice 
Finally, the research team invited a panel of 7 Belgian community pharmacists to select those items 
that were applicable in the contemporary community pharmacy practice, using the same methodology 
as in steps 3 and 4: a two-round Delphi consisting of a first written round and a second verbal round. 
Panellists were asked the following question “How do you rate the feasibility of a check on this item in 
the current community pharmacy practice?” and “How do you rate the feasibility of the proposed 
alternative strategy?”. To clarify that the goal of this developmental stadium was merely a selection of 
items that are presently applicable, pharmacists were instructed to consider practical aspects of 
pharmacy workflow and cost implications rather than assess the clinical relevance of each item.   
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RESULTS 
Literature review  
Eighteen published lists of potentially inappropriate medications for older patients were retrieved 
from the literature, mentioning a total of 398 different items, each of them categorized in one of the 
predefined parts of the GheOP³S-tool. After applying selection criteria mentioned in Appendix 2.2.1 
(e.g., availability in at least 4 European countries), a total of 121 items were retained, each 
complemented with the best available scientific evidence considering older patients. The specific lists 
used for each part of the GheOP³S-tool are displayed in Table 2.2.3. The flow of the items through the 
development process is shown in Table 2.2.4. 
Table 2.2.3: Published lists, used as basis for the GheOP³S-tool. 
 Part 1 Part 2 Part 3 Part 4 Part 5 
Beers-list (2012 update) 10 X X  X  
Austrian list12 X     
Australian list11 X X    
Laroche-criteria13 X   X  
Rancourt-criteria14 X   X  
PRISCUS-list15 X     
Lindblad-list16  X    
NORGEP-criteria17 X   X  
McLeod-criteria18 X X  X  
IPET19 X X    
START20   X   
STOPP21 X X  X  
Winit-Watjana-criteria22 X X  X  
Zhan-criteria23 X     
ACOVE-criteria30   X  X 
HARM-Wrestling report31  X X X X 
KNMP-guidelines32  X    
Hines et al33    X  
ACOVE: Assessing Care of Vulnerable Elders; HARM: Hospital Admissions Related to Medication; IPET: improving prescribing in the 
elderly tool; KNMP: Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie NORGEP: Norwegian General Practice; START: 
screening tool to alert to right treatment; STOPP: screening tool of older people's prescriptions;  
 
Table 2.2.4: Flow of the items through the development process of the GheOP³S-tool.   
 Part 1 Part 2 Part 3 Part 4 Part 5 Total 
Number of different items retrieved in the literature  188 67 22 117 4 398 
Number of items in literature-based list of potential items  53 33 7 24 4 121 
Number of items added during the first Delphi round  13 1 3 5 6 28 
Number of items in preliminary list of clinically relevant items  65 34 10 29 10 148 
→ of which to be discussed in second Delphi round because of 
‘disagreement’ 
33 13 5 17 8 76 
Number of items in final list of clinically relevant items  32 26 7 28 6 99 
Number of items in the GheOP³S-tool  31 11 6 29 6 83 
 
First Delphi round: written individual evaluation 
In the first Delphi round, panellists reached immediate consensus on 73 of the 121 literature-based 
items (Part 1: 33/53; Part 2: 21/33; Part 3: 5/7; Part 4: 12/24 and Part 5: 2/4), leaving 48 items for 
discussion in the second Delphi round. Furthermore, an additional 28 items were proposed by the 
panellists. Only one item concerning loperamide was considered of no clinical relevance and was 
omitted from the preliminary list of items for the tool. 53 of the 121 alternative therapeutic options 
were rated with disagreement and were also to be discussed in the second Delphi round.  
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Second Delphi round: face-to-face meeting 
During the second Delphi round, all items rated “with disagreement” after the first round (48 items) 
were discussed as well as the 28 additional panellist-proposed items. The panel decided to group some 
of the items together (e.g. instead of including all individually named long-acting sulfonylurea 
derivatives such as glibenclamide and glimepiride, a new item was created: “Any long-acting 
sulfonylurea derivative”) (Table 2.2.1 Part 1a). After discussion, consensus was reached for all 
proposed alternatives. After sending out the final list of 99 clinically relevant items and their 
therapeutic alternatives for approval, no further changes were requested by participating panellists.  
 
Retaining items applicable in contemporary community pharmacy practice 
The panel of community pharmacists selected 83 items that they found to be applicable in the 
contemporary community pharmacy setting. One DDI was divided into two different items because of 
feasibility of the management plan (oral antidiabetic/insulin + beta blocker replaced by: oral 
antidiabetic/insulin + non-selective beta-blocker and oral antidiabetic/insulin + cardioselective beta-
blocker). The 83 items define the final GheOP³S-tool (Table 2.2.1 and Table 2.2.2). For all of these items, 
extended information with rationales, management plans and scientific literature was compiled 
(currently only available in Dutch and French34). Items with clinical relevance for primary care, but not 
(yet) applicable in the community pharmacy practice, are displayed in Table 2.2.5. 
 
Table 2.2.5: Items deleted from each GheOP³S-part because of current inapplicability in the community pharmacy 
Part 1: Drugs, inappropriate for older patients, independent of diagnosis 
Sotalol for rate control 
Part 2: Drugs, inappropriate for older patients, dependent on diagnosis 
RAAS-inhibitors in renal impairment  
Any potassium sparing diuretic in renal impairment 
Chlortalidon and thiazides in renal impairment 
Allopurinol in renal impairment 
Amoxicillin with full dose clavulanic acid in renal impairment 
Ciprofloxacin in renal impairment 
Dabigatran in renal impairment 
Digoxin in renal impairment 
Diltiazem in congestive heart failure 
Metformin in renal impairment 
Nitrofurantoin in renal impairment 
Norfloxacin in renal impairment 
Sotalol in renal impairment 
Verapamil in congestive heart failure 
Part 3: PPOs for older patients  
When a patients has elevated total cholesterol, a statin in secondary prevention should be started when the patient has a good life 
expectancy 
Part 4: Drug-Drug interactions of specific relevance in older patients 
None 
Part 5: General care-related items for older patients to be addressed in the community pharmacy 
None 
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DISCUSSION 
Main finding of this study 
In this study, we developed the GheOP³S-tool, a screening tool consisting of 83 items for identifying 
PIP in older patients in the community pharmacy practice. The items of the GheOP³S-tool were 
categorized in 5 different parts: Part 1: Potentially inappropriate drugs, independent of diagnosis, Part 
2: Potentially inappropriate drugs, dependent on diagnosis, Part 3: PPOs, Part 4: DDIs of specific 
relevance and Part 5: General care-related items to be addressed in the community pharmacy (Table 
2.2.1 and Table 2.2.2). For every item, an alternative therapeutic option was offered.  
 
What is already known on this topic 
Worldwide, the need for PIP-screening is rising in order to reduce prevalence of ADE35 36. As PIP-
screening is part of pharmaceutical care, it is an assigned task of the community pharmacist37 38. 
Therefore, it is surprising that screening tools, specifically developed for this setting, are lacking. 
Community pharmacists have nevertheless shown to be effective in detecting PIP, even when non-
specific or adapted tools were used9 25 39. The access to both the over the counter (OTC) and 
prescription medication record is also a major benefit, as missing OTC-data is an established risk factor 
for overlooking PIP in older patients40. Moreover, including a pharmacist in a multidisciplinary team to 
approach a patient’s pharmacotherapy has been shown to be the safest and most rational way of 
prescribing9.  
 
What this study adds 
An ideal screening tool for routine use in community pharmacy practice should be user-friendly, 
evidence-based, inexpensive to apply and interchangeable between countries. To meet these 
requirements, the GheOP³S-tool was developed as an explicit screening tool designed for community 
pharmacists. Where practical issues with implicit lists may arise (i.e. often lacking the necessary clinical 
and laboratory information), an explicit screening tool provides community pharmacists with a 
reference that supports pragmatic PIP-screening in a systematic and straightforward way. Moreover, 
the explicit character of the GheOP³S-tool allows future automatization of the screening, giving 
pharmacists the time to focus on checking patient-specific relevance, on inter-care giver 
communication and on drawing up a management plan. Furthermore, the grouping of items in Part 1a 
(e.g., “any non-steroidal anti-inflammatory drug (NSAID)” instead of naming each locally marketed 
NSAID) facilitates transition between countries, where different drugs in a particular drug class are 
available. Additionally, it anticipates the commercialisation of new molecules that were not yet 
marketed at the time of the tool-development.  
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A unique aspect of the GheOP³S-tool is the incorporation of a subset of items that evaluates the 
delivery of pharmaceutical care to the community-dwelling older patient (Table 2.2.1, Part 5: “General 
care-related items to be addressed in the community pharmacy”). In this section, the community 
pharmacist checks in an implicit way whether sufficient basic pharmaceutical care is provided. This 
includes – for example – verifying the need for a medication scheme or a regular evaluation of the 
medication adherence.  
 
Limitations of this study 
The development of the presented GheOP³S-tool using the RAND/UCLA methodology has some 
limitations. However, the methodological quality of the development was guaranteed by a thorough 
selection of the participating experts, extended scientific evidence for all included items and 
information about prevalence of ADEs attributable to PIP. Moreover, the setting in which the tool 
should be used was sufficiently taken into account by adding an extra step in the development process 
and by providing panellists with access to prescribing and sales data of the proposed items. Because 
the GheOP³S-tool is designed for routine implementation, it is evident that also a feasibility study, 
which in the meantime has been initiated, is necessary.  
Additionally, as well as for all explicit screening tools, it is stressed that the screening is aimed at 
assisting in clinical decision making for the older patients and not at making the decision on its own. 
We emphasize that an eventual adaptation of the treatment plan remains the result of a shared 
decision-making process. Finally, although all currently employed pharmacists have an adequate 
education in pharmacology, basic pathophysiology, basic diagnostic testing and pharmacotherapy, PIP-
screening, on the other hand, was barely a part of the curriculum. The delivery of continuing post-
academic professional development will therefore be a prerequisite for the correct implementation of 
the GheOP³S-tool and correct interpretation of results.  
 
Implications for future research 
Since the GheOP³S-tool is specifically developed for use in the community pharmacy, it could 
address previously described and widely spread PIPs in community-dwelling older patients, such as 
long-term proton pump inhibitors (PPI) or benzodiazepine use41-43. As previous trials have shown that 
screening for PIP could have a positive clinical and economic impact44 45, a routine use of the GheOP³S-
tool in the community pharmacy practice could have an impact on patient’s health and health care 
budgets. A future (cost-) effectiveness trial should therefore study the efficacy of a screening with the 
GheOP³S-tool by a community pharmacist on patient centred outcomes (i.e. hospital admissions, 
utilisation of health care resources, etc.). This way, the clinical and content validity of the screening 
tool as well as the efficacy of screening would be evaluated.  
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Since polypharmacy and older age are major risk factors for PIPs and ADEs24 46, it is desirable to 
focus such a trial on an older population taking five or more drugs a day. However, if (limited) 
laboratory data such as renal function, would be available in trial context or in the community 
pharmacy because of policy changes, items from Table 2.2.5 can be added to the GheOP³S-tool.  
 
Conclusion 
The GheOP³S-tool is the first explicit screening tool, specifically designed for use in the community 
pharmacy practice. The developmental design of the GheOP³S-tool offers a high flexibility in terms of 
adding or modifying specific parts of the tool. The GheOP³S-tool is intended to be used for PIP-
screening in routine community pharmacy practice and to facilitate patient and caregiver 
communication. Using this tool, community pharmacists could play a supportive role as an advocate 
for the patient in which the most beneficial and clinically effective medication with the lowest possible 
risk for ADEs is delivered. Future research is required to determine whether screening for PIP with this 
tool results in detection of clinically relevant drug related problems and in optimization of drug therapy 
for older patients and whether it can reduce the cost of PIP.  
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APPENDIX 2.2.1: CRITERIA TO WITHHOLD ITEMS FOR EVALUATION BY THE DELPHI-PANEL WERE DETERMINED FOR EACH 
PART OF THE TOOL 
 
Criteria to withhold items in Part 1 (Potentially inappropriate medication for older patients, independent of 
diagnosis)  
Starting from all existing lists with explicit criteria on potentially inappropriate medication for older 
patients, independent of diagnosis, we withheld all items that were mentioned on at least 4 lists, as well as all 
OTC-available drugs mentioned on at least 1 list. Subsequently, we retained only those items considering drugs 
that are available in at least 4 European countries.  
 
Criteria to withhold items in Part 2 (Potentially inappropriate medication for older patients, dependent on 
diagnosis)  
Starting from all existing lists with explicit criteria on potentially inappropriate medication for older 
patients with certain diseases, we withheld all items mentioned on ≥2 lists. Items considering drugs not available 
in at least 4 European countries were deleted. Because of clinical relevance, 10 recommendations of the 
Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie (KNMP)32 and the HARM-Wrestling 
report31 concerning drugs administered in patients with renal impairment were added to the list. 
 
Criteria to withhold items in Part 3 (Potential Prescribing Omissions)  
Starting from all existing lists with explicit criteria on potential prescribing omissions in older patients, 
we only withheld items confirmed by recommendations of the HARM-Wrestling report31 or ACOVE quality 
indicators30. Items considering drugs not available in at least 4 European countries were deleted. 
 
Criteria to withhold items in Part 4 (Drug-Drug interactions of specific relevance in older patients)  
Starting from all existing lists with explicit criteria on drug-drug interactions (DDI) of specific relevance 
in older patients, we only withheld  DDIs of which clinical relevance in older patients was confirmed through the 
HARM-Wrestling report31 or the systematic review of Hines et al33. DDIs considering drugs not available in at least 
4 European countries were deleted.  
 
Criteria to withhold items in Part 5 (General care-related items for older patients to be addressed in the 
community pharmacy)  
Starting from all existing lists with explicit criteria on General care-related items for older patients to be 
addressed in the pharmacy, we withheld items if they have a contribution to drug-related problems (e.g. 
recording of fall frequency and long-term benzodiazepine use). None of the lists mentioned care-centred items. 
However, ACOVE-criteria30 and the HARM-Wrestling report31 mentioned four care-related items. For each of 
these statements, scientific evidence for being on the list was evaluated. 
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ABSTRACT 
 
Purpose: The Ghent Older People’s Prescriptions community Pharmacy Screening (GheOP³S-) tool was 
recently developed as an explicit screening method to detect Potentially Inappropriate Prescribing 
(PIP) in the community pharmacy. We aimed to validate the GheOP³S-tool as an effective screening 
method for PIP.   
 
Methods: All patients admitted to the acute geriatric ward at the Sint-Vincentius hospital (Deinze, 
Belgium) were consecutively screened for inclusion (≥70 years and ≥5 drugs chronically). PIP 
prevalence was evaluated by applying the GheOP³S-tool on the complete medication history. For each 
PIP-item, clinical relevance of the detected item, relevance of proposed alternative and subsequent 
acceptance by the geriatrician were evaluated. Additionally, contribution to the current admission and 
preventability were assessed. The completeness of a PIP-screening with the GheOP³S-tool was 
evaluated through comparison with the adapted Medication Appropriateness Index (aMAI). 
 
Results: We detected 250 GheOP³S-items in 57 of 60 included patients (95%) (Median: 4 PIP-items per 
patient; IQR: 3-5). Clinical relevance was scored ‘serious’ for 182 items (73%) and ‘significant’ for 67 
items (26%). Proposed alternative treatment plans were accepted for 79% of the PIP-items (n=198). 
The aMAI detected 536 items, of which 145 were incorporated in 131 PIP-items detected by the 
GheOP³S-tool. 119 PIP-items were additionally detected by the GheOP³S-tool.  
 
Conclusion: The clinical relevance of the PIP-items detected with the GheOP³S-tool is high, likewise the 
acceptance rate of proposed alternatives. One third of the items detected by the aMAI were found 
using the GheOP³S-tool and a substantial amount (18%) of extra PIP-items, considered relevant by the 
physician, were only detected by the GheOP³S-tool.  
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INTRODUCTION 
Multimorbidity and associated polypharmacy are very common in older people. Combined with 
changed pharmacodynamics and pharmacokinetics, this leads to a higher risk of drug related problems 
(DRPs) 1 2. DRPs can cause hospitalization and about half of those admissions seem preventable3 4. 
Potentially Inappropriate Prescribing (PIP) is established as one of the main factors, associated with 
DRPs 5-9. PIP is defined as “the prescribing of medication that could introduce a significant risk of a DRP, 
in particular when there is an equally or more effective alternative with lower risk available” 10 11. There 
are three main categories of PIP: overprescribing, underprescribing and misprescribing 12.  
Multiple screening methods are currently used to identify PIP, both implicit and explicit. Implicit 
methods such as the (adapted) Medication Appropriateness Index (MAI) judge the appropriateness of 
therapy using clinical information of an individual patient 13 14. Explicit methods on the other hand, 
consist of lists of drugs that should be avoided or started in certain clinical conditions15 16. Both 
methods are most often applied by general practitioners, specialists or hospital pharmacists.  
Recently however, the Ghent Older People’s Prescription community Pharmacy Screening 
(GheOP³S-)tool was developed to identify PIP with high clinical relevance in primary care settings with 
limited or no information about the clinical situation of the patient. A screening with the GheOP³S-tool 
specifically aims at initiating a multidisciplinary medication review in primary care, on the basis of the 
detailed medication history available in the patient’s pharmacy 17. The GheOP³S-tool is an explicit 
method, consisting of 83 items, categorized into 5 parts (Table 2.3.1) 17. For each PIP-item on the list a 
rationale, an alternative treatment plans and scientific background are provided. In a previous 
observational study, conducted in 204 Belgian community pharmacies, the usability and feasibility of 
the GheOP³S-tool were positively evaluated (personal communication, unpublished results). However, 
the clinical relevance of the detected items, as well as a possible contribution of the detected items to 
hospital admissions has not yet been evaluated. This is however essential in order to evaluate whether 
the initial goal of the GheOP³S-tool (detecting items with a high clinical relevance), was achieved. If 
this goal could be confirmed, a systematic application of the GheOP³S-tool by the community 
pharmacy, might uncover PIP in a very early stage and therefore prevent possible DRPs.  
Therefore, in this study the GheOP³S-tool was applied on the medication history upon admission of 
older patients with polypharmacy, admitted to an acute geriatric ward. The results of the GheOP³S-
screening by the pharmacist were communicated to the treating geriatrician. The specific aims were 
to evaluate the clinical relevance of the PIP-items, detected with the GheOP³S-tool, the acceptance of 
the proposed alternative treatment plans and the possible contribution of the detected PIP-items to 
the current hospitalization. Finally, we aimed to evaluate the completeness of a PIP screening using 
the GheOP³S-tool, compared to a full clinical medication review, conducted with the aMAI. 
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METHODS  
Study design, setting and participants 
From October 2014 to March 2015, a prospective observational single centre study was performed 
at the Sint-Vincentius hospital in Deinze (Belgium). All patients admitted to the acute geriatric ward 
were consecutively screened for inclusion. Patients could be included if they were 70 years or older 
and chronically taking 5 or more drugs. Patients were excluded if they were already admitted to the 
hospital during the 3 previous months. Failures and refusals were documented. The study was granted 
ethical approval from the Ghent University Hospital. A written informed consent was provided, either 
by the patient or by the legal representative.  
 
Data collection 
For each patient, data on age, gender, living situation, reason for admission, medical history, 
relevant laboratory data and drug use (dose, frequency of treatment) were obtained by the treating 
geriatrician, based on the (hetero-)anamnesis and the medical record. Drug use was obtained at 
admission, based on the procedure of Nielsen et al (Appendix 2.3.2), resulting in a preliminary 
medication history 18. Additionally, the participants’ community pharmacist was contacted to obtain 
all data about both prescribed and Over-The-Counter (OTC-)medication, previously stopped drugs and 
non-chronic therapy (e.g. vaccination), resulting in the complete medication history. Discrepancies 
between the preliminary and the complete medication history and their involvement in PIP were also 
recorded. 
 
Table 2.3.1: The GheOP³S-tool & the adapted MAI 
The GheOP³S-tool The adapted MAI 
Part 1 Potentially inappropriate drugs, independent of 
diagnosis – Drug classes 
1 Indication  
 Potentially inappropriate drugs, independent of 
diagnosis – Specific molecules 
2 Choice 
Part 2 Potentially inappropriate drugs, dependent of 
diagnosis – Drug classes 
3 Dosage  
 Potentially inappropriate drugs, dependent of 
diagnosis – Specific molecules 
4 Correct directions/Modalities 
Part 3 Potential Prescribing Omissions 5 Drug–drug interactions 
Part 4 Drug-Drug Interactions (DDIs) of specific relevance 6 Drug–disease interactions 
Part 5 General care-related items to be addressed in the 
community pharmacy 
7 Duration 
  8 Adverse drug reaction 
   Underuse 
GheOP³S: Ghent Older People’s Prescription community Pharmacy Screening 
MAI: Medication Appropriateness Index 
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PIP prevalence 
PIP prevalence was evaluated by applying the GheOP³S-tool. In this study, Part 1 to Part 4 was used 
(item 1 to item 77) (Table 2.3.1). The PIP-screening with the GheOP³S-tool was performed by a 
pharmacist (ET) within 24 hours after patient inclusion and was based on the complete medication 
history. For each patient, a report was made to the treating geriatrician (CK) containing information 
about detected PIP-items, rationale and a possible alternative treatment plan (e.g., withdrawal 
scheme, alternative therapy options etc.).  
 
Estimating clinical relevance of detected PIP-items 
The validated method of Overhage et al 19 was used to measure the severity of the detected PIP-
items and the value of the pharmacist’s recommendations. First, the severity of the detected PIP was 
analysed and classified into ‘potentially lethal’, ‘serious’, ‘significant’, ‘minor’ and ‘no error’. This 
quantifies the potential impact of the adverse outcome that could have resulted if the pharmacist had 
not intervened. Second, evaluation of the value of the pharmacist’s clinical intervention was 
categorized into ‘extremely significant’, ‘very significant’, ‘significant’, ‘somehow significant’, ‘no 
significance’ and ‘adverse significance’ (Appendix 2.3.1) 19. This represents the potential impact of the 
pharmacist’s recommendations on the patient’s care. The clinical relevance of the detected PIP-items 
was evaluated by the treating geriatrician (CK). In case of doubt, another out-of-hospital geriatrician 
(MP) was consulted until consensus was reached. 
 
Evaluating acceptance of proposed alternative treatment plans 
The geriatrician’s acceptance of the proposed alternative treatment plan was categorized as ‘fully 
accepted’, ‘partially accepted’ or ‘not accepted’. The latter could be due to intolerance, the patient not 
accepting the change or insufficient reason for stopping or starting therapy. Furthermore, the patient 
could be palliative. If the drug information was incorrect or incomplete the term ‘not applicable’ was 
used. 
 
Correlation with hospital admission 
The determination of a (possible) contribution with the current hospital admission was based on a 
previously published method 20. The contribution was categorized as ‘dominant’, ‘partly contributing’, 
‘less important’ or ‘non-contributing’, meaning that the DRP is the main, the substantial or the minor 
reason for admission or had no influence on the admission, respectively. The correlation between the 
detected PIP-items and the current hospital admission was evaluated by the treating geriatrician (CK). 
In case of doubt, another out-of-hospital geriatrician (MP) was consulted until consensus was reached. 
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Furthermore, the preventability of the detected PIP-items that were positively associated with the 
current hospital admission was evaluated, using a previously published method21 
 
Comparing GheOP³S to a full medication review 
To evaluate the completeness of a PIP-screening, using the GheOP³S-tool, we compared it to the 
results of a full clinical medication review obtained by applying the aMAI. This is an implicit instrument 
developed for hospitalized older patients using 8 criteria to assess the appropriateness of each drug 
(Table 2.3.1). An overall MAI score is calculated using weighted factors for each item 14. The aMAI was 
applied on the complete medication history, with access to medical file including diagnosis and 
laboratory data, by a clinical pharmacist (AS), extensively trained in geriatric pharmacotherapy.  
 
Statistical Analysis 
Prevalence of PIP-items is described as the number of patients with at least one PIP. Additionally, 
the median number of PIP-items with inter quartiles ranges (IQR) per patient is presented. Basic 
characteristics will be described appropriately by means of standard deviations, medians with IQRs 
and counts with percentages.  
 
  
 
 
 
Medication screening in the community pharmacy setting – Chapter 2  
83 
RESULTS 
We screened 158 patients for eligibility, of which 60 were eventually included in the study (Figure 
2.3.1). Mean age of the patients was 86 years (SD = 6) and 48 were female (80%) (Table 2.3.2). The 
included population used a total of 610 drugs, with a mean of 10.2 drugs per patient (SD = 3.2). Most 
frequent drug classes are reported in Table 2.3.2. For 25 of the included patients the preliminary 
medication history, obtained at admission, was not consistent with the information from the 
community pharmacy. We detected 63 medication discrepancies, mostly concerning missing drugs. 
 
 
Figure 2.3.1: Flowchart of patient inclusion 
 
 Table 2.3.2: Basic characteristics of the included population (n=60)   
Age, Mean (SD) 85.7 6.5 
 Age ≥ 85j, n (%) 31 52% 
Female gender, n (%) 48 80% 
No. of drugs, median (IQR) 10 8-12 
No. of drugs, mean (SD) 10.2 3.2 
Living situation, n (%)   
Ambulant with minimal (≤ 1 time a week) professional helpa 18 30% 
Ambulant with (> 1 time a week) professional helpa  23 38% 
Residential care 19 32% 
Reason for admission, n (%)   
Fall incident 11 18% 
Pneumonia 8 13% 
Bronchitis 8 13% 
Deterioration of general condition 6 10% 
Severe gastro-enteritis 5 8% 
Syncope 4 7% 
Confusion 3 5% 
Other 15 25% 
Comorbidities, n (%)   
Cardiovascular Disease 47 78% 
Dementia 17 28% 
Osteoporosis 17 28% 
Diabetes 16 27% 
Obstructive Lung Disease 7 12% 
Parkinson’s disease 4 7% 
Depression 1 2% 
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Table 2.3.2 (Continued): Basic characteristics of the included population (n=60)   
Drug use of the included population, n (%)   
ANTITHROMBOTIC AGENTS 42 70% 
Platelet aggregation inhibitors excl. Heparin 34 57% 
Vitamin K antagonists 9 15% 
DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE  32 53% 
Proton pump inhibitors 28 47% 
H2-receptor antagonists 5 8% 
OTHER ANALGESICS AND ANTIPYRETICS 28 47% 
Anilides (i.e. paracetamol, possibly in combinations) 27 45% 
Salicylic acid and derivatives 2 3% 
ANTIDEPRESSANTS 25 42% 
Other antidepressants 13 22% 
Selective serotonin reuptake inhibitors 12 20% 
Non-selective monoamine reuptake inhibitors 2 3% 
DRUGS FOR CONSTIPATION 25 42% 
Osmotically acting laxatives 22 37% 
Contact laxatives 4 7% 
Bulk-forming laxatives 2 3% 
LIPID MODIFYING AGENTS, PLAIN 26 43% 
HYPNOTICS AND SEDATIVES 25 42% 
Benzodiazepine derivatives 15 25% 
Benzodiazepine related drugs 8 13% 
Other hypnotics and sedatives 3 5% 
BETA BLOCKING AGENTS 24 40% 
aProfessional help defined as help by a nurse or ‘home help' with a fixed visiting regimen 
 
PIP exposure according to the GheOP³S-tool 
In total, 250 GheOP³s-items were detected in 57 patients (95%), resulting in a median of 4 PIP-items 
per patient (interquartile range: 3-5). Most frequent detected items are listed in Table 2.3.3. The 
complete prevalence list is presented in Appendix 2.3.3. The 63 detected medication discrepancies 
were involved in 20 PIP-items detected with GheOP³S-tool. 
 
Table 2.3.3: Most prevalent PIP-items according to the GheOP³S-tool 
 GheOP³S-item No. of 
patients 
% of patients 
(n=60) 
1 The patient has an elevated risk for osteoporosis (determined via FRAX-tool) and is not prescribed 
Calcium/Vitamin D supplementation 
41 68% 
2 Any intermediate acting benzodiazepine or Z-product at full dose or any dose ≥30 subsequent days 27 45% 
3 Any antidepressant ≥1year 24 40% 
4 The patient is not reminded and proposed to undergo yearly influenza vaccination 18 30% 
5 Any combination of anticholinergic drugs 16 27% 
6 Anticholinergics with constipation 15 25% 
7 The patient is taking narcotic analgesics and is not prescribed appropriate preventative bowel regimen 
(preferably macrogol or lactulose) 
10 17% 
8 Any PPI at full dose ≥8 weeks 9 15% 
9 Tramadol 7 12% 
10 Any short  or long-acting benzodiazepine 6 10% 
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Estimating clinical relevance of detected PIP-items 
None of the detected GheOP³S items were estimated as potentially lethal. Of the 250 PIP-items 
detected by the GheOP³S-tool, 182 (73%) were classified as serious and 67 (27%) as significant. One 
item was classified as ‘no error’.  
Second, the evaluation of the value of the pharmacist’s clinical interventions for these PIP-items 
resulted in the categorization of 6 items (2%) as ‘very significant’, 235 items (94%) as ‘significant’, 7 
items (3%) as ‘somehow significant’ and 1 item as ‘not significant’ (Table 2.3.4). 
 
Evaluating acceptance of proposed alternative treatment plans & contribution to hospital admission 
The geriatrician fully accepted 52% of the proposed alternative treatment plans (n=130) and 
partially accepted 27% (n=68). Eighteen percent (n=44) of the alternative treatment plans were not 
accepted. Main reasons for not accepting are presented in Table 2.3.4, the majority being insufficient 
reason to stop or start. 
Of the 250 PIP-items, 3 dominantly contributed to the current hospitalization. These 3 PIP-items 
appeared in 3 different patients. They consisted of the type and side-effects of an opioid in two cases 
and the long-term use of a high dose of benzodiazepine in the other case. Two of these 3 PIP-items 
were preventable, one not. Eleven detected PIP-items (present in 6 different patients) partially 
contributed to the hospitalization. All of these PIP-items were preventable. In total, for 9 patients 
(15%), the hospitalization was considered related to a PIP, detected with the GheOP³S-tool (Table 
2.3.4).  
 
Comparing the GheOP³S-tool to a full medication review 
The screening with the aMAI detected a total of 536 items. Of these 536 items, 145 items (27%) 
had also been detected with the GheOP³S-tool, albeit within only 131 of the 250 items. This is a 
consequence of duplicate detections. For example, according to the aMAI-score, long-term treatment 
with a full dose PPI was noted as two items (‘dosage’ and ‘duration’), where the GheOP³S-tool detects 
this as 1 PIP-item. On the other hand, the GheOP³S-tool detected 119 items that were not detected by 
the aMAI. Figure 2.3.2 describes in detail the type of items, the clinical relevance, acceptance, hospital 
contribution and most frequently detected ATC-codes of the 145 items commonly detected by the 
GheOP³S-tool and the aMAI, as well as of the 119 items additionally detected only by the GheOP³S-
tool.  
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Table 2.3.4: Clinical relevance of the items detected with the GheOP³S-tool, the value of the pharmacist’s clinical intervention, the 
acceptance of the proposed alternative treatment plans and contribution to hospital admission (n=250) 
 No. of items detected 
by GheOP³S 
% (n=250) 
Severity of detected PIP 
Potentially lethal 0 0% 
Serious  182 73% 
Significant  67 27% 
Minor  0 0% 
No error 1 0% 
 No. of items detected 
by GheOP³S 
% (n=249) 
Value of pharmacists’ clinical intervention 
Extremely significant 0 0% 
Very significant 6 2% 
Significant  235 94% 
Somehow significant 7 3% 
No significance 1 0% 
Adverse significance 0 0% 
Acceptance of the proposed alternative treatment plans 
Fully accepted 130 52% 
Partially accepted 68 27% 
Not accepted 44 18% 
Intolerance for higher dose 0 0% 
Not accepted by the patient 8 18% 
Insufficient reason  for stop or start 36 82% 
Palliative patient 0 0% 
Not applicable 7 3% 
Already applied by the patient 7 100% 
Deceased patient 0 0% 
Contribution with hospital admission 
Dominant 3 1% 
Partly  11 4% 
Less important 24 10% 
Non-contributing 211 85% 
GheOP³S: Ghent Older People’s Prescriptions community Pharmacy Screening; MAI: Medication Appropriateness Index  
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DISCUSSION  
In this study, we applied the GheOP³S-tool to the complete medication history of 60 older patients 
with polypharmacy, hospitalized at an acute geriatric ward. At least one PIP was detected in 95% of 
patients, with a median of 4 PIP-items per patients (IQR: 3-5). The clinical relevance of the detected 
PIP was considered ‘serious’ for 73% of the detected items and ‘significant’ for the remaining 27%. 
Additionally, acceptance rates were high, with a full or partial acceptance of the proposed alternative 
treatment plans in 79% of cases. Fourteen PIPs, detected in 9 patients, were dominantly or partly 
contributing to the current hospital admission.  
The GheOP³S-tool mainly detects PIP-items related to duration of therapy, underuse of medication 
and DDIs. However, all types of PIP (underuse, overuse and misuse) were at least detected once. This 
supports the validity of the GheOP³S-tool as an all-round screening tool that tackles all types of PIP17. 
Also, as practically all detected items were considered relevant by a geriatrician, the developmental 
goal of the GheOP³S-tool – to deliver a tool that detects PIP-items with high clinical relevance – was 
confirmed17.   
The acceptance of the proposed alternative treatment plans was remarkably high (79% of proposed 
alternative treatment plans were accepted), since acceptance has been a troublesome step in the 
implementation process of multiple other trials22 23. This high rate could be explained by multiple 
factors. First, the pharmacist felt empowered by the availability of substantial scientific background. 
Second, the close collaboration between the geriatrician and pharmacist and the quick exchange of 
information to one another was a decisive factor for implementing specific recommendations. This 
suggests that the possibility for immediate mutual contact is an environmental prerequisite for an 
optimal medication review process. As well, all researchers had a positive attitude towards the 
implementation of medication review in the current practice. There were no constraints towards 
executing the review within the present time-frame, meeting for follow-up consultations or sharing 
necessary patient data.  
For a significant amount of patients (15%), the hospitalization was to a certain extent related to a 
PIP-item detected with the GheOP³S-tool. Three PIPs in 2 patients seemed to dominantly contribute 
to the hospital admission, which could have been avoided if the PIP-item had been detected 
beforehand. This shows that medication review in the primary care setting may have a substantial 
impact on health care utilization. However, this has to be confirmed by a larger, controlled study.  
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The GheOP³S-tool detected one third of PIP in comparison with a full clinical medication review. 
The items that are commonly detected by the aMAI and the GheOP³S-tool mainly concern the long-
term use of drugs that influence the central nervous system (i.e. antidepressants, anxiolytics, hypnotics 
and sedatives), the underuse of calcium/vitamin D supplements and the use of NSAIDs in pain 
management. In addition, concerning the 119 items that are solely detected by the GheOP³S-tool a 
significant amount of DDIs (mainly combinations of anticholinergic drugs) were observed, as well as 
the underuse of influenza vaccination and DDIs with corticosteroids for systemic use.  
All of the items, whether commonly detected by the aMAI and the GheOP³S-tool or solely by the 
GheOP³S-tool, are considered of ‘serious’ or ‘significant’ relevance. Comparison with results from 
other studies is challenging as some studies used adapted classifications. The study of Bosma et al23 
for example rated a pharmacists’ recommendations based upon drug related problems such as 
inappropriate drug choice, inappropriate dosing, therapeutic duplication, side effects, and drug–drug 
interactions using the method of Overhage et al 19, but merging the severity of the detected PIP-items 
and the value of the pharmacist’s recommendations . Eventually, thirty to fifty percent of interventions 
were rated as (extremely) significant. Somers et al 24 on the other hand, only used the value of the 
pharmacist’s recommendations part of the method of Overhage et al 19, however rating the 
recommendations as ‘(very) significant’ in 58% of cases and ‘somehow significant’ in  38% 24. Both 
studies observed lower significance than in our study, which could be due to the fact that the 
assessment was done retrospectively by independent raters, and that implicit detection methods were 
used in both trials. Implicit methods are all-embracing and therefore inherently also detect minor 
problems. During the developmental process of the GheOP³S-tool though, it was a specific goal to only 
withhold items with high clinical relevance for primary practice 17. 
Furthermore, as the GheOP³S-tool detects additional clinically relevant PIP-items, our results 
confirm that using the GheOP³S-tool – an explicit method – is complementary to an implicit method 
and has therefore an added value for the medication review process. Other methods, such as the 
Systematic Tool to Reduce Inappropriate Prescribing, also effectively used the combination of implicit 
and explicit methods25. This can be explained by the fact that implicit methods rely on the knowledge 
and attitudes of the user and are therefore very much rater-dependent. It is evident that for example 
not all interactions are known by heart.   
  
  
 
 
 
Medication screening in the community pharmacy setting – Chapter 2  
91 
Strengths and limitations  
Obtaining a complete medication history was a significant strength in this study. Contacting the 
patient’s community pharmacy provided important additional information concerning the medication 
use of the patient. In almost half of the included population there were multiple discrepancies between 
the patient-provided list and the dispensing database provided by the community pharmacy, which 
delivered 20 extra PIP-items during screening by the GheOP³S-tool.  
On the other hand, this study has some limitations. First, only one geriatrician estimated the clinical 
relevance, evaluated the proposed alternative treatment plan and determined a contribution with the 
hospital admission. However, this was partly corrected with the consensus method, made in case of 
doubt about the right categorization.  Second, the study includes only 60 patients. Nevertheless, it still 
supports that using an explicit method such as the GheOP³S-tool is complementary to an implicit 
method in the medication review process.  
  
Future perspectives  
Performing medication review is an initiative that captures the priorities and aims of current 
guidelines concerning medicines optimisation26. However, the success of medication review on patient 
related outcomes relies on its integration into primary care as PIPs leading to hospitalization can then 
still be prevented. To achieve this, multiple barriers, including insufficient integration, underdeveloped  
relationships  between  a  patient’s pharmacist and general practitioner, relatively  inaccessible  patient 
records, poorly devised strategies for targeting services and the reluctance of some health care 
workers to involve in medication review processes, still have to be tackled and have – until now – 
hampered the implementation of community pharmacy-led clinical services 27-29.  
Facilitation is needed but is however possible as the GheOP³S-tool is an explicit method. This 
enables a complete digital integration into the pharmacy software and would facilitate routine PIP-
screening. Additionally, tailoring the software systems to ease (local) pharmacist-physician 
communication is required. Nevertheless, to confirm the value of a systematic screening with the 
GheOP³S-tool including follow-up pharmacist-physician contacts in the primary care setting, the 
application on a larger scale in a controlled trial is needed. Besides hospitalizations and health care 
utilization, such a study should also include patient centred outcomes such as quality of life and 
satisfaction.  
Further analysis of the aMAI items not detected by the GheOP³S-tool will offer the opportunity to 
optimize the GheOP³S-tool. The current data will reveal the items with high clinical relevance and those 
that are highly related to hospital admissions. 
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Conclusion  
The clinical relevance of the PIP-items detected with the GheOP³S-tool is high, as well as the 
acceptance of the proposed alternative treatment plan. About one third of the items detected by a 
clinical medication review were detected using the GheOP³S-tool. Furthermore, a substantial amount 
of extra PIP-items were detected by the GheOP³S-tool, all of which considered relevant by the clinician. 
The advantage of the GheOP³S-tool is the application on a regular basis in the community pharmacy, 
with limited or no information about clinical situation of the patient, but with detection of clinically 
relevant PIP-items. Therefore, application of the GheOP³S-tool has the potential of preventing drug 
related problems and hospitalizations in older community dwelling patients with polypharmacy. 
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APPENDIX 2.3.1: METHOD OF OVERHAGE ET AL TO MEASURE THE SEVERITY OF THE DETECTED PIP-ITEMS AND THE 
VALUE OF PHARMACIST’S RECOMMENDATION 
 
Appendix 2.3.1: Method of Overhage et al to measure the severity of the detected PIP-items and the value of pharmacist’s 
recommendation 
OVERHAGE ET AL – SEVERITY OF DETECTED PIP OVERHAGE ET AL – VALUE OF PHARMACIST’S RECOMMENDATION 
Potentially lethal Extremely significant 
 High potential for life-threatening adverse reactions 
 Potentially lifesaving drug at a dosage too low for the disease 
begin treated 
 High dosage (≥ 10 times normal) of drug with low therapeutic 
index 
 Recommendation qualified by extremely serious 
consequences or potential life-and-death situation 
Serious Very significant 
 Route of administration could lead to severe toxicity 
 Low dosage of drug for serious disease in patient with acute 
distress 
 High dosage (4-10 times normal) of drug with low therapeutic 
index 
 Dosage resulted in serum drug concentration in potentially 
toxic range 
 Drug could exacerbate the patient’s condition (related to 
warnings or contraindications) 
 Misspelling or mix-up in medication order could lead to 
dispensing of wrong drug 
 Documented allergy to drug 
 High dosage (10 times normal) of drug without low 
therapeutic index 
 Omission of pre-test for drug hypersensitivity 
 Recommendation qualified by a potential or existing 
dysfunction in a major organ 
 Avoidance of serious adverse drug interaction or 
contraindication to use 
Significant Significant 
 High dosage (1.5-4 times normal) of drug with low therapeutic 
index 
 Drug dosage too low for patient’s condition 
 High dosage (1.5-10 times normal) of drug without low 
therapeutic index 
 Errant dual-drug therapy for single condition 
 Inappropriate dosage interval 
 Omission from medical order 
 Recommendation would bring patient care to a more 
acceptable, appropriate level (i.e., standard of practice), 
including quality-of-life issues with evidence from the 
patients or documentation elsewhere, as well as issues of 
cost and convenience. 
Minor  Somehow significant 
 Incomplete information in medication order 
 Unavailable or inappropriate dosage form 
 Nonformulary drug 
 Noncompliance with standard formulation and hospital 
policies 
 Illegible, ambiguous or nonstandard abbreviation 
 Patient’s benefit from the recommendation could be 
neutral depending on professional interpretation (to 
distinguish this rank from rank 3, where a standard of 
practice would support the recommendation) 
 More information or a clarification must be obtained by 
the pharmacist from the physician, nurse, or other 
appropriate health care professional before an order can 
be processed.  
No error No significance 
 Information or clarification requested by physician or other 
health care professional from pharmacist 
 Cost savings only  
 Information only 
 Recommendation not patient specific 
 Adverse significance  
  Recommendation inappropriate; its implementation may 
lead to adverse outcomes 
 
  
 
 
 
Medication screening in the community pharmacy setting – Chapter 2  
95 
APPENDIX 2.3.2: PROCEDURE FOR RECRUITING AT THE GERIATRIC WARD 
 
Appendix Table 2.3.2: Procedure for recruiting at the acute ward / geriatric wad 
Workflow  Task Procedure 
Patient is 
admitted to 
acute ward 
and referred 
to the 
geriatric 
ward 
Screen  Inclusion criteria: 
- Patient ≥ 70 years 
- Unplanned hospitalization 
 First hospitalization 
 Repeated hospitalization: only one inclusion 
possible & no hospitalization till 3 months before 
- ≥ 5 chronic medications 
 Patient or legal representative wants to take part of the study (cfr. 
informed consent) 
If inclusion 
criteria are 
fulfilled 
Compile relevant medical information 
 
 
 
 
 
Compile preliminary medication list 
 Check relevant sources for information on 
- Medications, if present: 
- Previous medical records 
- Referral papers 
- Home care or nursing home notes, or personal medication 
lists 
 Medication history 
- Compile medication history using the patient own 
medication and/or preliminary medication list as interview 
guide 
- Ask specifically for OTCs such as; pain-, allergy- or 
alimentary preparations. 
- Ask specifically for herbal- and dietary supplements 
- Ask specifically for non-oral medications, such as; 
inhalation-, ophthalmic-, dermatologic-, nasal-, sublingual-, 
or rectal preparations 
- Ask for the patient’s perceived effect of the medication 
- Ask about compliance and adverse drug reactions 
- Ask about known allergies or alerts, such as; antibiotics, 
opiates, NSAIDs, iodide, food dyes 
- Also ask relatives or caregivers if they are present, especially 
if patient has aphasia, dyspnoea or otherwise cannot 
participate well in the interview 
 Explain purpose of the interview 
 Obtain patient’s own medication if present 
 Comprise medication history using the patient own medication and/or 
preliminary medication list as interview guide 
 Ask if the patient has drug-related questions 
 Contact generalist if needed 
 Ask pharmacy 
If medication 
history is 
complete as 
possible 
Obtaining more information  Contact community pharmacy by pharmacist (medication history past 6 
months and OTC medication) 
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APPENDIX 2.3.3: COMPLETE PREVALENCE LIST ACCORDING TO THE GHEOP³S-TOOL  
Appendix Table 2.3.3: Complete prevalence list according to the GheOP³S-tool 
No. GheOP³S-criterion N, % (relative to 
total population, 
n=60)  
N, % (relative to 
diagnosis positive 
patients) 
Part 1b: Potentially inappropriate drugs, independent of diagnosis – Drug classes 
1 Any antidepressant ≥1year 24 40%  
2 Any antipsychotic drug ≥1 month 5 8%  
3 Any drug for arterial vascular disorders  3 5%  
4 Any intermediate acting benzodiazepine or Z-product at full dose or any dose ≥30 
subsequent days 
27 45%  
5 Any short or long-acting benzodiazepine  6 10%  
6 Any long-acting sulfonylurea derivative  5 8%  
7 Any nasal vasoconstrictor ≥1 month 0 0%  
8 Any oral NSAID 6 10%  
9 Any PPI at full dosea ≥8 weeks  9 15%  
10 Any recently marketed drug (black triangles) 2 3%  
11 Any sedating antihistaminic drug  2 3%  
Part 1b: Potentially inappropriate drugs, independent of diagnosis - Specific molecules 
12 Alizapride 2 3%  
13 Bisacodyl 1 2%  
14 Clonidine 0 0%  
15 Codeine and its derivatives for acute cough 0 0%  
16 Dabigatran 0 0%  
17 Digoxin >0,125mg/day 0 0%  
18 Dipyridamole monotherapy (without ASA) 2 3%  
19 Ginkgo biloba or Panax ginseng 1 2%  
20 Liquid paraffin 0 0%  
21 Methyldopa  0 0%  
22 Metoclopramide 1 2%  
23 Pentazocine 0 0%  
24 Phenobarbital 0 0%  
25 Pseudoephedrine oral 0 0%  
26 Rivaroxaban or Apixaban 0 0%  
27 Senna glycosides 0 0%  
28 Picosulfate 3 5%  
29 Theophylline 1 2%  
30 Ticlopidine, new prescription 0 0%  
31 Tramadol, new prescription 7 12%  
Part 2a: Potentially inappropriate drugs, dependent on diagnosis - Drug classes 
32 Any  antipsychotic other than quetiapine and clozapine with Parkinson’s disease 1 2% 1/3 (33%) 
33 Anticholinergics (e.g. Antihistamines, Antidepressants, Antipsychotics, Antispasmodics…) 
with dementia or cognitive impairment 
4 7% 4/8 (50%) 
34 Anticholinergics (e.g. Antihistamines, Antidepressants, Antipsychotics, Antispasmodics…) 
with constipation 
15 25% 15/23 (65%) 
35 Anticholinergics (e.g. Antihistamines, Antidepressants, Antipsychotics, Antispasmodics…) 
with BPH 
0 0% 0/1 (0%) 
36 Calcium Channel Blockers with constipation 2 3% 2/17 (12%) 
37 Non-selective beta-blockers with asthma or COPD 0 0% 0/5 (0%) 
38 Oral corticosteroids >1 week with diabetes 2 3% 2/10 (20%) 
39 Oral corticosteroids >1 week with hypertension 5 8% 5/36 (14%) 
40 Thiazide and loop diuretics with gout 2 3% 2/4 (50%) 
Part 2b: Potentially inappropriate drugs, dependent on diagnosis - Specific molecules 
41 Alizapride with Parkinson’s disease 1 2% 1/4 (25%) 
42 Metoclopramide with Parkinson’s disease 0 0% 0/4 (0%) 
Part 3: Potential prescribing omissions  
43 The patient is taking ≥ an equivalent of 7.5 mg of oral prednisone for ≥3 months and is not 
prescribed Ca/VitD supplementation and bisphosphonates. 
0 0% 0/0 (-) 
44 The patient is taking narcotic analgesics and is not prescribed appropriate preventative 
bowel regimen (preferably macrogol or lactulose). 
10 17% 10/12 (83%) 
45 The patient has an elevated risk for osteoporosis (determined via FRAX-tool30) and is not 
prescribed Calcium/Vitamin D supplementation. 
41 68% 41/49 (84%) 
46 The patient is taking oral corticosteroids for ≥1 month and is not prescribed Ca/VitD 
supplementation. 
2 3% 2/4 (50%) 
47 The patient is not reminded and proposed to undergo yearly influenza vaccination. 18 30% 18/59 (31%) 
48 The patient is taking methotrexate and is not prescribed folic acid supplementation. 
 
0 0% 0/1 (0%) 
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Part 4: Drug-Drug interactions of specific relevance  
49 VKA + oral NSAIDs 0 0%  
50 RAAS-inhibitor + potassium sparing diuretic/potassium supplements/potassium containing 
drugsb 
0 0%  
51 VKA + Antiplatelet drugs (esp. ASA), unless prescribed by internist/cardiologist 6 10%  
52 VKA + TMP/SMX 2 3%  
53 Oral NSAID + Oral Corticosteroids 0 0%  
54 Oral NSAID + Diuretic 0 0%  
55 Digoxin + Macrolide antibiotics 1 2%  
56 Digoxin + Verapamil/Diltiazem 0 0%  
57 Lithium + RAAS-inhibitors 0 0%  
58 Lithium + Oral NSAID 0 0%  
59 Lithium + Diuretics 0 0%  
60 Theophylline + Quinolones/Macrolides 0 0%  
61 RAAS-inhibitor + Oral NSAID 1 2%  
62 Oral NSAID + SSRI/SNRI 2 3%  
63 RAAS-inhibitor + TMP/SMX 0 0%  
64 Oral antidiabetics/insulin + non-selective beta-blocker 1 2%  
65 Oral antidiabetics/insulin + cardioselective beta-blocker 6 10%  
66 Alprazolam/Midazolam/Triazolam/Zolpidem/Zopiclone + Strong CYP3A4 inhibitor 1 2%  
67 CCB + Strong CYP3A4 inhibitor 0 0%  
68 Oral NSAID + Antipletelet drugs 0 0%  
69 Phenytoin + TMP/SMX 0 0%  
70 First dose RAAS-inhibitor at full dosage + pre-treatment with diuretic 0 0%  
71 Tamoxifen + strong CYP2D6 inhibitors  0 0%  
72 Calcium + Quinolones/Tetracyclines 1 2%  
73 Calcium + Stontium ranelate 0 0%  
74 Calcium + Levothyroxine 2 3%  
75 Bisphosphonate + Calcium, Magnesium, Zinc, Iron or Aluminium 1 2%  
76 VKA + Vitamin K containing drugs/supplementsc 0 0%  
77 Any combination of anticholinergic drug 16 27%  
 
ASA: Acetylsalicylic acid; BPH: Benign prostatic hyperplasia; CCB: Calcium Channel Blocker; COPD: Chronic Obstructive Pulmonary Disease; CV-
risk: Cardiovascular risk; GI-risk: Gastro-intestinal risk; GP: General Practitioner; NSAID: Non Steroidal Anti-Inflammatory Drug; INR: 
International Normalized Ratio; PPI: Proton Pump Inhibitor; RAAS-inhibitor: Renin-Angiotensin-Aldosteron System Inhibitors; SNRI: Serotonin and 
Noradrenalin Reuptake Inhibitor; SSRI: Selective Serotonin Reuptake Inhibitor; TMP/SMX: Trimetoprim/Sulfamethoxazol; VKA: Vitamin K 
Antagonist. 
 
a Full dose defined as: >20 mg (es)omeprazole, >20mg pantoprazole, >30mg lansoprazole, >20mg rabeprazole  
b Some drugs contain considerable potassium amounts: Glucosamine in potassium salt (up to 300mg/tablet), oral nutritional supplements (up to 
200mg/unit).... (Recommended Daily Dose: 3000mg/day for ≥60 year old patients) 
c Some supplements such as oral nutritional supplements contain considerable Vitamin K amounts (up to 13µg/unit). (Recommended Daily Dose: 
50-70µg/day for ≥60 year old patients) 
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ABSTRACT 
 
Purpose. In this study, we aimed to (1) determine the prevalence of potentially inappropriate 
prescribing (PIP) in community-dwelling older polypharmacy patients using the GheOP³S-tool, (2) 
identify the items that account for the highest proportion of PIP and (3) identify the patient variables 
that may influence the occurrence of PIP. Additionally, pharmacist-physician contacts emerging from 
PIP-screening with the GheOP³S-tool and feasibility of the GheOP³S-tool in daily practice were 
evaluated. 
 
Methods. A prospective observational study was carried out between December 2013 and July 2014 
in 204 community pharmacies in Belgium. Patients were eligible if they were (1) ≥70 years, (2), 
community-dwelling, (3) using ≥5 chronic drugs (4) a regular visitor of the pharmacy and (5) 
understanding Dutch or French. Community pharmacists used a structured interview to obtain 
demographic data and medication use and subsequently screened for PIP using the GheOP³S-tool. A 
Poisson regression was used to investigate the association between different covariates and the 
number of PIP. 
 
Results. In 987 (97%) of 1016 included patients, 3721 PIP items were detected (median of 3 per patient; 
IQR: 2-5). Most frequently involved with PIP are drugs for the central nervous system such as 
hypnosedatives, antipsychotics and antidepressants. Risk factors for a higher PIP prevalence appeared 
to be a higher number of drugs (30% extra PIPs per 5 extra drugs), female gender (20% extra PIPs), 
higher BMI (20% extra PIPs per 10-unit increase in BMI) and poorer functional status (30% extra PIPs 
with 6-point increase). The feasibility of the GheOP³S-tool was acceptable although digitalization of 
the tool would improve implementation. Despite detecting at least one PIP in 987 patients, only 39 
physicians were contacted by the community pharmacists to discuss the items. 
 
Conclusion. A high prevalence of PIP in community-dwelling older polypharmacy patients in Belgium 
was detected which urges for interventions to reduce PIP.   
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INTRODUCTION 
Potentially inappropriate prescribing (PIP) is defined as the prescribing of medication that 
significantly increases the risk of an adverse drug reaction (ADR), in particular when there is an equally 
or more effective alternative with lower risk available1 2. PIP encompasses three main categories: 
overuse, underuse and misuse3. As PIP is a major risk factor for ADRs, it can put substantial pressure 
on the safety of medication use4 5.  
A recent systematic review6 showed that PIP prevalence in community dwelling European older 
adults is high (average estimated prevalence: 22.6%, confidence interval (CI): 19.5-26.7%). This shows 
that PIP is a wide-spread issue. Furthermore, a variety of factors seem to contribute to the prevalence 
of PIP in older community-dwelling adults, such as polypharmacy, older age, depression, moderate 
self-rated health quality, low activities of daily living (ADL)-score and poor economic situation4-6. A 
periodic screening for PIP could be a strategy to diminish its burden7. In the literature, there is 
agreement that such a periodic screening should be applied to older patients with polypharmacy or 
other additional risk factors. PIP screening in primary care could reduce the risk for ADR and ADR-
related hospitalization8 and research showed it is probably cost-neutral9 10.  
Community pharmacists are ideally placed to perform periodic screening for PIP because of their 
medication-specific knowledge and the availability of an electronic dispensing record in the pharmacy 
that ideally includes all dispensed over-the-counter (OTC) medication. Moreover, multiple studies 
showed that the community pharmacist can intervene and assist in significantly reducing the 
occurrence of a lot of specific PIPs. The EMPOWER-study for example showed that direct-to-consumer 
education from the community pharmacy effectively reduced overuse of benzodiazepines11. Another 
study, performed in French community pharmacies, shows that providing the community pharmacist 
with the patients’ renal functions can resolve several PIPs concerning incorrect dosing12. 
However, general screening for PIP in the community pharmacy is more comprehensive and 
requires an evidence-based screening tool specifically suitable for this setting. The Ghent Older 
People’s Prescriptions community Pharmacy Screening (GheOP³S-)tool13 was recently developed to 
detect PIP with high clinical relevance for primary care, taking into account the limited availability of 
clinical data in the community pharmacy setting. The GheOP³S-tool consists of 83 items, addressing 
overuse, underuse and misuse of medication. For each item of the tool, an alternative therapeutic 
option is offered. Furthermore, pharmacists could perform a medication screening on a regular base 
or at every moment a change in pharmacotherapy is made.   
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This observational research was the first to use the GheOP³S-tool in the community-pharmacy 
setting. We aimed (1) to determine the prevalence of PIP in community-dwelling older polypharmacy 
patients with the GheOP³S-tool, (2) to identify the items that account for the highest proportion of PIP 
and (3) to identify the patient variables that may influence the occurrence of PIP. Additionally, (4) 
pharmacist-physician contacts resulting from PIP-screening with the GheOP³S-tool and (5) feasibility 
of the GheOP³S-tool in daily practice was evaluated.   
 
 
 
Medication screening in the community pharmacy setting – Chapter 2  
103 
METHODS 
Study design & setting  
This manuscript describes a prospective observational study, carried out between December 2013 
and July 2014 in all 204 community pharmacies counselling a pharmacist in training from the Ghent 
University or the University of Liège, during the academic year of 2013-2014 (i.e. a final year pharmacy 
student, performing obligatory six-month pre-registration community pharmacy training). Ethical 
approval was granted by the ethical committees of the Ghent University Hospital (for Flanders) and 
Centre Hospitalier Universitaire de Liège (for Wallonia). All participants provided written informed 
consent. The STROBE standardized reporting guidelines for cross-sectional studies were followed to 
ensure the uniform conduct and reporting of the research14.  
 
Participants 
All older patients filling a prescription at a participating pharmacy were consecutively approached 
and invited to participate in the study. They were eligible when meeting the following inclusion criteria: 
(1) aged 70 years of older, (2), community-dwelling, (3) using 5 of more chronic drugs (i.e. intake 
follows a fixed regimen) registered in the Belgian Commented Drugs Repertory15 (4) being a regular 
visitor of the pharmacy and (5) speaking and reading Dutch or French. Each pharmacy planned to 
recruit 5 patients. Recruiting patients that regularly visited the pharmacy warranted a patient-
pharmacist relationship of respect and trust. 
 
Data collection and outcome measures 
Participating patients were interviewed by a pharmacist in training using a structured 
questionnaire. The questionnaire assessed information about demographics, self-rated health16, 
functional status, cognitive impairment (using the MiniCog17), fall incidents, hospitalizations and 
emergency visits in the previous year, and current medication use (including detailed information 
about dose, frequency, time of administration, starting date etc). For current medication use, the 
electronic dispensing records at the participating pharmacy were consulted as a starting point. In 
addition, patients were specifically asked about the use of over-the-counter (OTC-) and herbal drugs. 
The structured interview took place at the pharmacy or at the patient’s home (according to patient 
preference), and was fully documented on paper. 
Using the data from the structured interview and the electronic dispensing record, the pharmacist 
in training subsequently screened each patient’s medication for PIP by applying the GheOP³S-tool13.  
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The choice to use this screening tool was deliberate. First, the GheOP³S-tool makes it possible to 
screen for PIP in settings where clinical data are not available. Second, the GheOP³S-tool is adapted to 
the European market and addresses all types of PIP. Third, the GheOP³S-tool offers the pharmacists a 
backbone to get started with the process of a medication review. An elaborate document describing 
rationale, alternative treatment plans and scientific background information of all included items 
empowers the pharmacists to initiate pharmacist-physician contacts to discuss the considered 
clinically relevant PIP-items. 
The GheOP³S-tool is subdivided into 5 different parts: Part 1: Potentially inappropriate drugs, 
independent of diagnosis; Part 2: Potentially inappropriate drugs, dependent on diagnosis; Part 3: 
Potential prescribing omissions (PPOs); Part 4: Drug-drug interactions (DDIs) of specific relevance; and 
Part 5: General care-related items to be addressed in the community pharmacy. The items in the latter 
part are not strictly considered to be PIP, according to the definition in the introduction, but they are 
considered relevant to be checked for in community pharmacy practice as they evaluate the 
appropriateness of the provided pharmaceutical care. With regard to the diagnoses in Part 2, drug 
proxies were used. Only diagnoses that could unambiguously be derived from the patient’s medication 
(e.g. diabetes from insulin, gout from allopurinol, etc) were taken into account. In this study, all 83 
criteria of the GheOP³S-tool were used.  
An extensive training session on the use of the GheOP³S-tool for PIP screening (with example cases 
as well as one real-life trial case) was completed by each pharmacist in training before the start of the 
study. In addition, all screenings included in the study were double-checked by a member of the 
research team (ET). As pharmacist-physician contacts considering PIP are not yet common practice in 
Belgium, the decision to initiate such a contact from the pharmacy was left to the supervising 
pharmacist, based on his/her personal judgement of the detected PIPs. All initiated physician contacts 
and their outcomes were documented. The acceptance of the proposed alternative treatment plans 
by the pharmacist was categorized as ‘accepted’, ‘partially accepted’ or ‘not accepted’. Reasons for 
not accepting the treatment plan were also recorded.  
Subsequently, all participating pharmacists evaluated the feasibility of the GheOP³S-tool, using a 
slightly adapted version of the system usability scale (SUS) (Appendix 2.4.1)18 19. The SUS is a validated 
tool for assessing feasibility, consisting of 10 items, each to be scored on a 5-point scale. It provides an 
easy-to-understand overall score from 0 (lowest feasibility) to 100 (highest feasibility). Although no 
explicit cut-off for feasibility is determined, it is generally accepted that SUS-scores >50 are sufficient 
to consider the tool feasible in current practice19. Research by Lewis et al. showed that SUS can be 
divided into two separate factors, specifically representing the usability (8 items) and learnability (2 
items) of the evaluated tool18.  
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The participating pharmacists transferred all obtained anonymized patient data and results of the 
written document through an electronic platform to the Ghent University study centre. Data input was 
double-checked using the written document by the principal investigator (ET) before processing. 
During this process, each medicine was assigned a seven-digit code in accordance with the Anatomical 
Therapeutic Chemical (ATC) Classification System formulated by the World Health Organization 
Collaborating Centre for Drug Statistics Methodology20.  
 
Statistical analysis  
Descriptive statistics are provided as counts with percentages, means with standard deviations or 
medians with interquartile ranges as appropriate. Prevalence of PIP is represented as the proportion 
of patients with at least one PIP and the median number of PIPs per patient. 
Poisson regression was used to investigate the association between different covariates and the 
number of PIP. Patient covariates considered as predictors in the model, were: number of drugs, age, 
gender, body mass index (BMI), smoking status, education, self-rated health status, functional status, 
living situation, cognitive impairment, emergency department visits, hospitalizations, recent falls and 
presence of ADRs. Continuous covariates, such as ‘number of drugs’, ‘age’ and ‘BMI’ were centered 
around 5, 70 years and 25 kg/m², respectively. After covariate selection, based on “backward 
elimination” at the 5% level of significance, the linearity assumption for the continuous covariates in 
the final model was assessed. Education (scale: 1-4 with 4 as highest education), functional status 
(scale: 0-6 with 6 as worst functional status), self-rated health status (scale: 1-5 with 5 as best health 
rate), and cognitive impairment (scale: 0-5 with 5 as no cognitive impairment) were set as ordinal 
variables. Furthermore, a likelihood-ratio-test was performed to test whether overdispersion should 
be accounted for. Finally, once the final model was developed, likelihood-ratio-testing was performed 
at the 5% level of significance to test whether 2-way interaction terms should be added to the model.  
Fitting of the models to the observed data and post-hoc evaluations of the model’s goodness-of-fit was 
performed in R® (R foundation for statistical computing, Vienna, Austria).  
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RESULTS 
Participants 
In total, 2228 patients were screened for eligibility. 726 patients did not meet the inclusion criteria 
(547 took less than 5 drugs, 89 were not regular visitors of the participating pharmacy, 45 didn’t 
sufficiently understand Dutch or French and 45 were not community-dwelling). Additionally, 486 
refused to participate (221 did not have time to participate, 194 were not interested and 71 stated 
other reasons). Eventually, 1016 older community dwelling polypharmacy patients were included in 
the study. Mean age (± SD) was 78.8 (±5.5) years and 58% of the population was female. The total 
number of medicines taken was 10568, with a range of 5-29 per patient and a median of 10 per patient 
(interquartile range 8-12) (Table 2.4.1). 
 
Table 2.4.1: Basic characteristics of the study population (n=1016)   
Age, Mean (SD) 78.8 (5.5) 
 Age ≥ 85j, n (%) 162 (16%) 
Female gender, n (%) 592 (58%) 
BMI, Mean (SD) 26.6 (4.3) 
No. of drugs, Median (IQR) 10 (8-12) 
No. of drugs, Mean (SD) 10.4 (3.4) 
Current smoker, n (%) 57 (6%) 
Education a 
  
Primary school 257 (25%) 
Secondary school  580 (57%) 
Higher education 176 (17%) 
Living alone, n (%) 434 (43%) 
Functional status; need help with, n (%) 
  
Bathing/showering 110 (11%) 
Dressing 54 (5%) 
Toileting  19 (2%) 
Community mobility 117 (12%) 
Eating 39 (4%) 
Cleaning 382 (38%) 
Self-rated health status, n (%)   
Excellent 19 (2%) 
Very good 104 (10%) 
Good  497 (49%) 
Fair / Moderate 343 (34%) 
Poor 53 (5%) 
Positive for cognitive impairment (according to the Mini-Cog), n (%) 335 (33%) 
Emergency department visits   
Patients with emergency department visit in previous year, n (%) 229 (23%) 
Number of emergency department visits per patient year, Median (IQR) 1 (1-2) 
Hospitalizations   
Patients with hospitalization in previous year, n (%) 394 (39%) 
Number of hospitalizations per patient year, Median (IQR) 1 (1-2) 
Fall incidents   
Patients with fall incident in previous year, n (%) 333 (33%) 
Number of fall incidents per patient year, Median (IQR) 1 (1-3) 
a 3 patients did not answer this question   
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Potentially inappropriate prescribing 
Considering Part 1 to Part 4 of the GheOP³S-tool, a total of 3721 PIPs were detected in 987 (97%) 
of participants (Median: 3; IQR: 2-5). However, with regard to the full GheOP³S-tool, thus also including 
list 5 “General care-related items to be addressed in the community pharmacy”, an additional 3186 
items considering general care-related items were detected. This led to a total of 6907 items in 1008 
(99%) participants (Median: 7; IQR: 5-8) (Figure 2.4.1). 
 
Figure 2.4.1: Distribution of the number of GheOP³S-criteria detected per patient (n = 1016; Part 1: Potentially inappropriate 
drugs, independent of diagnosis, Part 2: Potentially inappropriate drugs, dependent on diagnosis, Part 3: Potential 
prescribing omissions, Part 4: Drug-drug interactions of specific relevance and Part 5: General care-related items to be 
addressed in the community pharmacy). 
 
The 5 most prevalent items of each part of the GheOP³S-tool are reported in Table 2.4.2. The items 
of Part 2 and Part 3 are displayed in two ways; relative to the total population and relative to the 
overall drug or disease prevalence. For example, of the 130 patients taking narcotic analgesics, 99 
(76%) did not receive an appropriate preventative bowel regimen, however relative to the total 
population (n=1016), this considers only 10%. The full list of the prevalence of all GheOP³S-criteria is 
reported in Appendix 2.4.2. 
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Table 2.4.2: The 5 most prevalenta criteria of each part of the GheOP³S-tool, n = 1016 
 GheOP³S-item N, %a (relative 
to total 
population)  
N, %a (relative to 
overall drug or 
disease 
prevalence) 
Part 1: Potentially inappropriate drugs, independent of diagnosis 791 (78%)  
1 Any intermediate acting benzodiazepine or Z-product at full dose or any dose ≥30 
subsequent days OR any short  or long-acting benzodiazepine 
510 (50%) 
  
 
 Any intermediate acting benzodiazepine or Z-product at full dose or any dose ≥30 
subsequent days 
448 (44%)  
 Any short  or long-acting benzodiazepine 93 (9%)  
 Any intermediate acting benzodiazepine or Z-product at full dose or any dose ≥30 
subsequent days AND any short  or long-acting benzodiazepine 
31 (3%)  
2 Any antidepressant ≥1 year 216 (21%)  
3 Any oral NSAID 146 (14%)  
4 Any PPI at full dose ≥8 weeks 145 (14%)  
5 Any antipsychotic drug ≥ 1 month 71 (7%)  
Part 2: Potentially inappropriate drugs, dependent on diagnosis  276 (27%)  
1 Thiazide and loop diuretics with gout 88 (9%) 88/151 (58%) 
2 Anticholinergics with constipation 84 (8%) 84/147 (57%) 
3 Calcium Channel Blockers with constipation 43 (4%) 43/144 (30%) 
4 Oral corticosteroids >1 week with hypertension 43 (4%) 43/810 (5%) 
5 Anticholinergics with benign prostate hyperplasia 40 (4%) 40/93 (43%) 
Part 3: Potential prescribing omissions 727 (72%)  
1 The patient has an elevated risk for osteoporosis (determined via FRAX tool) and is not 
prescribed calcium/Vitamin D supplementation. 
545 (54%) 545/710 (77%) 
2 The patient is not reminded and proposed to undergo yearly influenza vaccination. 306 (30%)  
3 The patient is taking narcotic analgesics and is not prescribed appropriate preventative 
bowel regimen (preferably macrogol or lactulose). 
99 (10%) 99/130 (76%) 
4 The patient is taking oral corticosteroids for ≥1 month and is not prescribed calcium and 
vitamin D supplementation. 
39 (4%) 39/54 (72%) 
5 The patient is taking an equivalent of 7.5 mg of oral prednisone or more for ≥3 months and 
is not prescribed calcium/Vitamin D supplementation and bisphosphonates. 
23 (2%) 23/24 (96%) 
Part 4: Drug-drug interactions of specific relevance 523 (51%)  
1 Oral antidiabetics/insulin + beta-blocker 226 (22%)  
 Oral antidiabetics/insulin + non-selective beta-blocker 44 (4%)  
 Oral antidiabetics/insulin + cardioselective beta-blocker 187 (18%)  
2 Any combination of anticholinergic drug  135 (13%)  
3 RAAS-inhibitor + potassium sparing diuretic/ potassium supplements/ potassium containing 
drugs 
81 (8%)  
4 RAAS inhibitor + oral NSAID 74 (7%)  
5 Oral NSAID + antiplatelet drugs 71 (7%)  
Part 5: General care-related items to be addressed in the community pharmacy 872 (86%)  
1 Adherence for all new medication was not checked or discussed at first refill during the past 
year. 
Adherence for all chronic medication was not checked or discussed during the past year 
(refill rate). 
701 (69%) 
 
681 (67%) 
 
2 Contra-indications that can unambiguously be derived from patient’s medication were not 
added to the electronic patient record. 
626 (62%)  
3 The patient was not asked which aspects of pharmaceutical care could be improved for 
him/her. 
463 (46%)  
4 Polypharmacy patients (chronically taking ≥ 5 drugs) were not questioned about whether a 
clear medication scheme was available to him/her. 
441 (43%)  
5 Dispensation of over-the-counter medication (NSAID, ASA…) was not added in the electronic 
patient record. 
253 (25%)  
ASA: Acetyl Salicylic Acid; NSAID: Nonsteroidal Anti-Inflammatory Drugs; PPI: Proton Pump Inhibitor 
a Prevalence is expressed as the percentage of patients to whom this item applies, whether relative to the total population or whether relative 
to the overall disease/drug prevalence 
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Factors associated with PIP  
The estimated parameters from the final Poisson regression model are shown in Table 2.4.3. The 
number of drugs, gender, BMI and functional status were predictive for the observed number of PIPs. 
From the estimated parameters we can calculate that a baseline patient (female patient with a 
functional status of 0, a BMI of 25, taking 5 drugs) has an estimated average number of PIPs of 2.7 [= 
elog (intercept)]. Compared to this “baseline” patient, a very poor functional status (6 compared to 0) 
is associated with an average of 30% extra PIPs. Furthermore, male gender and BMI are associated 
with a decrease of 23% and an increase of 20% (BMI 35 vs 25) in the estimated number of PIPs, 
respectively. Finally, the number of PIPs increases with the number of drugs taken. For instance, 
patients taking an additional 5 drugs have a 30% increase in expected PIPs as compared to otherwise 
similar patients. 
Table 2.4.3: Estimated parameters of the Poisson regression model (outcome: number of PIPs, considering list 1-4 of the GheOP³S-tool) 
with calculation example. 
Risk factor Estimate 95% CI 
Intercept 1.001*** 0.932 – 1.071 
No. of drugs (continuous, centered around 5) 0.057*** 0.049 – 0.066 
Gender (1 = male, 0 (female) as reference) -0.266*** -0.958 – -0.197 
BMI (continuous, centered around 25) 0.017*** 0.009 – 0.024 
Functional status (scale 0-6, 0 as reference) 0.043** 0.016 – 0.070 
CI: Confidence Interval; PIP: Potentially Inappropriate Prescribing; No.: Number; BMI: Body Mass Index; GheOP³S: Ghent Older People’s 
Prescriptions community Pharmacy Screening - *** p<0.001; **p<.01 
 
Calculation example: For a man with 6 chronic drugs, a BMI of 30 and a functional status of 1, the estimated number of PIPs can be 
determined through the following formula:  
 
Ln (estimated number of PIP) = 1.001 + 0.057*(6-5) - 0.266*1 + 0.017*(30-25) + 0.043*(1-0) 
Estimated number of PIP = e0,92 = 2,5 
 
Pharmacist-physician contacts 
In total, 22 supervising pharmacists decided to initiate contact with at least one prescribing 
physician to discuss the detected PIPs. In total 39 physicians were contacted. Thirteen refused to 
participate (reasons for refusal: no time (n=12), not interested (n=1)) and 1 could not be reached. The 
remaining 25 physicians agreed to participate and discussed a total of 77 detected PIP-items with the 
pharmacists. For 28 of the 77 items (36%), the alternative treatment plan proposed by the pharmacist 
was accepted. For 2 items, the alternative treatment plan was partially accepted. For 47 items, the 
physician did not accept the proposed treatment plan of the community pharmacists (Table 2.4.4). 
 
Table 2.4.4: Reasons for the family physician not to accept the proposed alternative treatment plan (n = 47)  
The family physician did not provide a rationale for not accepting the alternative treatment plan  13 
The alternative treatment plan was not feasible due to clinical reasons (e.g. intolerance for alternative) 12 
The alternative treatment plan had already been implemented before with insufficient result or relapse 7 
The alternative treatment plan was not accepted by the patient 6 
Adequate monitoring had already been provided (e.g. frequent measurement of kidney function) 3 
Physician is unwilling to change a therapy initiated by a colleague (e.g. specialist or former family physician) 2 
PIP was detected on the basis of incorrect data (e.g. flu vaccination was administered but incorrectly registered in pharmacy 
software)  
4 
PIP: Potentially Inappropriate Prescribing   
 
 
 
 
110 
Chapter 2 – Medication screening in the community pharmacy setting 
 
Usability and feasibility 
The mean SUS-score was 61.2 (SD: 12.2), with a learnability score of 63.4 (SD: 17.5) and a usability 
score of 60.7 (SD: 12.9). Reviewing the comments of the users, the most frequent remark was the lack 
of digitalization or integration of the GheOP³S-tool in the software which renders the tool too time-
consuming. Mean duration of an evaluation using the GheOP³S-tool including the estimation of the 
clinical relevance of the detected items was 38 minutes (SD = 27 min).   
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DISCUSSION 
Main findings of the study 
In this observational study, we found that in 99% of included patients, at least one GheOP³S-item 
was detected. Specifically focusing on PIPs (i.e. Part 1 to Part 4 of the GheOP³S-tool), a median of 3 
(IQR: 2-5) PIPs per patient was observed. When the general care-related items of Part 5 of the 
GheOP³S-tool were also included, a median of 7 items (IQR: 5-8) per patient was detected. Risk factors 
most frequently associated with higher number of PIPs were higher number of drugs, female gender, 
higher BMI and poorer functional status. 
 
What is already known on this topic 
Similar studies, also conducted in community pharmacies, are scarce. A study in France using the 
Laroche-list21 observed that 37.1% of the 393 included patients had at least one PIP22, which is 
markedly lower than the observations in this study. A possible explanation might be that the French 
Laroche list does not include DDIs, drug-disease interactions (DDisI) or PPOs21. Additionally, in the 
French study, all older adults were included, regardless of polypharmacy, where in this study, only 
older adults taking 5 or more chronic drugs were included.  
Studies conducted in other primary care settings but using similar inclusion criteria (older age and 
5 or more chronic drugs), presented higher prevalence numbers for PIP23-25. A Spanish study using the 
START/STOPP criteria24, a Danish study using the MAI-criteria25 and an Austrian study using the 
PRISCUS list23, detected at least one PIP in respectively 76.4%, 94.3% and 37.3% of patients. The low 
prevalence of the Austrian study should however be nuanced with the fact that 93.5% of patients took 
at least one non-evidence based medication, that 56.2% had at least one dosing error and that 59.2% 
had at least one clinically significant drug-drug interaction23. 
 
What this study adds 
In the current study, the prevalence of all types of PIP (i.e. overuse, misuse and underuse) was 
remarkably high. The fact that almost all patients had at least one PIP could raise questions about 
whether the tool needs to be more discriminatory. During the development of the GheOP³S-tool 
however, the experts unanimously agreed that it was clinically relevant to check for all of the items 
included in the GheOP³S-tool in ambulatory older adults. Whether the detected potential problems 
are clinically relevant for the specific individual patient, still needs to be assessed during a pharmacist-
physician and follow-up patient consultation. Actual inappropriate prescribing will therefore probably 
be somewhat lower. Nevertheless, these results show that there is a large potential for improvement 
in the appropriateness of prescribing and provided pharmaceutical care for ambulatory older patients 
with polypharmacy.  
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The specific criteria with the highest prevalence are the overuse of benzodiazepines and the 
underuse of preventive anti-osteoporotic medication, respectively in 50% and 54% of included 
patients. A review of studies using STOPP/START criteria also showed that both of these items are 
frequently detected26. At first instance, it appears that DDisIs are not very prevalent (up to 9% of 
included patients). However, relative to the number of patients with a certain diagnosis, this is still 
significant (e.g. 43% of patients using drugs for benign prostate hyperplasia receive anticholinergic 
medication).  
Furthermore, taking into account that only DDIs with high risk for hospitalization were included in 
the GheOP³S-tool, the observed high frequency (i.e. in up to 22% of patients) implies serious potential 
health consequences and healthcare costs.  
Risk factor assessment showed that a higher number of drugs, female gender, a higher BMI and a 
poorer functional status are associated with a higher prevalence of PIP. Recent systematic research on 
risk factors for PIP showed that polypharmacy and a poor functional status are indeed consistently 
positively associated with PIP6. BMI could be present due to its association with metabolic syndrome, 
however, literature is not consistent considering this risk factor’s association with PIP27 28. Analogously, 
there is no consistency in the literature on the association between the female gender and a higher 
prevalence of PIP. However, this might be explained by differences in prescribing attitude towards the 
genders and by differences between genders in educational and socio-economic characteristics29.  
The evaluation of the feasibility of the GheOP³S-tool showed that the tool is functioning well in the 
current community pharmacy setting. There is, nevertheless, still room for improvement. It would be 
interesting to re-evaluate the feasibility of the GheOP³S-tool, once the tool is available in a digital 
format.  
The low number of pharmacist-initiated contacts with physicians to discuss the detected PIPs must 
however be seen as a point of concern (only 39 initiated contacts for 987 patients with at least one 
PIP). These numbers are a real-world representation of the extensively present barriers for 
collaboration between pharmacists and physicians30-32. A Canadian research project identified barriers 
for pharmacist-physician collaboration which include lack of financial remuneration and insufficient 
time32. Furthermore, although community pharmacists considered patient counseling and advising 
physicians about drug interactions, dosages and drug information as core tasks, physicians did not 
perceive this as an important role for the community pharmacist32. Other recent research showed 
however that prescribers indicate that pharmacists’ input is preferred as well as collaborations with 
other levels of care30. Additionally, potential facilitators have been established such as 
interprofessional experiences and facilitated communication31.  
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Strengths and limitations of this study 
This was the first study using the newly developed GheOP³S-tool, a community pharmacy specific 
list for settings in which limited clinical data are available. The study was protocol-based and reported 
following the STROBE statement14. Because of the prospective nature and the inclusion of patient 
interviews, accurate dosing information and complete medication use (i.e. OTC-medication, herbal 
therapies etc) was available. Additionally, this was the first study evaluating PIP in community dwelling 
older adults in Belgium. The study also evaluated usability and learnability of the GheOP³S-tool which 
is a very important aspect for future implementation research.  
On the other hand, this study has some limitations. The first is inherently linked to the use of the 
GheOP³S-tool as screening method. As the GheOP³S-tool is an explicit list, it does not take into account 
all patient factors in evaluating a patient’s pharmacotherapy, e.g. the diagnoses and evolution of the 
patient’s diseases, the patient’s own preferences and earlier attempts to prohibit the use of potentially 
inappropriate drugs. The few pharmacist-physician contacts to discuss the detected items made it 
difficult to estimate which part of the items were of no or limited clinical relevance.  
Second, some limitations are linked to the study design. As the study was merely observational, the 
possible clinical effects of reduced inappropriate prescribing could not be assessed. Moreover, we only 
evaluated the feasibility of the GheOP³S-tool in the community pharmacy practice, where it also would 
have been interesting to evaluate how the tool performs in a broader primary health care team, 
including the general practitioner, nurses, physiotherapists, etc. Third, about 20% of potential 
participants refused study participation. Potential bias caused by those who refused could not be 
assessed as the ethical committee prohibited data collection in study refusers. The impact on the roll-
out of any future intervention based on the current results is therefore unclear. Finally, generalizability 
of the results to other countries is difficult. Prescribing patterns vary along health care settings, which 
are very country-specific. However, throughout Belgium, we increased generalizability as much as 
possible by recruiting a patient sample using all 204 participating pharmacies as one recruitment 
center.  
 
Future perspectives 
A study evaluating the reduction of PIP in older ambulatory patients using the GheOP³S-tool should 
be conducted. Ideally, the impact (clinical and economic) of this improved pharmacotherapy should 
be measured. To reach this, we need to start with a study that evaluates the discrepancy between the 
potential inappropriate prescribing detected with the GheOP³S-tool and the actual inappropriate 
prescribing detected after pharmacist-physician consultation. Moreover, such a study could easily 
integrate an evaluation of all aspects of pharmacist-physician consultations upon PIP detection with 
the GheOP³S-tool (i.e. barriers, modalities, facilitators, etc).  
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As PIP is a complex matter, it is however unlikely that a single intervention will be sufficient to 
substantially improve the quality of prescribing and patient centred outcomes. Research showed that 
more integrated approaches are needed to significantly reduce the burden of PIP33 34. In that light, 
developing a complex intervention will be key. A proposition to such an intervention could be as 
follows. A digital screening of the medication history with the GheOP³S-tool is performed in the 
community pharmacy. This screening would yield a list of potential inappropriate pharmacotherapy. 
Subsequently, in consultation with a multidisciplinary healthcare team, these potential issues are 
discussed and a list of actual inappropriate pharmacotherapy with recommendations for change is 
decided on. After consultation with the patient, a final treatment plan is set up. This patient 
consultation could be performed by any healthcare provider of the multidisciplinary healthcare team. 
Final decisions are communicated to all healthcare providers of the team through a secure electronic 
platform.  
To realize a significant degree of implementation, the proposed complex intervention would benefit 
from some optimization in different levels of care: the governmental level, the informatics level and 
the healthcare providers’ level. First, governments could provide incentives to perform medication 
screening in the ambulatory setting by financing pilot projects at first and by eventually remunerating 
this service in case of positive results. Additionally, a clear legal outline of the specific role of each 
healthcare provider in the medication screening process could empower each one of them to take up 
their role31 32 35. In order to enhance interprofessional collaborations, governments could support the 
organization of local interdisciplinary conferences31. Other strategies could include financial rewards 
or penalties when specific quality indicators are (not) met.  
Second, informatics and software companies could be of major help in facilitating interprofessional 
communication by developing communication channels that are secure and easy to use31. 
Furthermore, automatizing the screening of medication lists or medication histories, including clinical 
support systems could enhance the implementation of this intervention strategy as this would limit 
the time needed to perform the review. Both limited time and difficult communication are often 
mentioned as barriers to implement medication review30 31.  
Finally, healthcare providers should be educated to perform medication review and about their 
potential role in the process. This includes recognizing each healthcare provider’s role while none 
claiming a position of superiority. As healthcare providers may not always feel confident prescribing 
for older adults or evaluating their pharmacotherapy, specific courses on geriatric pharmacotherapy 
should be organized30. 
With regard to this proposed complex intervention, our study is of help and reveals some pitfalls to 
which we can further anticipate. To start with, the high prevalence of PIP confirms there is an urge for 
initiatives such as the proposed complex intervention. The evaluation of risk factors for PIP in the 
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current study shows the intervention should be targeted towards older patients with polypharmacy 
and poor functional status. Community pharmacists feel it is feasible to perform medication screening 
using the GheOP³S-tool, but it could be helped by digitalization of the tool. Finally, and most 
importantly, this observational study confirms that the current pitfall lies in the extreme low number 
of initiated pharmacist-physician consultations to discuss detected PIP items. All strategies to improve 
these collaborations should therefore be exploited. At the same time, we have to be aware of the fact 
that the current differences between healthcare levels, IT systems and variability between healthcare 
providers will influence the results of the studies that will evaluate this complex intervention.   
 
Conclusion 
Screening with the GheOP³S-tool revealed a high prevalence of PIP in community-dwelling older 
polypharmacy patients in Belgium. Drugs or drug groups most often associated with PIP are drugs for 
the central nervous system such as hypnosedatives, antipsychotics and antidepressants. Also, 
potential prescribing omissions are highly present. A higher number of drugs, female gender, a higher 
BMI and a poorer functional status are risk factors for a higher PIP prevalence. The usability of the 
GheOP³S-tool is acceptable although digitalization of the tool would improve its feasibility. Despite the 
high number of detected PIPs however, only a small number of physicians were contacted by the 
community pharmacists.   
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APPENDIX 2.4.1: ORIGINAL AND ADAPTED VERSION OF THE SYSTEM USABILITY SCALE 
Appendix table 2.4.1: Original and adapted version of the system usability scale 
Original version of the System Usability Scale  Adapted version of the System Usability Scale 
1. I think that I would like to use this system frequently. 
2. I found the system unnecessarily complex. 
3. I thought the system was easy to use. 
4. I think that I would need the support of a technical person 
to be able to use this system. 
 
5. I found the various functions in this system were well 
integrated. 
 
6. I thought there was too much inconsistency in this system. 
7. I would imagine that most people would learn to use this 
system very quickly. 
8. I found the system very cumbersome to use. 
9. I felt very confident using the system. 
 
10. I needed to learn a lot of things before I could get going with 
this system. 
 
1. I think that I would like to use this tool frequently. 
2. I found this tool unnecessarily complex. 
3. I thought this tool was easy to use. 
4. I think that I would need the support of someone with more 
knowledge about pharmacotherapy to be able to use this 
tool. 
5. I found that the various types of potentially inappropriate 
prescribing were well integrated in this tool. 
6. I thought there was too much inconsistency in this tool. 
7. I would imagine that most people would learn to use this 
tool very quickly. 
8. I found this tool very cumbersome to use. 
 
9. I felt very confident concerning the decision I made for each 
detected item of this tool. 
10. I needed to learn a lot of things before I could get going with 
this tool. 
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APPENDIX 2.4.2: FULL LIST OF PREVALENCE OF ALL GHEOP³S-CRITERIA 
Appendix table 2.4.2: Full list GheOP³S-criteria prevalence 
No. GheOP³S-criterion N, % (relative to 
total population, 
n=1016)  
N, % (relative to 
diagnosis positive 
patients) 
Part 1a: Potentially inappropriate drugs, independent of diagnosis – Drug classes 
1 Any antidepressant ≥1year 216 21%  
2 Any antipsychotic drug ≥1 month 71 7%  
3 Any peripheral vasodilator 33 3%  
4 Any intermediate acting benzodiazepine or Z-product at full dose or any dose ≥30 
subsequent days 
448 44%  
5 Any short  or long-acting benzodiazepine  
 
93 9%  
6 Any long-acting sulfonylurea derivative  69 7%  
7 Any nasal vasoconstrictor ≥1 month 11 1%  
8 Any oral NSAID 146 16%  
9 Any PPI at full dosea ≥8 weeks  145 14%  
10 Any recently marketed drug (black triangles) 54 5%  
11 Any sedating antihistaminic drug  21 2%  
Part 1b: Potentially inappropriate drugs, independent of diagnosis - Specific molecules 
12 Alizapride 3 0%  
13 Bisacodyl 15 1%  
14 Clonidine 2 0%  
15 Codeine and its derivatives for acute cough 15 1%  
16 Dabigatran 26 3%  
17 Digoxin >0,125mg/day 14 1%  
18 Dipyridamole monotherapy (without ASA) 2 0%  
19 Ginkgo biloba or Panax ginseng 43 4%  
20 Liquid paraffin 2 0%  
21 Methyldopa  0 0%  
22 Metoclopramide 9 1%  
23 Pentazocine 0 0%  
24 Phenobarbital 4 0%  
25 Pseudoephedrine oral 4 0%  
26 Rivaroxaban or Apixaban 45 4%  
27 Senna glycosides 15 1%  
28 Picosulfate 7 1%  
29 Theophylline 17 2%  
30 Ticlopidine, new prescription 0 0%  
31 Tramadol, new prescription 15 1%  
Part 2a: Potentially inappropriate drugs, dependent on diagnosis - Drug classes 
32 Any  antipsychotic other than quetiapine and clozapine with Parkinson’s disease 2 0% 2/26 (8%) 
33 Anticholinergics (e.g. Antihistamines, Antidepressants, Antipsychotics, Antispasmodics…) 
with dementia or cognitive impairment 
7 1% 7/21 (33%) 
34 Anticholinergics (e.g. Antihistamines, Antidepressants, Antipsychotics, Antispasmodics…) 
with constipation 
84 8% 84/147 (57%) 
35 Anticholinergics (e.g. Antihistamines, Antidepressants, Antipsychotics, Antispasmodics…) 
with BPH 
40 4% 40/93 (43%) 
36 Calcium Channel Blockers with constipation 43 4% 43/147 (29%) 
37 Non-selective beta-blockers with asthma or COPD 18 2% 18/145 (12%) 
38 Oral corticosteroids >1 week with diabetes 13 1% 13/298 (4%) 
39 Oral corticosteroids >1 week with hypertension 43 4% 43/810 (5%) 
40 Thiazide and loop diuretics with gout 88 9% 88/151 (58%) 
Part 2b: Potentially inappropriate drugs, dependent on diagnosis - Specific molecules 
41 Alizapride with Parkinson’s disease 0 0% 0/26 (0%) 
42 Metoclopramide with Parkinson’s disease 0 0% 0/26 (0%) 
Part 3: Potential prescribing omissions  
43 The patient is taking ≥ an equivalent of 7.5 mg of oral prednisone for ≥3 months and is not 
prescribed Ca/VitD supplementation and bisphosphonates. 
23 2% 23/24 (96%) 
44 The patient is taking narcotic analgesics and is not prescribed appropriate preventative 
bowel regimen (preferably macrogol or lactulose). 
99 10% 99/130 (76%) 
45 The patient has an elevated risk for osteoporosis (determined via FRAX-tool36) and is not 
prescribed Calcium/Vitamin D supplementation. 
545 54% 545/710 (77%) 
46 The patient is taking oral corticosteroids for ≥1 month and is not prescribed Ca/VitD 
supplementation. 
39 4% 39/54 (72%) 
47 The patient is not reminded and proposed to undergo yearly influenza vaccination. 306 30%  
48 The patient is taking methotrexate and is not prescribed folic acid supplementation. 5 0% 5/23 (22%) 
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Part 4: Drug-Drug interactions of specific relevance  
49 VKA + oral NSAIDs 4 0%  
50 RAAS-inhibitor + potassium sparing diuretic/potassium supplements/potassium containing 
drugsb 
81 8%  
51 VKA + Antiplatelet drugs (esp. ASA), unless prescribed by internist/cardiologist 6 1%  
52 VKA + TMP/SMX 1 0%  
53 Oral NSAID + Oral Corticosteroids 14 1%  
54 Oral NSAID + Diuretic 67 7%  
55 Digoxin + Macrolide antibiotics 0 0%  
56 Digoxin + Verapamil/Diltiazem 3 0%  
57 Lithium + RAAS-inhibitors 0 0%  
58 Lithium + Oral NSAID 0 0%  
59 Lithium + Diuretics 0 0%  
60 Theophylline + Quinolones/Macrolides 2 0%  
61 RAAS-inhibitor + Oral NSAID 74 7%  
62 Oral NSAID + SSRI/SNRI 22 2%  
63 RAAS-inhibitor + TMP/SMX 0 0%  
64 Oral antidiabetics/insulin + non-selective beta-blocker 44 4%  
65 Oral antidiabetics/insulin + cardioselective beta-blocker 187 18%  
66 Alprazolam/Midazolam/Triazolam/Zolpidem/Zopiclone + Strong CYP3A4 inhibitor 8 1%  
67 CCB + Strong CYP3A4 inhibitor 5 0%  
68 Oral NSAID + Antipletelet drugs 71 7%  
69 Phenytoin + TMP/SMX 0 0%  
70 First dose RAAS-inhibitor at full dosage + pre-treatment with diuretic 0 0%  
71 Tamoxifen + strong CYP2D6 inhibitors  0 0%  
72 Calcium + Quinolones/Tetracyclines 1 0%  
73 Calcium + Stontium ranelate 1 0%  
74 Calcium + Levothyroxine 47 5%  
75 Bisphosphonate + Calcium, Magnesium, Zinc, Iron or Aluminium 46 5%  
76 VKA + Vitamin K containing drugs/supplementsc 2 0%  
77 Any combination of anticholinergic drug 135 13%  
Part 5: General care-related items to be addressed in the community pharmacy 
78 Dispensation of over-the-counter medication (NSAID, ASA…) was not added in the electronic 
patient record. 
253 25%  
79 Contra-indications that can unambiguously be derived from patient’s medication were not 
added to the electronic patient record.  
626 62%  
80 Availability of assistance in medication/health issues (by nurse, neighbour, children etc.) was 
not checked nor discussed in frail older patients or older patients with reduced cognition, 
especially when taking drugs needing strict intake scheme. 
21 2%  
81 The patient was not asked which aspects of pharmaceutical care could be improved for 
him/her (Translated into practical questions for the specific patient: e.g. correct inhaler use, 
splitting tablets…). 
463 46%  
82 a/ Adherence for all chronic medication was not checked or discussed during the past year 
(refill rate). 
b/ Adherence for all new medication was not checked or discussed at first refill during the 
past year? 
681 
 
701 
67% 
 
69% 
 
83 Polypharmacy patients (chronically taking ≥ 5 drugs) were not questioned about whether a 
clear medication scheme was available to him/her. 
441 43%  
 
ASA: Acetylsalicylic acid; BPH: Benign prostatic hyperplasia; CCB: Calcium Channel Blocker; COPD: Chronic Obstructive Pulmonary Disease; CV-
risk: Cardiovascular risk; GI-risk: Gastro-intestinal risk; GP: General Practitioner; NSAID: Non Steroidal Anti-Inflammatory Drug; INR: 
International Normalized Ratio; PPI: Proton Pump Inhibitor; RAAS-inhibitor: Renin-Angiotensin-Aldosteron System Inhibitors; SNRI: Serotonin and 
Noradrenalin Reuptake Inhibitor; SSRI: Selective Serotonin Reuptake Inhibitor; TMP/SMX: Trimetoprim/Sulfamethoxazol; VKA: Vitamin K 
Antagonist. 
 
a Full dose defined as: >20 mg (es)omeprazole, >20mg pantoprazole, >30mg lansoprazole, >20mg rabeprazole  
b Some drugs contain considerable potassium amounts: Glucosamine in potassium salt (up to 300mg/tablet), oral nutritional supplements (up to 
200mg/unit).... (Recommended Daily Dose: 3000mg/day for ≥60 year old patients) 
c Some supplements such as oral nutritional supplements contain considerable Vitamin K amounts (up to 13µg/unit). (Recommended Daily Dose: 
50-70µg/day for ≥60 year old patients) 
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ABSTRACT 
 
Purpose. The emerging high level of medication use in nursing home residents makes prescribing in 
this setting a complex and challenging task. The Ghent Older People’s Prescriptions community 
Pharmacy Screening (GheOP³S-)tool was recently developed to screen for potentially inappropriate 
prescribing (PIP) by community pharmacists. We aim (1) to determine the prevalence of PIP in older 
nursing home residents with polypharmacy using the GheOP³S-tool and (2) to identify those PIPs that 
are most frequently detected with the GheOP³S-tool. 
 
Methods. This was a cross-sectional study, carried out between February and June 2014 in 10 nursing 
homes in Belgium, supplied by a community pharmacy chain. For each nursing home, 40 residents 
aged 70 years or older, using 5 or more chronic drugs were included. The PIP prevalence was 
determined using the GheOP³S-tool. 
 
Results. Four hundred nursing home residents were included, with a mean age (± SD) of 86.2 (±6.3) 
years and a median number of 10 drugs per resident (Interquartile Range (IQR): 7-12). A total of 1728 
PIPs were detected in 387 (97%) participants (Median: 4; IQR: 2-6). The most prevalent items can be 
assigned to three categories: long-term use of drugs that influence the central nervous system (i.e. 
benzodiazepines, antidepressants and antipsychotics), use of anticholinergic drugs (mutual 
combinations and with underlying constipation or dementia) and underuse of osteoporosis 
prophylaxis. 
 
Conclusion. Screening for PIP by means of the GheOP³S-tool revealed a high prevalence of PIP among 
older nursing home residents with polypharmacy. This finding urges for initiatives on the patient-level, 
but also on a broader, institutional level.   
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INTRODUCTION 
Nursing home residents are particularly vulnerable to (potentially) inappropriate prescribing 
((P)IP) as they are more fragile, receive therapy from multiple health care workers and are often 
prescribed a high number of drugs(1). It makes prescribing in this setting a complex and challenging 
task(2, 3).  Additionally, PIP (i.e. overuse, underuse and misuse of drugs) is often associated with 
increased prevalence of adverse drug events (ADEs) and health care utilization(4). Other health care 
professionals such as pharmacists and nurses, could assist physicians in the medication management 
process to ensure the most effective and safe pharmacotherapy for the patient(5).  
Screening of medication by pharmacists, preferably as a part of a full medication review with 
multidisciplinary consultation, is a proposed strategy to improve the appropriateness of prescribing(1, 
6, 7) and has been shown to be effective (5). However, significant improvements on hospitalizations 
or mortality are currently lacking(7). This is probably due to the use of inappropriate outcome 
measures (i.e. number of drugs, MMSE-improvement etc), a lack of power to detect statistically 
significant differences or – most importantly – the poor acceptance rate and continuation of 
recommendations resulting from the reviews(5, 8). Additionally, there exist practical barriers to the 
systematic performance of a medication review among nursing home residents. This includes the lack 
of pharmacists with specific training in geriatric pharmacotherapy, the lack of centralized medical 
records and insufficient computerized support(8).  
Recently, we developed the Ghent Older People’s Prescriptions community Pharmacy 
Screening (GheOP³S-) tool, an explicit screening tool to detect PIPs with high clinical relevance for older 
patients(9). This screening tool provides the community pharmacist with the possibility to initiate a 
medication review process in a systematic and straightforward way, solely based on medication 
dispensing data available in the community pharmacy. Ideally, the results of a medication screening 
with the GheOP³S-tool should be discussed with the prescribing physician to confirm clinical relevance 
for the specific patient. Based on the outcomes of the pharmacist-physician consultation, suggestions 
for medication changes are proposed. Lastly, these suggestions are to be discussed with the patient, 
and a final treatment plan is to be decided on.  
The GheOP³S-tool has already been tested in ambulatory patients(10), where it showed to 
detect all three categories of PIP: overuse, misuse and underuse. In the current observational study, 
we aim to perform a screening for PIP in nursing home residents using the GheOP³S-tool and to identify 
those PIPs that are most frequently detected.  
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METHODS 
This manuscript describes a cross-sectional study, carried out between February and June 
2014, in 10 nursing homes in Flanders (i.e. the Dutch speaking part of Belgium) supplied by a 
community pharmacy chain. The pharmacy chain provided the research centre with an anonymized 
dataset, previously set up to examine problems for robotic unit dose drug dispensing. This database 
was set up as follows: 10 nursing homes were randomly selected out of a sample of 33 nursing homes 
which are all supplied by the community pharmacy chain. From each selected nursing home, forty 
residents meeting the following inclusion criteria were randomly selected: (1) aged 70 years or older 
and (2) using 5 of more chronic (i.e. according to a set regimen) drugs registered in the Belgian 
Commented Drugs Repertory(11). The dataset contained the residents’ medication records and basic 
demographics (age & gender). Each drug was assigned a seven-digit code in accordance with the 
Anatomical Therapeutic Chemical (ATC) Classification System formulated by the World Health 
Organization Collaborating Centre for Drug Statistics Methodology(12).  
 We applied the GheOP³S-tool(9) to the received dataset. The choice to use this screening-tool 
was deliberate. First, the GheOP³S-tool makes it possible to screen for PIP in settings where clinical 
data are not available. Second, the GheOP³S-tool is adapted to the European market and addresses all 
types of PIP. Third, the GheOP³S-tool offers the pharmacists a backbone to get started with the process 
of a medication review. An elaborate document describing rationale, alternative treatment plans and 
scientific background information empowers the pharmacists to initiate pharmacist-physician contacts 
to discuss the considered clinically relevant PIP-items. The GheOP³S-tool consists of 83 items, 
categorized in 5 different parts (Part 1: Potentially inappropriate drugs, independent of diagnosis, Part 
2: Potentially inappropriate drugs, dependent on diagnosis, Part 3: Potential Prescribing Omissions 
(PPOs), Part 4: Drug Drug Interactions (DDIs) of specific relevance and Part 5: General care-related 
items to be addressed in the community pharmacy). Part 5 of the GheOP³S-tool was not applied in the 
current study as this part reflects on pharmacy work processes and is not applicable to the bulk 
supplying for nursing homes. With regard to the diagnoses in Part 2, drug proxies were used. Only 
diagnoses that unambiguously could be derived from the patient’s medication (e.g. diabetes from 
insulin, gout from allopurinol, etc) were taken into account. We also identified the GheOP³S-criteria 
that accounted for the highest proportion of PIP. The PIP screening with the GheOP³S-tool was 
performed manually by 3 researchers (EP, CVD and KM) and double-checked by the main investigator 
(ET). The STROBE standardized reporting guidelines for cross-sectional studies were followed to ensure 
the uniform conduct and reporting of the research(13). 
Descriptives were displayed as counts with percentages and means with standard deviations 
or medians with interquartile ranges as appropriate. The PIP prevalence is represented as the 
proportion of residents with at least one PIP and the median number of PIPs per resident. 
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RESULTS 
The 400 randomly included residents had a mean age (± SD) of 86.2 (±6.3) years with 63% of 
residents (250) being older than 85 years. Three quarters (298 residents) of the population was female. 
The total number of medicines taken was 4079, with an absolute range varying between 5 to 34 drugs 
per resident and a median of 10 per resident (Interquartile Range (IQR): 7-12). 
Considering Part 1 to Part 4 of the GheOP³S-tool, a total of 1728 PIPs were detected in 387 
(97%) participants (Median: 4; IQR: 2-6). Figure 2.5.1 represents the distribution of number of PIPs 
detected per patient according to the full GheOP³S-tool, as well as according to each part of the tool. 
All types of PIP (overuse, underuse and misuse) are detected. The 5 most prevalent items for each part 
of the GheOP³S-tool are reported in Table 2.5.1. The items of Part 2 and Part 3 are displayed in two 
ways; relative to the total population and relative to the overall drug or disease prevalence. A complete 
list of the prevalence of all individual GheOP³S-criteria is reported as Online Supplement.  
 
 
Figure 2.5.2: Distribution of the number of PIP-items detected per patient, using the GheOP³S-tool (n = 400; Part 1: Potentially 
inappropriate drugs, independent of diagnosis, Part 2: Potentially inappropriate drugs, dependent on diagnosis, Part 3: 
Potential prescribing omissions and Part 4: Drug-drug interactions of specific relevance) 
  
 
 
 
128 
Chapter 2 – Medication screening in the community pharmacy setting 
 
Table 2.5.1: Most prevalent GheOP³S-criteria of each part of the GheOP³S-tool, n = 400 
 GheOP³S-criterion N, % (relative 
to total 
population)  
N, % (relative to 
overall drug or 
disease 
prevalence) 
Part 1: Potentially inappropriate drugs, independent of diagnosis 341 (85%)  
1 Any intermediate acting benzodiazepine or Z-product at full dose or any dose ≥30 
subsequent days OR Any short- or long-acting benzodiazepine 
212 (53%)  
 Any intermediate acting benzodiazepine or Z-product at full dose or any dose ≥30 
subsequent days 
195 (49%)  
 Any short- or long-acting benzodiazepine 35 (9%)  
 Any intermediate acting benzodiazepine or Z-product at full dose or any dose ≥30 
subsequent days AND Any short- or long-acting benzodiazepine 
18 (5%)  
2 Any antidepressant ≥1 year 169 (42%)  
3 Any antipsychotic drug ≥1 month 117 (29%)  
4 Any PPI at full dose ≥8 weeks 73 (18%)  
5 Any oral non-steroidal anti-inflammatory drug 35 (9%)  
Part 2: Potentially inappropriate drugs, dependent on diagnosis  219 (55%)  
1 Anticholinergics with constipation 149 (37%) 149/199 (75%) 
2 Calcium channel blockers with constipation 43 (11%) 43/197 (22%) 
3 Anticholinergics with dementia or cognitive impairment 36 (9%) 36/51 (71%) 
4 Oral corticosteroids >1 week with hypertension 19 (5%) 19/221 (9%) 
5 Thiazide and loop diuretics with gout 18 (5%) 18/27 (67%) 
Part 3: Potential prescribing omissions 245 (61%)  
1 The patient has an elevated risk for osteoporosis and is not prescribed Calcium and Vitamin 
D supplementation. 
214 (54%) 214/295 (73%) 
2 The patient is taking narcotic analgesics and is not prescribed appropriate preventative 
bowel regimen. 
35 (9%) 35/84 (42%) 
3 The patient is taking oral corticosteroids for ≥1 month and is not prescribed a Calcium and 
Vitamin D supplementation. 
15 (4%) 15/25 (60%) 
4 The patient is taking an equivalent of 7.5 mg of oral prednisone or more for ≥3 months and 
is not prescribed calcium/Vitamin D supplementation and bisphosphonates. 
7 (2%) 7/11 (64%) 
5 The patient is taking methotrexate and is not prescribed folic acid supplementation. 1 (0%) 1/1 (100%) 
Part 4: Drug-drug interactions of specific relevance 230 (58%)  
1 Any combination of anticholinergic drug 163 (41%)  
2 Oral antidiabetics/insulin and β-blocker 41 (10%)  
 Oral antidiabetics/insulin and non-selective β-blocker 8 (2%)  
 Oral antidiabetics/insulin and selective β-blocker 37 (9%)  
3 Oral non-steroidal anti-inflammatory drug and diuretic 22 (6%)  
4 Bisphosphonate and calcium, magnesium, zinc, iron or aluminium 22 (6%)  
5 RAAS inhibitor and potassium sparing diuretic, potassium supplements or potassium 
containing drugs 
20 (5%)  
RAAS: Renin angiontensin aldosteron system 
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DISCUSSION 
In this observational study, we detected at least one PIP in 97% of the 400 randomly included 
nursing home residents, with a median of 4 PIPs per resident. This is in concordance with two other 
Belgian studies and with studies from other European countries(3, 5, 14, 15). Some studies report 
lower prevalence rates, however in these cases, the researchers evaluated PIP with a smaller subset 
of published criteria or only screened for one aspect of PIP (e.g. underuse)(16, 17). On the other hand, 
compared with a recent systematic review, estimating PIP prevalence in the ambulatory setting(18), 
the prevalence in nursing homes is markedly higher. Although, one previously performed study with 
the GheOP³S-tool in the ambulatory setting observed a comparable PIP prevalence (at least one PIP in 
97% of patients, median of 3 PIP per patient)(10).  
The fact that nearly all patients had at least one PIP shows that there is a large room for 
improvement on the appropriateness of prescribing. During the development of the GheOP³S-tool, the 
experts unanimously agreed on the clinical relevance of screening for all included items in older 
patients in general. Whether the detected problems are also clinically relevant for the individual 
patient, still needs to be assessed during a pharmacist-physician consultation and agreement. The 
actual rate of inappropriate prescribing will therefore probably be somewhat lower. 
The most prevalent PIP-items identified by the GheOP³s-tool can be assigned to the following 
three main categories: long-term use of drugs that influence the central nervous system (i.e. 
hypnosedatives, antidepressants and antipsychotics), use of anticholinergic drugs (mutual 
combinations and with underlying constipation or dementia) and underuse of osteoporosis 
prophylaxis. Additionally, the use of systemic NSAIDs and the long-term use of high-dose PPIs is 
frequent in this population. All of these items are also mentioned by other European observational 
studies(2, 8, 19). In the observational study, using the GheOP³S-tool in the ambulatory setting, the 
same items (except for the use of anticholinergic drugs) significantly added to the number of PIP(10). 
As the use of drugs that influence the central nervous system and drugs with anticholinergic 
effectssignificantly adds to the high number of PIP, with possible significant clinical consequences as a 
result, the inappropriate use of these drug classes should be targeted first. Multiple trials already 
addressed these specific issues and showed that deprescribing in nursing homes is possible, improves 
the quality of prescribing and has a positive effect on the quality of life of the patient.  
One example is the study by Bourgeois et al(20), in which 66% of chronic benzodiazepine users 
were successfully discontinued after 8 months, with an improved self-perceived sleep quality and 
significantly less midnight awakenings(20). Another example, a randomized controlled trial performed 
in 22 nursing homes, showed that the anticholinergic burden was significantly reduced by a 
pharmacist-initiated medication review(21).  
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Despite the fact that the GheOP³S-tool was developed to detect PIP on the patient level, this 
study also shows that an overall analysis, applied to all residents of one institution, could expose the 
most urgent issues on a more general level. This way, the GheOP³S-tool might serve as a benchmarking 
instrument for the prescribing behaviour in a nursing home. The result of such an overall analysis 
would be the ideal starting point for interdisciplinary case-conferences or the basis for targeted action 
plans. Using the GheOP³S-tool, the dispensing pharmacist is able to assist prescribers and the nursing 
home management to increase the quality of prescribing. 
 
Strengths and limitations 
This study shows that the recently developed GheOP³S-tool, a validated community pharmacy 
specific list where limited clinical data are available, is practical and straightforward in screening for 
PIPs in nursing home residents. This study has nevertheless some limitations. As the GheOP³S-tool is 
explicit of nature, it does not take into account all patient factors in evaluating the pharmacotherapy, 
e.g. diagnoses, patient preferences or earlier attempts to tackle PIP. Also, some relevant items might 
have been missed. To tackle this, a future study will compare a GheOP³s-screening with a full 
medication review. This way, the items that are systematically missed will be identified and added to 
the GheOP³S-tool in a future update. Additionally, there were no pharmacist-prescriber contacts to 
discuss the clinical relevance of the detected items. E.g. the clinical relevance of the interaction 
between a selective β-blocker and oral antidiabetics/insulin is minimal if glycemic control is good. Also, 
it is difficult to estimate generalizability to other countries as prescribing behavior can largely differ 
between geographical regions. Despite the fact that our results match findings from other European 
countries, it would still be interesting to compare our results to a GheOP³S-tool application in other 
European countries.  
 
Conclusion 
Screening for PIP by means of the GheOP³S-tool showed a high PIP prevalence in older nursing 
home residents with polypharmacy. This urges for initiatives on the patient-level, but also on a 
broader, institutional level.  The GheOP³S-tool could be part of such an evaluation process in which it 
could be the starting point for multidisciplinary interventions, initiated by the pharmacist. Such a 
process aims to improve the quality of prescribing for nursing home residents with polypharmacy.   
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APPENDIX 2.5.1: FULL LIST OF PREVALENCE OF ALL GHEOP³S-CRITERIA 
Appendix Table 2.5.1: Full list of prevalence of all GheOP³S-criteria 
No. GheOP³S-criterion N, % (relative to 
total population, 
n=400)  
N, % (relative to 
overall drug or 
disease 
prevalence) 
Part 1b: Potentially inappropriate drugs, independent of diagnosis – Drug classes 
1 Any antidepressant ≥1year 169 42%  
2 Any antipsychotic drug ≥1 month 117 29%  
3 Any drug for arterial vascular disorders  9 2%  
4 Any intermediate acting benzodiazepine or Z-product at full dose or any dose ≥30 
subsequent days 
195 49%  
5 Any short  or long-acting benzodiazepine  
 
35 9%  
6 Any long-acting sulfonylurea derivative  18 5%  
7 Any nasal vasoconstrictor ≥1 month 3 1%  
8 Any oral NSAID 35 9%  
9 Any PPI at full dosea ≥8 weeks  73 18%  
10 Any recently marketed drug (black triangles) 13 3%  
11 Any sedating antihistaminic drug  14 4%  
Part 1b: Potentially inappropriate drugs, independent of diagnosis - Specific molecules 
12 Alizapride 5 1%  
13 Bisacodyl 5 1%  
14 Clonidine 3 1%  
15 Codeine and its derivatives for acute cough 6 2%  
16 Dabigatran 3 1%  
17 Digoxin >0,125mg/day 8 2%  
18 Dipyridamole monotherapy (without ASA) 0 0%  
19 Ginkgo biloba or Panax ginseng 3 1%  
20 Liquid paraffin 1 0%  
21 Methyldopa  0 0%  
22 Metoclopramide 13 3%  
23 Pentazocine 0 0%  
24 Phenobarbital 1 0%  
25 Pseudoephedrine oral 0 0%  
26 Rivaroxaban or Apixaban 10 3%  
27 Senna glycosides 1 0%  
28 Picosulfate 4 1%  
29 Theophylline 10 3%  
30 Ticlopidine, new prescription 0 0%  
31 Tramadol, new prescription 30 8%  
Part 2a: Potentially inappropriate drugs, dependent on diagnosis - Drug classes 
32 Any  antipsychotic other than quetiapine and clozapine with Parkinson’s disease 13 3% 13/54 (24%) 
33 Anticholinergics (e.g. Antihistamines, Antidepressants, Antipsychotics, Antispasmodics…) 
with dementia or cognitive impairment 
36 9% 36/51 (71%) 
34 Anticholinergics (e.g. Antihistamines, Antidepressants, Antipsychotics, Antispasmodics…) 
with constipation 
149 37% 149/199 (75%) 
35 Anticholinergics (e.g. Antihistamines, Antidepressants, Antipsychotics, Antispasmodics…) 
with BPH 
13 3% 13/21 (62%) 
36 Calcium Channel Blockers with constipation 43 11% 43/197 (22%) 
37 Non-selective beta-blockers with asthma or COPD 9 2% 9/90 (10%) 
38 Oral corticosteroids >1 week with diabetes 8 2% 8/103 (8%) 
39 Oral corticosteroids >1 week with hypertension 19 5% 19/221 (9%) 
40 Thiazide and loop diuretics with gout 18 5% 18/27 (67%) 
Part 2b: Potentially inappropriate drugs, dependent on diagnosis - Specific molecules 
41 Alizapride with Parkinson’s disease 0 0% 0/54 (0%) 
42 Metoclopramide with Parkinson’s disease 0 0% 0/54 (0%) 
Part 3: Potential prescribing omissions  
43 The patient is taking ≥ an equivalent of 7.5 mg of oral prednisone for ≥3 months and is not 
prescribed Ca/VitD supplementation and bisphosphonates. 
7 2% 7/11 (64%) 
44 The patient is taking narcotic analgesics and is not prescribed appropriate preventative 
bowel regimen (preferably macrogol or lactulose). 
35 8% 35/84 (42%) 
45 The patient has an elevated risk for osteoporosis (determined via FRAX-tool(22)) and is not 
prescribed Calcium/Vitamin D supplementation. 
214 54% 214/295 (73%) 
46 The patient is taking oral corticosteroids for ≥1 month and is not prescribed Ca/VitD 
supplementation. 
15 4% 15/25 (60%) 
47 The patient is not reminded and proposed to undergo yearly influenza vaccination. 0 0% 0% 
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48 The patient is taking methotrexate and is not prescribed folic acid supplementation. 
 
1 0% 1/1 (100%) 
Part 4: Drug-Drug interactions of specific relevance  
49 VKA + oral NSAIDs 2 1%  
50 RAAS-inhibitor + potassium sparing diuretic/potassium supplements/potassium containing 
drugsb 
20 5%  
51 VKA + Antiplatelet drugs (esp. ASA), unless prescribed by internist/cardiologist 11 3%  
52 VKA + TMP/SMX 0 0%  
53 Oral NSAID + Oral Corticosteroids 4 1%  
54 Oral NSAID + Diuretic 22 6%  
55 Digoxin + Macrolide antibiotics 1 0%  
56 Digoxin + Verapamil/Diltiazem 0 0%  
57 Lithium + RAAS-inhibitors 0 0%  
58 Lithium + Oral NSAID 0 0%  
59 Lithium + Diuretics 0 0%  
60 Theophylline + Quinolones/Macrolides 2 1%  
61 RAAS-inhibitor + Oral NSAID 8 2%  
62 Oral NSAID + SSRI/SNRI 9 2%  
63 RAAS-inhibitor + TMP/SMX 2 1%  
64 Oral antidiabetics/insulin + non-selective beta-blocker 8 2%  
65 Oral antidiabetics/insulin + cardioselective beta-blocker 37 9%  
66 Alprazolam/Midazolam/Triazolam/Zolpidem/Zopiclone + Strong CYP3A4 inhibitor 3 1%  
67 CCB + Strong CYP3A4 inhibitor 0 0%  
68 Oral NSAID + Antipletelet drugs 16 4%  
69 Phenytoin + TMP/SMX 0 0%  
70 First dose RAAS-inhibitor at full dosage + pre-treatment with diuretic 5 1%  
71 Tamoxifen + strong CYP2D6 inhibitors  0 0%  
72 Calcium + Quinolones/Tetracyclines 13 3%  
73 Calcium + Stontium ranelate 5 1%  
74 Calcium + Levothyroxine 10 3%  
75 Bisphosphonate + Calcium, Magnesium, Zinc, Iron or Aluminium 22 6%  
76 VKA + Vitamin K containing drugs/supplementsc 1 0%  
77 Any combination of anticholinergic drug 163 41%  
ASA: Acetylsalicylic acid; BPH: Benign prostatic hyperplasia; CCB: Calcium Channel Blocker; COPD: Chronic Obstructive Pulmonary Disease; CV-
risk: Cardiovascular risk; GI-risk: Gastro-intestinal risk; GP: General Practitioner; NSAID: Non Steroidal Anti-Inflammatory Drug; INR: 
International Normalized Ratio; PPI: Proton Pump Inhibitor; RAAS-inhibitor: Renin-Angiotensin-Aldosteron System Inhibitors; SNRI: Serotonin and 
Noradrenalin Reuptake Inhibitor; SSRI: Selective Serotonin Reuptake Inhibitor; TMP/SMX: Trimetoprim/Sulfamethoxazol; VKA: Vitamin K 
Antagonist. 
 
a Full dose defined as: >20 mg (es)omeprazole, >20mg pantoprazole, >30mg lansoprazole, >20mg rabeprazole  
b Some drugs contain considerable potassium amounts: Glucosamine in potassium salt (up to 300mg/tablet), oral nutritional supplements (up to 
200mg/unit).... (Recommended Daily Dose: 3000mg/day for ≥60 year old patients) 
c Some supplements such as oral nutritional supplements contain considerable Vitamin K amounts (up to 13µg/unit). (Recommended Daily Dose: 
50-70µg/day for ≥60 year old patients) 
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PART 3.1: 
INTRODUCTION ON COPD AND COPD MANAGEMENT 
PATHOLOGY, PATHOPHYSIOLOGY, EPIDEMIOLOGY AND COPD MANAGEMENT  
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1. COPD PATHOLOGY AND PATHOGENESIS1-3 
COPD is characterised by poorly reversible airflow 
obstruction and an abnormal inflammatory response 
in the lungs to long term exposure to noxious 
particles and gases, particularly cigarette smoke. In 
general, the inflammatory response and the 
consequent structural changes in the airways 
increase with disease severity and persist even after 
smoking cessation. Two other processes further 
modify COPD pathogenesis; an imbalance between 
proteases and anti-proteases and oxidative stress. 
 
Figure 3.1.1: Pathology of Chronic Obstructive Pulmonary 
Disease. 
 
1.1. Inflammatory response in COPD 
The inflammatory response in patients with COPD is amplified compared to the normal 
inflammatory response of the respiratory tract to chronic irritants such as cigarette smoke. In patients 
with COPD there is an increased number of CD8+ Tc1 lymphocytes, neutrophils and macrophages, 
releasing inflammatory mediators. These mediators attract inflammatory cells from the circulation, 
amplify inflammatory processes and induce structural changes in the airways, lung parenchyma and 
pulmonary vasculature.  
 
1.2. Imbalance between proteases and anti-proteases 
In patients with COPD, an imbalance between proteases that break down connective tissue and 
anti-proteases that protect against it, is observed. The imbalance originates in an increased production 
and release of proteases in the macrophages and neutrophils and an augmented inactivation of anti-
proteases. Protease-mediated destruction of elastin, a major component of lung parenchyma, is 
believed to be an important feature of emphysema and is likely to be irreversible.  
 
1.3. Oxidative Stress 
Oxidative stress is a significant contributor to COPD pathogenesis. Sources of oxidants include 
cigarette smoke and reactive oxygen and nitrogen species released from inflammatory cells (e.g.  
macrophages, neutrophils). Biomarkers of oxidative stress (e.g. hydrogen peroxide) are increased in 
the exhaled breath condensate, sputum and systemic circulation of patients with stable COPD and 
even further amplified during exacerbations. Excessive oxidative stress leads to altered (anti-)protease 
activities and stimulation of mucous production. It can also amplify inflammation by enhancing 
transcription factor activation and hence the gene expression of pro-inflammatory mediators. 
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2. PATHOPHYSIOLOGY1-3 
The pathogenic mechanisms result in the pathological changes found in COPD such as parenchymal 
tissue destruction. On their turn, they result in physiological abnormalities such as mucus 
hypersecretion, progressive airway obstruction and air trapping, gas exchange abnormalities, and 
systemic effects. 
 
2.1. Mucus Hypersecretion 
Mucus hypersecretion is not necessarily associated with COPD and conversely, not all patients with 
COPD have mucus hypersecretion. However when present, it results in a chronic productive cough and 
is due to an increased number of goblet cells and enlarged submucosal glands in response to chronic 
airway irritation.  
 
2.2. Airflow obstruction and air trapping 
The airflow obstruction mainly occurs in the small airways, because of fibrosis and inflammatory 
exudates. Other contributing factors include loss of the lung elastic recoil (due to destruction of 
alveolar walls) and destruction of alveolar support (from alveolar attachments). The airway obstruction 
progressively traps air during expiration, resulting in hyperinflation. Hyperinflation diminishes 
inspiratory capacity and increases functional residual capacity, particularly during exercise. This results 
in the typical breathlessness and limited exercise capacity for patients witch COPD.  
 
2.3. Gas exchange abnormalities 
Abnormalities in gas exchange appear in advanced COPD and result in characteristic arterial 
hypoxaemia with or without hypercapnia. Multiple processes contribute to this observation. First, gas 
transfer of both oxygen and carbon dioxide worsens as the disease progresses, and second, reduced 
ventilation leads to a decreased ventilator drive.  
 
2.4. Exacerbations 
Exacerbations of respiratory symptoms often occur in patients with COPD. They can be triggered 
by (concomitant) bacterial or viral infection, environmental pollution or other, unknown factors. 
However, bacterial and viral episodes have a characteristic response with increased inflammation. 
During exacerbations, there is increased hyperinflation and air trapping, with reduced expiratory flow 
and hence accounting for the increased dyspnoea. There is also a worsening in gas exchange 
abnormalities, possible resulting in hypoxaemia and respiratory acidosis.  
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3. EPIDEMIOLOGY & BURDEN OF COPD 
As COPD is the result of cumulative exposure to tobacco smoke, occupational and indoor air 
pollution over decades, the prevalence varies widely across countries and across different groups 
within countries4. In Belgium and in the Netherlands, the prevalence of COPD is currently estimated to 
be about 2 to 3%, which increased since the early nineties5 6. Equal to the prevalence, the incidence of 
COPD is dependent on age and gender. Based on data of the Rotterdam Study7, the incidence of COPD 
is estimated to be about 9.2/1000 person-years (PY), with a higher incidence for men (14/1000 PY) 
compared to women (6/1000 PY) in a cohort of patients ≥55 year. COPD appears to be a leading cause 
of morbidity and mortality worldwide and results in a substantial economic and social burden. 
Morbidity traditionally includes physician visits, emergency department visits and hospitalizations. 
As patients with COPD are often affected by multiple comorbid conditions, data about morbidity 
specifically related to COPD are less available and difficult to interpret. Mortality data on the other 
hand are more readily available. According to a study in 2010, COPD was the 5th ranked cause of death 
in the United States. Mortality increased in the last 30–40 years, however, more recently, it decreased 
in men in several countries, while increasing or stabilizing in women. This may be explained by 
differences in smoking patterns and a greater vulnerability in women to the adverse effects of smoking. 
A main reason for this increase in mortality is mainly driven by the expanding epidemic of smoking, 
reduced mortality from other common causes of death and aging of the world population. Under-
recognition and under-diagnosis of COPD still affect the accuracy of morbidity and mortality data. 
Actual numbers are probably much higher. 
The economic burden for treating COPD is substantial. Direct costs can be divided into specialty 
care and hospitalization costs (± 45%), medication costs (± 35%), primary care and physiotherapy costs 
(± 15%) and other therapies (± 5%). In addition, indirect costs related to COPD are considerable, due 
to work productivity losses and disability pension paid8. Treatment of COPD and its exacerbations 
contribute substantially to overall healthcare costs. In the European Union the costs approximately 
account for 6% of the total European healthcare budget1. According to the National Institute for Health 
and Disability Insurance (INAMI), in Belgium, the expenditures of reimbursed drugs for COPD for 
patients >45 years is increasing, up to € 149 million in 20109.  
Where mortality offers a limited perspective on the human burden of a disease, the Disability-
Adjusted Life Years (DALYi) can be used. In 2010, COPD was ranked second, based on number of DALYs 
lost in the United States10, and was ranked 4th based on number of life-years lost. Finally, COPD was 
ranked 6th for years lived with disability10.   
                                                          
i The DALYs for a specific condition are the sum of years lost because of premature mortality and years of life lived with disability, adjusted 
for the severity of disability. 
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4. GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE (GOLD) 
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) is a worldwide organization that 
works together with health care professionals and public health officials. The primary goals are to raise 
awareness of COPD and to improve the prevention and treatment of this disease. GOLD started with 
the development of evidence-based strategy documents for COPD management in 1997 and regularly 
updated this document ever since, with the last update in January 20151. The GOLD report is to be 
used by health care professionals to implement effective management programs based on available 
health care systems and evidence. 
 
4.1. Classification of COPD 
The classification of COPD helps to determine the severity of the disease, including its impact on 
the patient’s health status and the risk of future events (such as exacerbations or hospital admissions)1. 
Before 2011, COPD was classified based on spirometry. Spirometry is a physiological test, measuring 
exhalation or inhalation volumes of air as a function of time11. To classify COPD, the Forced Vital 
Capacity (FVC) and Forced Expiratory Volume in one second (FEV1) are used. The FVC is the volume 
delivered during an expiration made as forcefully and completely as possible starting from full 
inhalation. The FEV1 is the volume delivered in the first second of that attempt11. Both can be measured 
before and after the use of a bronchodilator. The presence of a post-bronchodilator FEV1/FVC < 0.70 
confirms the diagnosis of COPD1. The FEV1 is consequently used to estimate the severity of disease 
(Table 3.1.1).  
 
Table 3.1.1: Spirometric classification of COPD, before 2011 
GOLD stage Spirometry 
I: Mild FEV1/FVC < 0.70 
FEV1 ≥ 80% of FEV1 predictedii 
II: Moderate FEV1/FVC < 0.70 
50 % ≤ FEV1 < 80% of FEV1 predicted 
III: Severe FEV1/FVC < 0.70 
30 % ≤ FEV1 < 50% of FEV1 predicted 
IV: Very severe FEV1/FVC < 0.70 
FEV1 < 30% of FEV1 predicted 
FEV1: Forced Expiratory Volume in one second; FVC: Forced Vital Capacity 
 
However, lung function alone does not cover the burden of the disease completely. Therefore, 
breathlessness (according to the mMRC-scaleiii), health status impairment (according to the CAT-
scaleiv) and exacerbations are currently also included to estimate COPD severity (Figure 3.1.2)1. 
                                                          
ii The FEV1 predicted is defined as the FEV1 of the patient divided by the average FEV1 in the population for any person of similar age, sex 
and body composition. 
iii Scores on the modified Medical Research Council dyspnea scale can range from 0 to 4, with a score of 4 indicating the patient is too 
breathless to leave the house or becomes breathless when (un)dressing. 
iv The COPD Assessment Test scale is a unidimensional scale evaluation patients’ COPD symptoms; ranges from 0-40, a higher score 
indicates a worse health status 
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Figure 3.1.2: Classification of COPD severity (after 2011)  
 
CAT: COPD Assessment Test; GOLD: Global Initiative for Chronic Obstructive Lung Disease;  
mMRC: modified Medical Research Council 
 
4.2. Non-pharmacologic treatment of COPD 
Non-pharmacologic strategies for patients with COPD are mainly aimed at reducing symptoms, 
improving quality of life and increasing participation in everyday activities1. At first instance, smoking 
cessation counselling should be offered to every patient diagnosed with COPD that is still smoking12. 
Second, individualized exercise training and nutrition counselling are recommended to increase 
exercise capacity and prevent muscle wasting and weight loss13 14. Finally, education about the disease 
can help patients playing a pro-active role in their disease management. These four action points are 
merged under the term ‘pulmonary rehabilitation’1. Furthermore, for patients with COPD and chronic 
respiratory failure, oxygen therapy has demonstrated to increase survival when there is resting 
hypoxemia present15. Ventilator support, lung volume reduction surgery and lung transplantation are 
optional possibilities for patients with very advanced COPD1. 
 
4.3. Pharmacologic treatment of COPD 
As COPD is an irreversible and progressive disease, the main goals of pharmacologic treatment are 
to reduce symptoms and to reduce the number of exacerbations. As COPD is a respiratory disease, a 
great deal of the medication is administered locally, through inhalation therapy. This can be on an as 
needed basis or on a regular basis. Besides, there are some oral possibilities, including 
methylxanthines, oral corticosteroids and antibiotics. However, the latter two are mostly used during 
exacerbations.    
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4.3.1. Inhalation therapy 
Bronchodilators, including anticholinergics and β2-agonists, and inhaled corticosteroids are 
administered through inhalation for the treatment of patients with COPD (Table 3.1.2).  
 
4.3.1.1. Anticholinergics  
Anticholinergics act by blocking muscarinic receptors in respiratory tissue. Both short- and long-
acting anticholinergic agents exist where long-acting agents such as tiotropium have a duration of 
action of more than 24 hours16. Tiotropium reduces exacerbations and related hospitalisations 
compared to placebo and ipratropium17. It also improves health-related quality-of-life and symptoms 
among patients with moderate and severe disease17. Aclidinium and glycopyrronium seem to have 
similar action on lung function and breathlessness as tiotropium18 19, however, less data are available 
for other outcomes18.  
 
4.3.1.2. β2-agonists 
β2-agonists stimulate the β2-receptors in the airways and consequently relax airway smooth muscle 
cells. As well, both short-acting (4 to 6 hours ) and long-acting (up to 12 hours and more) β2-agonists 
agents exist16. Formoterol and salmeterol significantly improve spirometry measures, dyspnea, health-
related quality of life and exacerbation rate20. However no effect on decline in lung function or 
mortality is observed20. Similar effects are seen for indacaterol (long-acting, up to 24 hours)21.  
 
4.3.1.3. Inhaled corticosteroids 
The inhibitory effects of inhaled corticosteroids on both pulmonary and systemic inflammation in 
patients with COPD are controversial. Their role in the management of stable COPD is therefore 
limited1. For patients with an FEV1 < 60% predicted, regular treatment with inhaled corticosteroids 
may reduce exacerbation frequency22 23. However, it shows no effect on decline in lung function or 
mortality24. Additionally, they have significant local side-effects.  
 
Table 3.1.2: Drugs, available through inhalation for treatment of COPD on the Belgian market25  
Anticholinergics β2-agonists Anticholinergic/ β2-agonist 
combinations 
Inhaled corticosteroids Inhaled corticosteroid/ β2-
agonist combinations 
Ipratropium (S) Fenoterol (S) Ipratropium/Salbutamol (S) Beclometason Beclometason/Formoterol (L) 
Aclidinium (L) Salbutamol (S) Ipratropium/Fenoterol (S) Budesonide Budesonide/Formoterol (L) 
Umeclidinium (L) Indacaterol (L) Glycopyrronium/Indacaterol (L) Fluticason Fluticason/Formoterol (L) 
Glycopyrronium (L) Salmeterol (L) Umeclidinium/Vilanterol (L)  Fluticason/Vilanterol (L) 
Tiotropium (L) Formoterol (L) Aclidinium/Formoterol (L)  Fluticason/Salmeterol (L) 
 Vilanterol (L)    
L: Long-acting drug; S: Short-acting drug 
 
 
  
 
 
 
Chapter 3 – Community pharmacy counselling for patients with COPD 
 
144 
4.3.1.4. Inhalation therapy difficulties 
Administration through inhalation requires very specific handling and leads to practical issues. The 
correct handling of inhalation devices seems to be problematic for many patients with COPD. Mehuys 
et al reported that 21% of patients with COPD made major inhalation errors, such as failing to remove 
the inhaler cap and/or failing to shake the pMDI26. Indeed, other research confirmed that inhaler 
mishandling remains common and is even associated with reduced disease control27. It is suggested 
that repeated training is necessary as positive effects of interventions disappear over time. This would 
require long-term and continuous monitoring of patients with COPD28.  
 
4.3.2. Oral treatment options 
4.3.2.1. Methylxanthines 
Methylxanthines act as non-selective phosphodiesterase inhibitors16. They increase intracellular 
cAMP by inhibiting breakdown, consequently stimulating airway smooth muscle cells to relax16. 
Theophylline is the most used methylxanthine in treatment of COPD. However, it is less effective and 
less well tolerated than inhaled long-acting bronchodilators. Therefore, and because of its narrow 
therapeutic window it is not recommended as first-line therapy29.  
 
4.3.2.2. Oral corticosteroids & Antibiotics 
Oral corticosteroids and antibiotics are not recommended for maintenance therapy in patients with 
COPD as long-term use causes significant adverse effects such as increased risk of pneumonia and 
osteoporosis16 25. However, they play a significant role in the management of exacerbations (see 
further)1.  
 
4.3.3. Treatment guidelines 
4.3.3.1. Managing stable COPD 
For all patients with COPD, all non-pharmacological measures should be taken (e.g. smoking 
cessation, flu vaccination etc.). Additionally, to control symptoms and reduce severity and frequency 
of exacerbations, pharmacological therapy should be added. All patients are advised SABA/SAMA 
therapy in case of symptoms of shortness of breath (as needed) and during acute exacerbations. From 
COPD GOLD B stage onwards, a maintenance treatment with one or two long-acting bronchodilators 
is warranted. In patients with frequent exacerbations, inhaled corticosteroids might be added to long-
acting bronchodilator(s).   
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4.3.3.2. Managing exacerbations 
An exacerbation is defined as an ‘acute event characterized by a worsening of the patient’s 
respiratory symptoms that is beyond normal day-to-day variations and leads to a change in 
medication’1. As severe exacerbations accelerate the rate of lung function decline and are associated 
with significant mortality30, fast and effective treatment is needed. In all cases, immediate relief of 
bronchoconstriction is necessary, for which short-acting bronchodilators are the first-choice1. 
Consequently, systemic corticosteroids are the first option as they improve airflow, decrease the rate 
of treatment failure and risk of relapse, and decrease the length of hospital stay31. Antibiotics for COPD 
exacerbations showed inconsistent beneficial effects across outcomes of patients with a COPD 
exacerbation32. Also, antibiotics had no statistically significant effect on mortality and length of hospital 
stay in inpatients and almost no data on patient-reported outcomes exist32. Hence, antibiotics should 
only be given to patients where clear bacterial colonisation is observed. This can be assessed by three 
cardinal symptoms: increase in dyspnoea, sputum volume and sputum purulence1.  
 
Table 3.1.3: Management of stable COPD and exacerbations 
 Stable COPD Exacerbation 
Goal Symptom reduction 
Reduction of exacerbation risk 
Minimize impact  
Prevent development of subsequent exacerbation 
Non-pharmacologic 
treatment options 
Smoking cessation 
Vaccination 
Pulmonary rehabilitation 
Oxygen therapy (optional) 
Ventilator support (optional) 
Pharmacologic treatment 
options 
(long-acting) Bronchodilators 
Inhaled corticosteroids  
(Theophylline) 
Short-acting bronchodilators 
Corticosteroids (oral and inhaled) 
Antibiotics  
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5. MEDICATION ADHERENCE IN PATIENTS WITH COPD 
5.1. Medication adherence33 
When a patient takes his or her medication as recommended, the patient is defined ‘adherent’. 
Adherence to medication is a process that encompasses 3 different parts: (1) the initiation of the 
therapy, (2) correct implementation of the therapy in the patient’s daily life, and (3) discontinuation 
of the therapy. Nonadherence to medications can subsequently occur in the following situations: late 
or non-initiation of the prescribed treatment, suboptimal implementation of the dosing regimenv, or 
early discontinuation of the treatment. 
When nonadherent behaviour is observed, this can be a deliberate choice of the patient, in which 
case we use the term ‘intentional nonadherence’. In case the patient is unaware of the exhibited 
behaviour, the term ‘unintentional nonadherence’ is used. Patients may exhibit both behaviours, in 
which case the term ‘overlapping nonadherence’ is used.  
 
5.2. Measures of (non)adherence 
A number of direct and indirect methods are available to measure the extent of (non)adherence 
(Table 3.1.4). All methods have advantages and disadvantages. In real-world situations however, 
pharmacy dispense records are preferred as they have shown a good correlation with actual use and 
are easy and cheap to obtain34. However, this method lacks discriminative properties to determine 
exhibited types of nonadherence. Therefore, qualitative patient interviews are required. To date, no 
gold standard to measure and define adherence in an unbiased, reliable, quick and low-cost way is 
defined.  
 
Table 3.1.4: Methods to measure nonadherence; advantages and disadvantages (Adopted and adapted from Lareau et al.35) 
 Advantages Disadvantages 
Clinicians’ estimates Easy to obtain Unreliable  
Patients’ self-report Easy to obtain Unreliable, overestimation  
Pill counts Easy to obtain Overestimates, pill dumping 
Pharmacy records Confirms prescription filling Incomplete, biased estimates 
Biologic measures Confirms ingestion Expensive, invasive, insensitive to inhaled drugs, affected by 
pharmacokinetic patient properties and polypharmacy  
Electronic monitoring Provides use patterns Expensive, limited availability and use, malfunctions 
 
  
                                                          
vv This includes (1) the proportion of prescribed drugs taken, (2) the proportion of days with the correct number of doses taken (3) the 
proportion of doses taken on time, (4) the number of drug holidays and (5) the longest interval between two doses. 
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5.3. Nonadherence, its determinants, and impact for patients with COPD 
Although COPD can be managed well with both non-pharmacological and pharmacological 
options1, adherence to therapy is often suboptimal36. Adherence rates reported in asthma and COPD 
vary largely with rates between 22% and 78%, depending on the population assessed and the methods 
of measure37. For patients witch COPD, adherence rates are mainly estimated to be about 50%36. An 
observational study performed in Belgian community pharmacies detected underadherence in 48% of 
patients and overadherence in 5% of patients26.  
There is no single factor that determines nonadherent behaviour in a patient. Nonadherence to 
COPD medication is multi-factorial and is influenced by the patient, the treatment and the society 
(Figure 3.1.3)36. Therefore, interventions aimed at improving adherence could never follow a ‘one-size-
fits-all’ approach, but need to be tailored to the individual’s need.  
Suboptimal adherence in patients with COPD has been associated with higher morbidity and 
healthcare use (i.e., general practitioner (GP) visits, emergency room visits and hospitalizations) due 
to more frequent episodes of worsening of symptoms, i.e. exacerbations38-40. Similarly, an association 
with increased mortality has been reported38 40.  
 
 
Figure 3.1.3: Determinants of nonadherence in patients with COPD (Adopted from Bourbeau et al.36) 
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ABSTRACT 
 
Aim. Few well-designed randomized controlled trials (RCT) regarding the impact of community 
pharmacist interventions on pharmacotherapeutic monitoring of patients with Chronic Obstructive 
Pulmonary Disease (COPD) have been conducted. We assessed the effectiveness of a pharmaceutical 
care program for patients with COPD. 
 
Methods. The PHARMACOP-trial is a single-blind 3-month RCT, conducted in 170 community 
pharmacies in Belgium, enrolling patients prescribed daily COPD medication, aged ≥50 years, and with 
a smoking history ≥10 pack-years. A computer-generated randomization sequence allocated patients 
to intervention (n=371), receiving protocol-defined pharmacist care, or control group (n=363), 
receiving usual pharmacist care (1:1 ratio, stratified by center). Interventions, focusing on inhalation 
technique and adherence to maintenance therapy, were carried out at start of the trial and at one 
month follow-up. Primary outcomes were inhalation technique and medication adherence. Secondary 
outcomes were exacerbation rate, dyspnea, COPD specific and generic health status and smoking 
behavior.  
 
Results. From December 2010 to April 2011, 734 patients were enrolled. 42 patients (5.7%) were lost 
to follow-up. At the end of the trial, inhalation score (Mean estimated difference [∆],13.5%; 95% 
Confidence Interval [CI], 10.8-16.1; P<.0001) and medication adherence (∆, 8.51%; 95%CI, 4.63-12.4; 
P<.0001) were significantly higher in the intervention group compared to the control group. In the 
intervention group, a significantly lower hospitalization rate was observed (9 vs 35; Rate Ratio, 0.28; 
95%CI, 0.12-0.64; P=.003). No other significant between-group differences were observed. 
 
Conclusion. Pragmatic pharmacist care programs improve the pharmacotherapeutic regime in patients 
with COPD and could reduce hospitalization rates.  
 
 
 
 
151 
Community pharmacy counselling for patients with COPD – Chapter 3 
 
INTRODUCTION 
Chronic Obstructive Pulmonary Disease (COPD) is a highly prevalent, chronic lung disease, 
characterized by a not fully reversible airflow limitation. Although preventable and treatable, COPD 
remains a leading cause of morbidity, mortality and elevated health care costs worldwide1. The natural 
decline in lung function can be aggravated by a temporarily worsening of symptoms – exacerbations, 
which contribute substantially to the overall economic and social disease burden. COPD is projected 
to be the seventh leading cause of lost Disability-Adjusted Life Years in 2030 and the third leading cause 
of death in 20201 2.  
To further improve management of COPD, the Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) develops and updates treatment guidelines1. As part of the management of stable COPD, GOLD 
recommends close monitoring of the patient’s pharmacotherapy, including patient’s adherence and 
inhalation technique. Indeed, in many COPD patients, inhalation technique and medication adherence 
have been shown to be suboptimal 3-5. 
Multidisciplinary collaborations addressing these topics in primary care could be successful 
strategies to improve disease management1 6-8. In Belgium, COPD management programs are mainly 
provided in hospital settings, while community pharmacists are only occasionally involved3 7 9. 
However, pharmacists are well-placed to engage in COPD care programs due to their frequent patient 
contacts upon prescription refill, and their specific medication-related expertise. Furthermore, recent 
research showed that mere self-management programs are insufficient to reduce severe 
exacerbations10. Consequently, monitoring and optimizing COPD maintenance therapy in a community 
pharmacy to improve COPD management could be a good balance between unsupervised self-
management and extensive hospital monitoring 8 11.  
In the present 3-month randomized controlled trial (RCT), we investigated the effectiveness of a 
community pharmacist intervention, focusing on optimal use of COPD maintenance therapy. In 
accordance with the GOLD guidelines about monitoring COPD pharmacotherapy, patient’s adherence 
and inhalation technique were chosen as primary outcomes. Given their association with suboptimal 
disease management4 5, improvements in both primary outcomes could serve as surrogate markers for 
enhanced effectiveness of the current pharmacotherapeutic regimen. Secondary outcomes were 
exacerbation rates, dyspnea, COPD specific and generic health status and smoking behavior. 
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METHODS 
Design Overview 
The PHARMACOP (PHARMAceutical Care for COPD) trial is a 3-month randomized, controlled, 
parallel group trial carried out between December 2010 and July 2011 in 170 community pharmacies, 
well-spread throughout Belgium. The study protocol was approved by the Ethical Committees of the 
Ghent University Hospital (for Flanders) and Centre Hospitalier Universitaire de Liège (for Wallonia). 
All patients provided written informed consent. General practitioners (GP) of all participants were 
notified about the study by letter. Clinicaltrials.gov Identifier: NCT01260389. 
 
Setting and Participants 
Patients filling a prescription for COPD medication (R03, Anatomical Therapeutic Chemical 
classification) at participating pharmacies were consecutively invited to participate when meeting 
following inclusion criteria: (1) prescription for daily COPD maintenance medication, (2) aged 50 years 
or older, (3) smoking history of at least 10 pack-years, (4) regular visitor to the pharmacy and (5) 
providing written informed consent. Patients with current asthma and analphabetic patients were 
excluded. Each pharmacy planned a maximum of 6 COPD patients to be recruited. Recruitment period 
ran from December 2010 through April 2011.  
Eligible patients were randomized to either control or intervention group (1:1 ratio), stratified by 
center, with each pharmacy accounting for one recruitment center. To conceal assignments, 
pharmacists performed allocation through a central web based randomization system, created by an 
independent investigator. As the intervention was educational, blinding of pharmacists was not 
possible. Patients, however, were not told to which study group they were assigned. After 
randomization, pharmacy visits were planned at 1 and 3 months. 
 
Intervention 
Before initiation of the trial, all participating pharmacists received a training session addressing 
pathophysiology of COPD, its nonpharmacological and pharmacological treatment (GOLD guidelines), 
important referral criteria and study protocol. Control group patients were given usual non protocol-
based pharmacist care. Patients in the intervention group received a protocol-defined two-sessions 
intervention; one session at the start of the study and one session at the 1-month follow-up visit (Table 
3.2.1), as described in detail in the trial’s protocol. All interventions were given during one-on-one 
counselling sessions. The content of the sessions was set around predefined themes, but adapted 
according to patients’ needs. Electronic medication records, performed inhalation technique and 
questionnaires completed at start of the study, served as starting point. Questionnaires included 
questions about behavioural issues concerning adherence, health issues etc.  
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Consequently, the focus of each counselling session could have been different. The duration of 
interventions was not predetermined, however, we estimate the duration between 15 and 25 
minutes.To support interventions, pharmacists were provided with information leaflets on COPD, 
demo inhaler units, and a list of practical solutions to specific nonadherent behavior12.  
 
Table 3.2.1:  Overview of pharmacist intervention 
Session 1: At start of trial (T = 0) 
Structured patient education (verbal and written form) about: 
 COPD pathophysiology  
 COPD medication 
  Dose and time of intake 
  Inhalation technique (including physical demonstration with demo inhaler unit) 
  Importance of adherence to maintenance therapy and current problems with adherence 
  Possible side effects 
 Self-management (e.g lifestyle advice) 
 Smoking cessation (if patient was current smoker) 
Session 2: 1-month follow-up (T = 1 month) 
Structured patient education (verbal only) about: 
 COPD medication 
  Inhalation technique (including physical demonstration with demo inhaler unit) 
  Changes in adherence to maintenance therapy since last visit 
 Self-management (e.g lifestyle advice) 
 Smoking cessation (if patient was current smoker) 
 
Primary outcomes 
Inhalation Technique. The participating pharmacist scored inhalation technique using a checklist 
(eight-point checklist for metered-dose inhalers (MDIs), ten-point checklist for MDIs with spacer and 
seven-point checklist for dry powder inhalers (DPIs)) at the start of the study and at 1- and 3-month 
follow-ups3 (Appendix 3.2.1). One point was assigned for each correctly performed step and the sum 
score was expressed as percentage of correct steps. Patients committing major inhalation technique 
errors (for MDI: failure to remove cap and/or fail to shake MDI; for DPI: failure to load device correctly 
and/or fail to inhale quickly and deeply through device) were assigned a sum score of zero. For ethical 
reasons, major inhalation technique errors were also corrected in control group patients.  
Adherence to maintenance therapy. Adherence was assessed at baseline and after 3 months, using 
a recommended measure of administrative data, i.e. Medication Refill Adherence (MRA)13. For each 
patient, MRA score was calculated by dividing the total days’ supply by the number of days of study 
participation. The number of days of study participation represents the number of days between 
inclusion date and the date of the second follow-up visit (after 3 months), which is more or less 90 
days. We refer to the protocol for technical aspects regarding MRA calculations. Patients with an MRA 
value ≥80 were considered adherent (cut-off selected based on previous use by other investigators5 
14). 
For patients using more than one inhaled drug, only inhalation technique and MRA score of the 
principal maintenance therapy was checked or calculated. 
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Secondary outcomes 
Dyspnea. The severity of dyspnea was determined by the modified Medical Research Council 
(mMRC) dyspnea scale15. This scale comprises five statements describing the entire range of 
respiratory disability from none (score 0) to almost complete incapacity (score 4). Patients completed 
the mMRC dyspnea scale at baseline and after 3 months.  
COPD specific health status. The COPD specific health status was measured using the COPD 
Assessment Test (CAT). The CAT is a simple and reliable questionnaire for quantifying the impact of 
COPD on the patient’s health16 17. It comprises 8 items: cough, phlegm, chest tightness, breathlessness 
going up hills/stairs, activity limitations at home, confidence leaving home, sleep and energy. Each item 
is scored from 0 to 5, giving an overall value ranging from 0 to 40 (corresponding to best and worst 
health status in patients with COPD, respectively). Patients completed CAT at baseline, after 1 month 
and after 3 months. 
Generic health status. Generic health status was assessed at start and at end of the trial, using the 
EuroQol five-dimension questionnaire (EQ-5D)18 19. The EQ-5D is a standardized, self-administered 
quality-of-life questionnaire that comprises a descriptive and a valuation section. The descriptive 
section inquires 5 domains: mobility, self-care, usual activities, pain/discomfort and 
anxiety/depression, each to be scored from 1 (no problem) to 3 (extreme problems). These numbers 
provide a 5-digit code that can be converted into a single index (utility score) through a set of weights. 
The index ranges from -0.18 (worst possible health status) to 1 (full health), using the weights for 
Belgium. The valuation section is a visual analogue scale (VAS), ranging from 0 (worst possible health 
status) to 100 (full health), where the respondent points out his self-perceived overall quality of life. 
 Smoking. The smoking status of patients was assessed through a questionnaire, including 
following questions: “Do you currently smoke?”,“Did you previously smoke?”, “How long do/did you 
smoke?” and  “How many cigarettes do/did you smoke a day?”, at start and end of the study.  
Exacerbations. Participants were asked to record occurrence and duration of moderate and severe 
exacerbations during the study period. We estimated the mean annual  exacerbation rate by dividing 
the total number of exacerbations in both study groups by the total follow-up time of the considered 
group (i.e. weighted approach)20. Exacerbations were defined functionally: exacerbations requiring 
treatment with oral corticosteroids or antibiotics were regarded as “moderate”. Exacerbations 
requiring an emergency department visit or hospitalization were regarded as “severe”21. 
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Statistical Analysis  
Descriptives were displayed as counts with percentages and means with standard deviations as 
appropriate. Minimal sample size was calculated based on the ability to simultaneously detect a 10% 
difference in inhalation technique score (SD=0.2) and a 5% difference in MRA score (SD=0.2) between 
the intervention group and the control group (i.e. equivalent of a 50%-increase in the number of 
patients with perfect inhalation technique or ≥80% adherence ) with 90% power at the 5% two-sided 
significance level. Allowing for a dropout rate of 5%, we aimed to enroll 706 patients.  
Consistent with the hypothesis, we compared the intervention group with the control group 
performing an intention-to-treat analysis for all primary and secondary outcomes. Missing data were 
handled as missing completely at random. To test for differences in mean changes between 
intervention and control group, we used mixed effect models for repeated measurements. For binary 
outcomes we used logistic regression models. Both models included terms for baseline measurement, 
study group, time, and timeXgroup interaction. Least-square means and Odds ratios, respectively, each 
with 95% confidence limits are reported. For exacerbations, a generalized linear model (i.e. Poisson 
regression analysis) was used as recommended in literature20. Subgroup analysis was performed to 
investigate the consistency of the trial conclusions among different subpopulations (age, gender, 
region). All statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC) by an 
academic statistician. Two-sided p-values of less than .05 were considered significant.  
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RESULTS 
The flow of participants through the study is shown in Figure 3.2.1. In 170 community pharmacies, 
1648 patients were pre-screened, of which 1067 (64.7%) were eligible. About 70% (n=734) of them 
agreed to participate and were randomized to control (n=363) or intervention (n=371). Both study 
groups showed similar baseline characteristics (Table 3.2.2). Almost 95% of patients (n=692) 
completed the trial, with a median follow-up time of 3 months (IQR, 3-3). Main reasons for dropout 
(n=42) were hospitalization and death. There was no significant difference between the number of 
dropouts in both study groups.  
 
Figure 3.2.1: Flow of participants through the study 
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Table 3.2.2: Baseline Characteristics  
Parameter Control group 
(n = 363) 
Intervention group 
(n = 371) 
Male Sex, No. (%) 249 (69) 236 (64) 
Age (y), mean (SD) 68.9 (9.7) 68.4 (9.6) 
BMI, kg/m², mean (SD) 25.9 (4.8) 25.9 (5.4) 
Smoking status, No. (%) 
  
 Current smoker 148 (41) 170 (46) 
 Ex-smoker 213 (59) 200 (54) 
Pack-years of current smokers, mean (SD) 40.8 (24.4) 38.54 (22.9) 
Pack-years of ex-smokers, mean (SD) 45.7 (31.3) 46.49 (29.1) 
COPD, duration (y), mean (SD) 11.2 (9.4) 10.84 (9.7) 
COPD management supervised by, No. (%) 
  
 GP only 134 (37) 149 (40) 
 Pneumologist only 46 (13) 43 (12) 
 Both GP and pneumologist 181 (50) 179 (48) 
Influenza vaccination, No. (%) 282 (78) 296 (80) 
mMRC score*, No. (%) 
  
 mMRC = 0 99 (28) 96 (26) 
 mMRC = 1 124 (34) 122 (33) 
 mMRC = 2 61 (17) 60 (16) 
 mMRC = 3 44 (12) 51 (14) 
 mMRC = 4 32 (9) 40 (11) 
CAT score†, mean (SD) 16.4 (7.6) 16.7 (7.8) 
History of exacerbations in preceding year   
 ≥ 1 in preceding yr, No. (%) 197 (54.3) 200 (54.1) 
 Moderate exacerbation rate‡, mean 0.47 0.50 
 Severe exacerbation rate‡, mean 0.23 0.21 
COPD maintenance medication, No. (%) 
  
 Short Acting β2-agonists – SABA  36 (10) 28 (8) 
 Long Acting β2-agonists – LABA  22 (6) 18 (5) 
 Short Acting Anticholinergics – SAAC   11(3) 6 (2) 
 Long Acting Anticholinergics – LAAC  284 (78) 260 (70) 
 SAAC + SABA  105 (29) 120 (32) 
 Inhaled Corticosteroids – ICS  26 (7) 37 (10) 
 ICS + LABA  296 (82) 269 (73) 
 Triple Therapy (LAAC+LABA+ICS) 236 (65) 192 (52) 
 Theophylline 6 (2) 10 (3) 
 Oral Corticosteroids 12 (3) 7 (2) 
Mean Number of COPD medications, mean (SD) 2.3 (1.0) 2.2 (1.0) 
BMI = Body Mass Index. COPD = Chronic Obstructive Pulmonary Disease. GP = General practitioner. SD = standard Deviation 
* Scores on the modified Medical Research Council dyspnea scale (mMRC) can range from 0 to 4, with a score of 4 indicating that a patient 
is too breathless to leave the house or becomes breathless when (un)dressing.  
† CAT: COPD Assessment Test; a higher score indicates a worse health status (range: 0 – 40) 
‡ Exacerbation rates are expressed as No./patient-year and calculated based on retrospective self-reported  patient data. 
 
Primary outcomes 
At baseline, mean percentages of correctly performed inhalation steps were about 68% in both 
groups (Table 3.2.3). At the end of follow-up, the improvement in inhalation technique was 
significantly higher in the intervention arm compared to the control arm (Mean estimated difference 
[∆], 13.5%; 95% confidence interval [CI], 10.8%-16.1%; P<.0001). The intervention corrected almost all 
major inhalation technique errors: 15.6% of intervention group patients received an inhalation score 
of 0% at baseline, which was reduced to 1.2% by the end of the trial, whereas in the control group, 
these percentages were 11.6% and 4.6% respectively (Odds Ratio [OR], 0.18; 95%CI, 0.06-0.53; P=.002). 
The increase in inhalation technique scores in the control group is predominantly caused by correction 
of major inhalation technique errors, as requested in the study protocol (for ethical reasons).  
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After 3 months, the odds of obtaining an inhalation score of 100% after receiving the intervention 
protocol vs no intervention was 3.03 (95%CI, 2.12-4.34; P<.0001) (Table 3.2.3). A supplementary table 
is included in Appendix 3.2.1, addressing detailed information on patients’ inhalation technique errors 
per inhaler device and per checklist item.  
Mean MRA scores were 82.7(23.9) in the control group and 84.0(23.5) in the intervention group at 
baseline. At three months, we detected a significantly higher improvement from baseline in the 
intervention group, compared to the control group (∆, 8.51; 95%CI, 4.63-12.4; P<.0001). Additionally 
at three months, the odds to obtain an MRA score ≥80 in the intervention group compared to the 
control group was 2.15 (95%CI, 1.46-3.14; P<.0001) (Table 3.2.3).  
 
COPD specific and generic health status 
At the end of the study, the number of patients having an mMRC score <2 did not differ between 
groups (P=.97). Similarly, no beneficial effects of the intervention were seen in CAT scores (P=.83), EQ-
5D utility scores (P=.19) or EQ-5D VAS (P=.15) (Table 3.2.3). At baseline, approximately 42% of patients 
reported to be current smokers. After three months, 9 (6.1%) control group patients and 15 (8.8%) 
intervention group patients had quit smoking. No significant between-group differences were 
observed (P=.33) (Table 3.2.3). 
 
Exacerbations  
During trial, 450 independent episodes of exacerbations among 302 patients were observed (Table 
3.2.4). There was no difference in estimated annual rate of moderate exacerbations between the two 
treatment arms (P=.14). In contrast, there was a significantly lower number of intervention group 
patients reporting to have had at least one severe exacerbation during the trial, compared to the 
control group (19 vs 33; OR, 0.55; 95%CI, 0.31-0.98; P=.038). Fifty-three independent severe 
exacerbations were reported in the control arm, compared to 24 in the intervention arm, which 
generated a significantly lower estimated annual severe exacerbation rate in the intervention group 
compared to the control group (0.27 vs. 0.61; Rate Ratio [RR], 0.45; 95%CI, 0.25-0.80; P<.007), mainly 
due to less hospitalizations in the intervention arm, compared to the control arm (9 vs. 35). The 
estimated annual hospitalization rate was 72% lower in the intervention group, compared to the 
control group (0.10 vs 0.40; RR, 0.28; 95%CI, 0.12-0.64; P=.003). No significant difference in the rate of 
ER-visits (P=.20), nor in the duration of the hospital stay (P=.84) was seen, but hospitalization days rate 
was reduced by 73% (0.87 vs 3.51; RR, 0.27; 95%CI, 0.21-0.35; P<.0001).  
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Subgroup Analysis 
Prespecified subgroup analyses on age, gender and region were performed (Figure 3.2.2). No 
significant interactions between study group and any subgroup were found (predetermined value for 
interaction: P<.01). However, subgroup analyses were slightly underpowered to detect modest 
differences in subgroup effects if they might exist.  
 
A Inhalation scores 
 
B MRA-scores 
  
 
C Moderate Exacerbation rates D Severe Exacerbation rates 
 
 
 
 
Figure 3.2.2: Subgroup Analysis. Mean estimated differences (black squares), rate ratios (black triangles), 95% confidence 
limits (horizontal Lines) and P values for the interaction between the study group effect and any subgroup variable. 
 
* The Dutch-speaking part of Belgium 
† The French-speaking part of Belgium 
‡ No significant interaction between the study group and subgroup variables was found, according to the predetermined 
value for interaction (P<.01). 
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DISCUSSION 
In the PHARMACOP-trial, we assessed the effectiveness of a protocol-based community pharmacist 
intervention in 734 patients with COPD. Outcomes were selected based on their association with 
suboptimal disease management3-5. The intervention significantly improved both primary outcomes, 
i.e. inhalation technique and medication adherence, and significantly decreased the estimated annual 
severe exacerbation rate. No significant differences in other health outcomes were observed. 
Only few studies have investigated community pharmacist interventions to improve 
pharmacotherapeutic management of COPD8 9 22. None of these trials distinguished between asthma 
and COPD patients, although management and health outcomes for both diseases are distinct. This 3-
month RCT confirms earlier indications that a pharmacist intervention can significantly improve 
inhalation technique9 22. Moreover, our trial is the first to demonstrate the positive effects of a 
community pharmacist intervention on medication adherence in patients with COPD, although 
comparable with results from trials performed in a hospital environment and led by a clinical 
pharmacist23 24. Most likely, improvements are due to the pharmacist-conducted patient education 
about correct use of the inhalers, their therapeutic effects and possible side effects. All intervention 
group patients received oral and written education along with a physical demonstration of inhalation 
technique, shown to be the most effective mode of instruction9 25. When entering the trial, 7% of 
patients had never been instructed about inhalation medication and only about 30% had yet received 
explanation from his pharmacist, offering a large room for improvement9.  
The significant decrease in severe exacerbation rate should be interpreted with caution, 
considering it being a secondary outcome and the short study duration. However, previous research 
indicated that integrated care7, as well as clinical pharmacy interventions23 24, similarly prevented 
hospitalizations. This effect of multidisciplinary care programs could be explained by diverse factors. 
Firstly, the intervention could result in enhanced self-management of the disease. Secondly, 
intervention patients could have perceived higher accessibility to primary healthcare professionals, 
prompting earlier detection and, consequently, better exacerbation management (i.e. decreased 
exacerbation recovery time and hospitalization risk)26. Hence it is plausible that pharmaceutical care 
protocols diminish the high health-care costs of severe COPD exacerbations, a presumption to be 
confirmed by proper pharmaco-economic analysis1 2.The exacerbation rate in the control group during 
the trial seems higher compared to other clinical trials in patients with COPD27 28. Because of the 
heterogeneous nature of COPD, different geography and the specific population under study, caution 
is needed when comparing exacerbation rates between trials29. Nevertheless, the time set of the trial 
(i.e. during winter) could be a main factor contributing to the perceived higher exacerbation rate30 31. 
Our trial did not detect significant changes in health status after 3 months, which is in accordance 
with other studies, although it concerns heterogenous pharmaceutical care programs and health-care 
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settings24 32 33. This might be due to the short time span of the trial and the progressive nature of COPD. 
Furthermore, health status of our sample was relatively high at start of the trial (mean CAT of 16, and 
39% with mMRC≥2), which decreases the available room for improvement. Furthermore, next to 
inhalation technique and medication adherence, other factors such as physical activity, motivation and 
nutrition could have influenced health related outcomes1. Though other trials have reported clinically 
relevant changes in health status after a pharmacist intervention, they ran over a longer period in time, 
recruited patients with worse baseline health status or were performed in a hospital setting8 23 34. Long-
term trials are needed to confirm whether this pharmaceutical care protocol in a primary care setting 
has a positive effect on health or smoking status. 
This RCT is the largest trial to investigate the effectiveness of a protocol-based community 
pharmacist intervention in patients with COPD and was conducted and reported following CONSORT 
guidelines35. The intervention was protocol-based and designed to be easily applicable in community 
pharmacies by different pharmacists. All actions executed during the trial’s scheduled intervention 
points were documented, both electronically and in written form. However, the trial has some 
limitations. A first limitation is the relatively short study duration. Regarding exacerbation frequency, 
this could lead to false negative results; however, observed differences confirm that the trial length is 
sufficient. Moreover, a recent meta-analysis detected no differences between short or long-term trials 
regarding hospitalizations due to COPD exacerbations36 37. Secondly, the absence of spirometric 
confirmation of COPD could be considered an important limitation; however, it supports the pragmatic 
aspect of the trial, since in practice, pharmacists do not have access to such data. The operational 
definition of COPD (prescription for COPD medication, aged ≥50 years, smoking history ≥10 pack-years 
and excluding patients with current asthma) was chosen in consultation with specialists and provided 
pharmacists with satisfactory certainty of COPD presence. Thirdly, pharmacists, carrying out the 
intervention, measured their own performance in teaching and training. This may be a potential source 
of bias. However, pharmacists had no gain in untruly reporting of an improvement. Counselling was 
not individually evaluated, nor did pharmacists receive a remuneration for improved patients. Finally, 
selection bias cannot be fully excluded, since participation to trials is usually accepted more frequently 
by motivated patients.  
To increase external generalizability of our study findings, we attempted recruiting a patient sample 
as representative as possible, using every pharmacy as one recruitment center. To confirm 
generalizability, we compared inhalation scores and medication adherence to results of other trials 
and similar scores were observed3 9 22. Moreover, subgroup analysis confirmed consistency of results 
in different regions and patient subgroups (Figure 3.2.2).  
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In conclusion, we conducted a 3-month RCT in 170 community pharmacies assessing the 
effectiveness of a protocol-based pharmaceutical care program in patients with COPD. Both primary 
outcomes, i.e. inhalation technique and medication adherence, were significantly more improved in 
the intervention group, compared to the control group. Furthermore, a trend towards a reduction in 
severe exacerbations was observed. This trial should encourage community pharmacists to engage in 
COPD care aiming to sustain an effective and safe pharmacotherapeutic treatment in patients with 
COPD. 
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APPENDIX 3.2.1: INHALATION TECHNIQUE SCORES PER INHALER DEVICE AND PER CHECKLIST ITEM 
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ABSTRACT  
 
Background. A protocol-based pharmaceutical care program (the PHARMACOP-protocol) focusing on 
patient counselling during prescription filling has shown to be effective in patients with Chronic 
Obstructive Pulmonary Disease (COPD). However, implementation of this protocol in daily practice has 
not yet been studied.  
 
Objective. To describe current implementation level of the items included in the PHARMACOP-
protocol in Belgian community pharmacies and to evaluate pharmacists’ perspectives on the 
implementation of this protocol in daily practice. 
 
Method. A cross-sectional study was conducted from April to June 2012, in randomly selected 
community pharmacies in Flanders. Pharmacists were questionned using structured interviews.  
 
Results. 125 pharmacies were contacted and 80 managing pharmacists (64%) participated. In >70% of 
pharmacies, 4/7 protocol items for first prescriptions and 3/5 protocol items for follow-up 
prescriptions were already routinely implemented. For first and follow-up prescriptions, respectively 
39 (49%) and 34 pharmacists (43%) stated they would need to spend at least 5 minutes extra to offer 
optimal patient counselling. Most mentioned barriers preventing protocol implementation included 
lack of time (80%), no integration in pharmacy software (61%) and too much administrative burden 
(58%). 
 
Conclusion. Approximately 50% of the PHARMACOP-protocol items are currently routinely provided in 
Belgian community pharmacies. Nearly all interviewed pharmacists are willing to implement the 
protocol fully or partially in daily practice.  
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INTRODUCTION 
For patients with Chronic Obstructive Pulmonary Disease (COPD), the close monitoring of patients’ 
pharmacotherapy is considered indispensable1]. Community pharmacists are ideally placed to engage 
in care for patients with COPD because of their frequent patient contacts upon prescription filling and 
their specific medication-related expertise concerning inhalation technique, adverse effects, etc1 2. 
Additional important roles for pharmacists in counselling patients with COPD are improving adherence 
to medication regimens, participating in education programmes, smoking cessation counselling and 
performing annual medication regimen reviews1 2. Pharmaceutical care programs focusing on these 
aspects, aim at reducing overall health care costs, as well as improving patients’ quality of life and 
productivity2. 
Previously, we conducted a randomized controlled trial, investigating the impact of a 
pharmaceutical care protocol for patients with COPD (the PHARMACOP-protocol)3. The PHARMACOP-
protocol showed to be effective in improving inhalation technique and adherence to inhaled 
medication3. Moreover, tailoring the follow-up may reduce the number of smoking patients and 
diminish the number of hospitalizations due to severe exacerbations3 4. However, implementation of 
the PHARMACOP-protocol in daily practice has not yet been promoted or studied.  
The aims of the present study are (1) to describe the current level of implementation of the 
different items of the PHARMACOP-protocol in Belgian community pharmacies and (2) to evaluate 
pharmacists’ perspectives on the implementation of this protocol in daily practice.   
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METHOD 
Pharmacy sample 
This cross-sectional observational study was conducted from April to June 2012, in randomly 
selected community pharmacies in Flanders (the Dutch-speaking part of Belgium, total number of 
pharmacies: 2657). Zipcodes were randomly selected and pharmacies in this zipcode were telephoned 
in alphabetical order to request participation until a maximum of 8 pharmacies per zipcode were 
included. Recruitment was continued until 80 managing pharmacists agreed upon participating. A 
pharmacy was eligible for participation if the managing pharmacist was available the day the 
researcher planned to visit the concerning geographical region. The Ethical Committee of Ghent 
University does not require an approval for studies that merely describe current practice without 
collecting patient data. 
 
The PHARMACOP-protocol 
The PHARMACOP-protocol was originally developed for the randomized controlled PHARMACOP-
trial3]. One item (i.e. “influenza vaccination”) was added to the original protocol, since the 
PHARMACOP-trial was conducted out of the influenza-vaccination season. The items of the protocol 
are presented in Table 3.3.1. 
 
Data collection 
The managing pharmacist of each participating pharmacy was interviewed using a structured 
interview. A questionnaire was specifically developed for this study and the interview was piloted with 
two pharmacists. It questioned (1) used sources for COPD information, (2) current provision of the 
protocol items for first and follow-up prescriptions for COPD medication in the participating pharmacy, 
(3) the pharmacist’s opinion about the relevance of the items of the protocol, and (4) the current 
duration and the presumed optimal duration of a first and follow-up prescription filling (including the 
counselling aspects).  
Subsequently, feasibility of implementing the PHARMACOP-protocol in daily practice was evaluated 
by registering pharmacists’ intention to implement the protocol if it was available to them and by 
asking for barriers and facilitators for implementation. Pharmacists were asked to estimate the 
percentage of patients with COPD that would be receptive for pharmacist counselling and whether 
they presume implementation of this protocol would increase patient satisfaction towards provided 
care in the pharmacy. Clarity of reporting is obtained by following STROBE-guidelines5].  
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Statistical analysis  
Data were analyzed in SPSS statistics 21 (SPSS Inc. Chicago, IL, USA). Results of open-ending 
questions were categorized since pharmacists were often unaware of exact numbers. For answers to 
specific questions, means with standard deviations or sum-scores with percentages are displayed. For 
relevancy, items were scored as “essential, neutral or unnecessary”. We checked if baseline factors 
were associated with current and presumed optimal duration of a first and follow-up prescription with 
regression analysis. 
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RESULTS 
Pharmacy sample 
In total, 125 pharmacies in 25 different zipcodes were contacted and 80 managing pharmacists 
(64%) agreed upon participating. Main reasons for declining were lack of time and absence of the 
managing pharmacist on the day the study investigator visited the pharmacy. The mean age of the 
managing pharmacists was 43.3 years (SD=11.8) and 50 of them (63%) were female. Pharmacies served 
an average of 82.5 prescriptions per day (SD=42.7) and an average of 123 patients per day (SD=56). 
Pharmacies employed a mean of 1.8 pharmacists (SD=0.8), and 0.8 pharmacy-assistants (SD=1.0), both 
expressed in full time equivalents. The mean number of patients per full-time equivalent employee 
per day was 53.9 (SD=21.8). Seven pharmacies (9%) had 1 to 5 regular visitors with COPD, 20 
pharmacies (25%) had 6 to 10 regular visitors with COPD and 53 (66%) pharmacies had more than 10 
regular visitors with COPD.  
 
Current and presumed optimal pharmaceutical care 
Sixty-six pharmacists (83%) stated they used their pharmacy software as a source for information 
about COPD and COPD medication, 46 pharmacists (58%) used the pharmacy guidelines for asthma 
and COPD from the Belgian Pharmacist Association and 41 (51%) used course material of post-graduate 
courses. Three pharmacists (4%) stated to use GOLD-guidelines1. 
Table 3.3.1 represents the different items of the PHARMACOP-protocol, their level of 
implementation in current practice, and their relevance as perceived by the managing pharmacists. 
The current duration and the presumed optimal duration of a prescription filling, including the 
counselling aspect, is presented in Table 3.3.2. For first and follow-up prescriptions respectively, 39 
(49%) and 34 pharmacists (43%) stated they would need to spend at least 5 minutes extra during 
dispensing in order to provide optimal patient counselling.  
Age, occupation and number of regular visitors with COPD in the pharmacy did not correlate with 
current duration or presumed optimal duration of prescription filling (i.e. including counselling). 
 
Table 3.3.2: Current and presumed optimal duration of presciription filling (i.e. including the counselling part) for patients with COPD  
 First prescription Follow-up prescription 
Duration of counselling Current practice, no 
(%) 
Presumed optimal 
practice, no (%) 
Current practice, no 
(%) 
Presumed optimal 
practice, no (%) 
0 to 5 minutes 18 (23) 4 (5) 69 (86) 36 (45) 
6 to 10 minutes 46 (57) 39 (49) 10 (13) 40 (50) 
11 to 15 minutes 14 (18) 26 (33) 1 (1) 3 (4) 
> 15 minutes 2 (3) 11 (14) 0 (0) 1 (1) 
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Feasibility of the PHARMACOP-protocol  
Forty pharmacists (50%) would fully implement the proposed protocol if it were available to them, 
37 (46%) would implement it partially and 3 (4%) would not implement it. Most mentioned barriers to 
implement the proposed protocol in daily practice included lack of time (80%), no integration in 
pharmacy software (61%) and too much administrative burden (58%). Lack of remuneration and 
insufficient knowledge about COPD were only mentioned as barriers by 25% and 18% of pharmacists 
respectively. 
Seventy-three pharmacists (91%) indicated that a complete integration of the protocol in the 
pharmacy software would facilitate implementation. Other facilitators were less administrative burden 
in general (71%), a remuneration for the extra service (54%) and provision of more background 
information (39%). Being asked to estimate the portion of patients that would be receptive for the full 
PHARMACOP-protocol, pharmacists reported a mean score of 58% (SD=21%). Nevertheless, 75 
pharmacists (94%) think that fully implementing the PHARMACOP-protocol would generate an 
increased satisfaction in patients with COPD. Almost all pharmacists (93%) felt the need for further 
education about the protocol to confidently implement it.  
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DISCUSSION 
This study evaluated which items of the PHARMACOP-protocol have already been implemented in 
current practice of Belgian community pharmacies. Additionally, we evaluated the perspectives of 
pharmacists on the implementation of the protocol. 
Concerning patient counselling when filling a first or follow-up prescription for COPD medication, 
the short duration of current counselling practice is in accordance with findings in other studies6. Only 
items related to COPD medication (e.g. inhalation technique demonstration, dosing, adherence, etc) 
and the recommendation for influenza vaccination are currently routinely provided by ≥70% of 
pharmacists. Nevertheless, all but two items of the PHARMACOP-protocol are considered essential by 
a majority of pharmacists. Only patient education about the pathophysiology of COPD and self-
management advice were considered less essential. Although it is not clear which educational topics 
contribute to successful COPD management, current practice guidelines recommend education 
tailored to the patient7. In this respect, the provision of simple and structured information about the 
pathophysiology and self-management of COPD could be additional to the information provided by 
the general practitioner. Indeed, patients experience the latter often as insufficient and efficacy of 
informing patients about self-management has been demonstrated6 8. Nevertheless, interviewed 
pharmacists indicated that they did not consider this a part of their job, that they were not aware of 
positive consequences, or that they had insufficient knowlegde about these topics.  
Opinions about the necessity of smoking cessation counselling and the provision of patient leaflets 
were very divergent. However, especially smoking cessation counselling should be routinely offered to 
smokers with COPD, as pharmacist counselling is proven effective4 and smoking cessation is the only 
intervention that can positively influence the natural course of COPD1. The provision of patient leaflets 
that can be looked into at home is reported to be essential for reinforcing verbal information9.  
 
Recommendation 
Multiple parties could engage in addressing barriers and implementing facilitators in order to 
optimize current provision of pharmaceutical care for patients with COPD. The government could 
simplify the administrative burden experienced by pharmacists and could provide a remuneration for 
delivered services. The lack of remuneration has been reported elsewhere as a barrier to 
implementation of pharmaceutical care interventions4. This was not confirmed in our study although 
pharmacists mentioned remuneration as a facilitating factor. The barrier ‘lack of time’ could be 
overcome by the pharmacists by making an appointment for first and follow-up prescriptions. This 
would provide pharmacists with sufficient time to prepare the conversation, including the collection 
of counselling aids such as demo inhaler units and patients leaflets and getting themselves updated 
with the most current guidelines, thereby also tackling the barrier ‘insufficient knowledge’.  
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Finally, software companies could integrate the PHARMACOP-protocol, including easy access to 
relevant patient leaflets, into the pharmacy software without however overlooking communication 
aspects because of a strong focus on computer checklists6.  
 
Limitations 
Neither a participation bias, nor socially desirable answersing by the interviewees could be 
excluded. The sample size was also limited, although baseline data are comparable with previously 
reported demographic data of Flemish pharmacists10.  
 
Conclusion 
In conclusion, approximately 50% of the PHARMACOP-protocol items are currently routinely 
provided by Belgian community pharmacists. Furthermore, nearly all interviewed pharmacists (96%) 
are willing to implement the protocol fully or partially in daily practice. Most mentioned barriers to 
implement the PHARMACOP-protocol were lack of time, no integration in pharmacy software and too 
much administrative burden.  
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ABSTRACT 
 
Background. Self-report is considered the most suitable method to measure medication adherence in 
routine clinical practice. However, accuracy of self-report as a quantitative measure of adherence is 
not well documented.  
 
Objective. To assess accuracy of a self-report measure of adherence (the Medication Adherence 
Report Scale, MARS-5) for identifying nonadherent users of inhalation medication among patients with 
COPD, compared to medication refill adherence (MRA) as reference. 
 
Methods. We used baseline data from the Pharmaceutical Care for Patients with COPD (PHARMACOP) 
trial (n=734): MARS-5 as self-report measure and MRA as reference measure of adherence to 
inhalation medication. Patients with incomplete MARS-5 and/or incomplete pharmacy refill records 
were excluded from analysis (n=121). Internal consistency of MARS-5 (Crohnbach α) and the 
Spearman's rank correlation (ρ) with MRA were calculated. To assess accuracy of MARS-5 for 
identifying nonadherence, different thresholds for nonadherence were used to calculate sensitivity, 
specificity and Positive Predictive Value (PPV), compared to dichotomized MRA (MRA≥80% = 
adherent). A Receiver Operating Characteristic (ROC) curve was plotted to determine the goodness of 
test and to detect an optimal cut-off threshold for the MARS-5 scale. 
 
Results. A total of 613 patients were included in the analysis. Mean adherence score by MARS-5 (range: 
5-25) was 23.5 (SD=2.6); mean adherence by MRA was 83.4% (SD=23.8%). Internal consistency of 
MARS-5 was high (α=0.77). Continuous MARS-5 scores correlated poorly with continuous MRA scores 
(ρ=0.10; P=.011). When lowering adherence threshold stepwise from 25 to 20, MARS-5 did not reach 
sufficient sensitivity (53% to 13%), specificity (57% to 94%) and PPV (42% to 57%) to detect 
nonadherers, compared to dichotomized MRA. ROC-curve plotting resulted in an area under the curve 
value of 0.56 (95% Confidence Interval, [0.521-0.616]; P=.005). 
 
Conclusion. Self-reported adherence measured by MARS-5 is inaccurate in identifying nonadherence 
to inhalation medication in patients with COPD.   
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INTRODUCTION 
Adherence to inhaler maintenance therapy is an important parameter in the management of 
chronic obstructive pulmonary disease (COPD)1. However, adherence to inhaler medication among 
patients with COPD is generally considered low2-5. Suboptimal adherence has been associated with 
higher morbidity and health care use (i.e., general practitioner (GP) visits, emergency room visits and 
hospitalizations) due to more frequent episodes of worsening of symptoms – exacerbations – in 
nonadherent patients6-8. Similarly, an association with increased mortality has been reported6, 8. 
Furthermore, treatment of COPD and its exacerbations contributes substantially to overall health care 
costs. In the United States, the direct costs of COPD are estimated to be around $29.5 billion and the 
indirect costs around $ 20.4 billion. In the European Union the costs approximately count for 6% of the 
total European health care budget1.  
The availability of an accurate method to measure adherence is therefore essential to health-care 
workers in detecting nonadherent patients and evaluating the effectiveness of the prescribed 
treatment. To measure adherence, a number of direct (e.g., observation, serum level checking, etc.) 
and indirect methods (e.g., prescription refill, self-report, pill counts, etc.) are available9. One indirect 
method, the use of self-report questionnaires, has been recommended as the measure most suitable 
for clinical practice10, 11, since these questionnaires are easy to use, inexpensive, and do not require a 
lot of time for both questioner and patient. However, self-report questionnaires require a patient-
questioner relationship based on mutual trust and only provide information when patients are aware 
of their nonadherent behavior. Partially because of these drawbacks, self-reported questionnaires 
generally tend to overestimate adherence10. Nevertheless, self-report measures have been 
increasingly applied during the last decade to assess drug adherence in multiple patient populations2, 
10, 12, 13, even though no ‘gold standard’ self-report questionnaire has been defined yet10.  
Only few studies have compared patients’ self-report with more objective measures such as 
prescription refill12, 14-17, electronic monitoring18, 19 or serum concentrations13, 20, 21. Overall, these 
studies described low correlations with the reference measure, unfavorable predictive values (PPV) 
and both low and high internal consistencies of the self-report questionnaire12-22. Furthermore, none 
of these studies exclusively focused on patients with COPD, although studies addressing adherence in 
patients with COPD, often use the Medication Adherence Report Scale (MARS-5) as a self-report 
measure of adherence2, 4, 23. As validation of self-report questionnaires as a measure of adherence in 
patients with COPD is lacking, this study aims to evaluate the accuracy of a self-report measure of 
adherence (MARS-5) in identifying nonadherent users of inhalation medication with pharmacy refill 
adherence as a reference.  
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METHODS 
Design and patient sample 
The data are drawn from a 3-month randomized controlled trial, the PHARMACOP-trial. The 
methods and results of the main study are reported in full elsewhere24. In brief, the PHARMACOP-trial 
was a longitudinal trial in 170 community pharmacies in Belgium, investigating the effectiveness of a 
pharmaceutical care program for patients with COPD. Patients filling a prescription for COPD 
maintenance medication (R03, Anatomical Therapeutic Chemical classification, which includes inhaled 
anticholinergics, inhaled β2-mimetics, inhaled corticosteroids, xanthine-derivatives, leukotriene 
receptor antagonist or any combination of these drugs) in a participating community pharmacy, were 
consecutively invited to participate in the PHARMACOP-trial when meeting following inclusion criteria: 
(1) prescription for daily COPD maintenance medication, (2) aged 50 years or older, (3) smoking history 
of at least 10 pack-years, (4) regular visitor to the pharmacy and (5) providing written informed 
consent. Patients with current asthma or with limited health literacy were excluded. The recruitment 
period ran from December 2010 to April 2011. The study was approved by the Ethical Committee of 
the Ghent University Hospital (Ghent, Belgium). 
The present cross-sectional analysis included patient data from self-administered written 
questionnaires and pharmacy records obtained at start of the PHARMACOP-trial. These data were only 
included if (1) a complete pharmacy refill record (i.e., at least six months of pharmacy records available 
for review) and (2) a fully completed self-report adherence questionnaire were available. 
 
Self-reported adherence 
Self-reported adherence was assessed using the Medication Adherence Report Scale (MARS-5)12, 13, 
15, 19, 25. The MARS-5 consists of 5 common patterns of nonadherent behavior that respondents score 
on a 5-point Likert scale (with 1=always, 2=often, 3=sometimes, 4=rarely, and 5=never). The exact 
wording of the questions is given in Table 3.4.1. The first statement of the MARS-5 questions patients 
about unintentional nonadherence, while the other four statements question intentional 
nonadherence. Scores are summed and totals range from 5 to 25, with higher scores indicating higher 
self-reported adherence. The MARS-5 was introduced to the patients in a way that it was clear it only 
considered their principal maintenance therapy.  
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Table 3.4.1: Descriptives of the Medication Adherence Report Scale (MARS-5) and  its individual items  
Item Mean (SD) 
(n=613) 
Median (IQR) 
(n=613) 
Range 
Item 1: “I forget to take my inhalation medication” 4.58 (0.71) 5 (4-5) 1 – 5  
Item 2: “I change the dosage of my inhalation medication” 4.65 (0.80) 5 (5-5) 1 – 5 
Item 3: “I stop taking my inhalation medication for a while” 4.83 (0.56) 5 (5-5) 1 – 5 
Item 4: “I decide to skip one of my inhalation medication dosages” 4.72 (0.70) 5 (5-5) 1 – 5 
Item 5: “I use my inhalation medication less than is prescribed” 4.70 (0.79) 5 (5-5) 1 – 5  
Sum score MARS-5a 23.49 (2.60) 25 (23-25) 7 – 25  
aThe Medication Adherence Report Scale (MARS-5) sum score was calculated by summing scores from each individual question (range: 5-
25). Higher scores indicate higher self-reported adherence.  
 
Medication refill adherence 
A more objective adherence measurement was performed using a recommended measure of 
administrative data, i.e. the Medication Refill Adherence (MRA)26. Pharmacy records of one year prior 
to the trial were used. The MRA score for each patient was calculated by dividing the total days’ supply 
in the year preceding enrollment into the trial, by the number of days the patient is prescribed his/her 
medication, with a minimum of 6 months and a maximum of one year. Patients with an MRA score 
≥80% were considered adherent. This cut-off point was selected based on previous use by other 
investigators6, 15, 27. MRA-scores ≤60% were double-checked, which included the verification that the 
considered patient had started his/her COPD medication for more than six months, that the patient 
hadn’t moved in the six months previous to the start of the trial, that the patient collected his/her 
medication at least every two months and that the patient was not frequently admitted to the hospital, 
in which case hospital supply would lead to incomplete dispensing records. If a patients was prescribed 
multiple inhalers, MRA was only calculated for the principal maintenance therapy (see Appendix 3.4.3). 
 
Statistical Analysis 
Data were analyzed in SPSS statistics 20 (SPSS Inc. Chicago, IL, USA). Descriptive statistics were 
displayed as counts with percentages, means with standard deviations or median with interquartile 
range as appropriate.  
Internal consistency of MARS-5 was determined using Cronbach’s α. Cronbach’s α indicates 
whether each item of the scale is appropriate for assessing the underlying concept and summarizes 
inter-item correlations between responses and individual MARS-5 questions. Values for Cronbach’s α 
theoretically range between 0 and 1; the closer they are to 0 the less the items are related to one 
another. Values above 0.70 are generally considered indicating good internal consistency. Values 
should not exceed 0.9028. 
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To evaluate correlation between MARS-5 and MRA, Spearman's rank correlation coefficient (ρ) was 
determined. To assess accuracy by sensitivity, specificity and PPV, the MARS-5 sum score was 
dichotomized into either ‘adherent’ or ‘nonadherent’ using different thresholds and compared to 
dichotomized MRA as reference (MRA≥80% = adherent). A positive outcome was defined as the 
detection of nonadherence. Furthermore, a Receiver Operating Characteristic (ROC) curve was created 
to determine the ‘goodness’ of the test through area under the curve (AUC) calculation. AUCs between 
0.5 and 0.7 are considered low, AUCs between 0.7 and 0.9 moderate and AUCs ≥ 0.9 high28. In addition, 
the ROC curve was used to detect the optimal cut-off threshold for the MARS-5 scale. The optimal 
threshold for the scale is the test score for which the ratio of the number of actual cases detected by 
our scale (true positives) to the number of non-cases erroneously labeled as cases (false positives) is 
the largest28. Additionally, we will evaluate if MARS-5- and MRA-scores differ between users of 
different device types and different maintenance therapy, using an ANOVA-test.    
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RESULTS 
Of the 734 patients enrolled in the PHARMACOP-trial, 613 patients had available MARS-5 scores 
and complete pharmacy refill records. 121 patients were excluded from the analysis after double-
checking MRA-scores ≤60%. Baseline characteristics of this patient sample are presented in Table 3.4.2. 
The mean scores of the COPD Assessment Test, questioning COPD specific health status, correlate with 
a medium health status impairment. Furthermore, about 40% of patients experienced some limitation 
of activity due to breathlessness during daily life (represented by a modified Medical Research Council 
score ≥2) (Table 3.4.2). No statistically significant differences in baseline characteristics were observed 
between excluded and included patients, except for gender (P=.037) and smoking status (P=.003). 
There were more males and less smokers in the included sample, compared to the excluded patients 
(67,6% vs 59,9% males and 41,0% vs 56,0% smokers, respectively). 
 
Table 3.4.2: Basic Characteristics  
Parameter Patient sample (n = 613) 
Male Sex, No. (%) 417 (68.0) 
Age (y), mean (SD) 68.6 (9.5) 
BMI, kg/m², mean (SD) 25.5 (4.1) 
Smoking status, No. (%)   
 Current smoker 253 (41.3) 
Pack-years of current smokers, mean (SD) 40.8 (24.7) 
Pack-years of ex-smokers, mean (SD) 46.1 (29.6) 
COPD, duration (y), mean (SD) 11.2 (9.3) 
COPD management supervised by, No. (%)   
 GP only 232 (37.8) 
 Pneumologist only 74 (12.1) 
 Both GP and pneumologist 306 (49.9) 
Influenza vaccination, No. (%) 499 (81.4) 
mMRC scorea, ref:35, No. (%)   
 mMRC = 0 161 (26.3) 
 mMRC = 1 210 (34.3) 
 mMRC = 2 103 (16.8) 
 mMRC = 3 80 (13.1) 
 mMRC = 4 59 (9.6) 
CAT scoreb, ref: 36, mean (SD)  16.6 (7.6) 
History of exacerbations in preceding year   
 ≥ 1 in preceding yr, No. (%) 335 (54.6) 
 Moderate exacerbation ratec, mean 1.0 (1.6) 
 Severe exacerbation ratec, mean 0.5 (1.1) 
Mean Number of COPD medication, mean (SD)d 2.3 (1.0) 
 
BMI = Body Mass Index. COPD = Chronic Obstructive Pulmonary Disease. GP = General practitioner.  
a Scores on the modified Medical Research Council dyspnea scale can range from 0 to 4, with a score of 4 indicating that a patient is too 
breathless to leave the house or becomes breathless when (un)dressing.  
b CAT: COPD Assessment Test; a higher score indicates a worse health status (range 0-40). 
c Exacerbation rates are expressed as No./patient-year and calculated based on retrospective self-reported  patient data. Exacerbations 
requiring antibiotics or oral steroids treatment are considered “moderate”. Exacerbations requiring an emergency room visit or 
hospitalization are considered “severe”.  
d All medications classified under R03 in the ATC-classification are considered. This includes both rescue and daily maintenance medication. 
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Self-reported adherence & Medication Refill Adherence 
Scores on the MARS-5 scale ranged from 7 to 25. The mean MARS-5 score was 23.49 (SD = 2.60) 
with a distribution skewed towards high scores (Figure 3.4.1). The median score was 25 (IQR: 23-25). 
Scores on the individual questions are reported in Table 3.4.1. The number of patients having a MARS-
5 sum score of 25 was 324 (52.9%). Internal consistency of MARS-5 was good, reaching an alpha value 
of 0.77. Deleting any item would lower overall alpha value, ranging from 0.69 to 0.77. Inter-item 
correlations ranged from 0.224 to 0.594. Evaluating inter-item correlations, it is clear that in 3 out of 
four cases, the unintentional item correlates the least with the intentional items (Table 3.4.3).  
 
 
Figure 3.4.1: Distribution of the MARS-5 sum scores 
Table 3.4.3: Inter-Item Correlation Matrix for individual items of the MARS-5 questionnaire 
Items of MARS-5 questionnairea Item 1 Item 2 Item 3 Item 4 Item 5 
Item 1: “I forget to take my inhalation medication” 1,000 ,224 ,412 ,320 ,386 
Item 2: “I change the dosage of my inhalation medication” ,224 1,000 ,277 ,457 ,473 
Item 3: “I stop taking my inhalation medication for a while” ,412 ,277 1,000 ,526 ,509 
Item 4: “I decide to skip one of my inhalation medication dosages” ,320 ,457 ,526 1,000 ,605 
Item 5: “I use my inhalation medication less than is prescribed” ,386 ,473 ,509 ,605 1,000 
 
Medication Refill Adherence (MRA-) scores ranged from 8.2% to 120.0%. The overall mean 
adherence rate calculated from the MRA was 83.4% (SD = 23.8%). The median score was 82.2% (IQR: 
66.0%-99.0%). The number of patients that had an MRA-score equaling or exceeding 80% was 386 
(63.0%). 
There was no significant difference in MRA- (P=.39) or MARS-5 (P=.05) scores between users of 
different device types. Furthermore, there were no significant between-group differences for MRA- or 
MARS-5 scores between users of different types of medication (P=.56 and P=.34, respectively). The 
detailed results are mentioned in the appendices 3.4.1 and 3.4.2).  
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Accuracy of self-reported adherence 
Continuous MARS-5 scores correlated poorly with continuous MRA scores (ρ = 0.103; P=.011). 
Furthermore, we compared MARS-5 to the reference standard using different thresholds for low 
adherence (Figure 3.4.2, Appendix 3.4.4 for 2x2 tables). Using a threshold of 25, the MARS-5 had a 
sensitivity of 53%, specificity of 57% and a positive predictive value of 42%. When lowering the 
threshold for low adherence stepwise to 20, the instrument achieved a strongly reduced sensitivity of 
13%, an increased specificity of 94% but an only moderately increased positive predictive value of 57%.  
 
Figure 3.4.2: The sensitivity, specificity and PPV-values of the MARS-5 sum-score for different thresholds of low adherence 
compared to the reference standard (i.e. Medication Refill Adherence, MRA) 
MARS-5 = Medication Adherence Report Scale; TP = True Positives; PPV = Positive Predictive Value 
 
Plotting a Receiver Operating Characteristic (ROC) curve (Figure 3.4.3), an AUC value of 0.56 was 
observed (95% Confidence Interval (CI), [0.521-0.616]; P=.005). In accordance to the definition, the 
optimal threshold would be the value for which the ratio of true positives to false positives (TP/FP) is 
the highest, but low sensitivity of the test prevented determination of an optimal cut-off threshold. 
For the current study, we considered a total 393280 drug doses, dispensed to 613 patients over an 
individually varying period of time (6 months – 1 year).  
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Figure 3.4.3: Receiver Operating Characteristic curve (AUC = 0.569; P=.005), evaluating the accuracy of the MARS-5 
compared to the reference standard (MRA). 
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DISCUSSION 
Our main objective was to investigate the accuracy of a self-report measure of adherence, MARS-
5, in patients with COPD. MRA was chosen as a reference, since it has been shown to be a very reliable 
instrument to quantify medication adherence29-33. Moreover, it is a non-invasive, objective and 
inexpensive method to obtain adherence values, especially in large populations26. In the present study, 
MARS-5 showed to have a low sensitivity, specificity and PPV when verified against refill adherence. 
The MARS-5 questionnaire is therefore inaccurate in identifying nonadherent users of inhalation 
medication in patients with COPD. In general, the questionnaire overestimated patients’ adherence.  
Adherence rates, measured in the present study are comparable with previously reported 
adherence rates for patients with COPD, determined for MRA and MARS-5 respectively2, 4, 6, 27. This 
study also confirms that self-reported adherence to maintenance therapy in COPD is highly skewed 
towards perfect adherence (Figure 3.4.1)2. The MARS-5 was used in a number of primary care studies, 
but to our knowledge, only two validation studies comparing MARS-5 with pharmacy refill adherence 
have been performed, presenting inconsistent findings12, 15. Menckeberg et al. recruited users of 
inhaled corticosteroids and found an acceptable correlation between MARS-5 and prescription refill 
records12. However, Van de Steeg et al. found MARS-5 to be inadequate for adherence measurements 
in users of antihypertensive drugs in a primary care setting15, which corresponds to our results. This 
discrepancy could be the result of the question method. In the study of Menckeberg et al., 
questionnaires were mailed to patients and could be returned without a health-care professional 
knowing about it. In the study of Van de Steeg et al., as well as in our study, there was a direct contact 
between patient and health-care professional. The latter could have resulted in giving more socially 
desirable answers, although it is the most pragmatic approach. In two other reports, MARS-5 was 
validated against electronic monitoring or serum level determination, again with contradictory 
results13, 19.  
Low agreement between both measures could have many reasons. Firstly, both measures lead to 
conceptually different scores. MRA results represent the availability of medication to a patient, where 
MARS-5 questions behavioral problems with adherence22, 26. Classification as (non)adherent is thus 
based on different characteristics. It should be noted that Morisky et al. originally designed the MARS-
5 to facilitate identification of problems and barriers for good adherence rather than to quantify 
adherence22. Therefore, self-reported adherence assessed by MARS-5 could be informative for 
identifying reasons for nonadherence in routine clinical practice. This type of information cannot be 
obtained through other measures of adherence. MARS-5 still has some shortcomings as a detection 
method for qualitative information on nonadherence, e.g. its limited ability to distinguish between 
intentional and unintentional nonadherence10. The differentiation between intentional an 
unintentional nonadherence is however essential since both types require a distinct handling-
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approach34. However limited, using MARS-5 could hereby be of help. Indeed, as displayed in Table 
3.4.3, item 1, questioning unintentional nonadherence, correlates the least with the other items, 
questioning intentional nonadherence. Secondly, pharmacy refill adherence reflects both 
unintentional and intentional nonadherence. Self-report, on the other hand, tends to underestimate 
unintentional nonadherence in a more distinct way than intentional nonadherence, since patients are 
simply unaware of it10, 14. Therefore, overall lower adherence values, measured through pharmacy refill 
adherence compared to self-report, could confirm presence of unintentional nonadherence in our 
study population. Finally, both measures represent adherence in a different time-frame. Pharmacy 
refill adherence covers adherence throughout a certain period in time (here: up to one year prior to 
enrollment in the trial), while the self-report measure only inquired about adherence at the time the 
questionnaire was completed, without specifying any recall period. 
The main limitations of this study are related to the use of MRA as a reference measure of 
adherence. Refill records provide only an estimate of the medication availability, rather than 
medication consumption, since calculations usually assume that patients start taking the drug on the 
day of dispensing, use the drug as prescribed, and consume all medications obtained.  Furthermore, 
using pharmacy refill adherence requires a complete refill database and the prescribed dosage has to 
be available26. If drugs were supplied in another pharmacy, adherence values could be underestimated. 
However, in this trial, we maximized validity of the refill adherence by only including patients that 
explicitly stated they filled their prescriptions exclusively at the recruiting pharmacy and by double-
checking all MRA-scores ≤60%. We acknowledge that exclusion of 121 patients (16.5%) after double-
checking MRA-scores ≤60%, is a high amount, however we feel confident this had no influence on the 
results of the analysis. 
In conclusion, we evaluated the accuracy of a widely used method for assessing adherence to drug 
treatment in clinical practice, self-report using MARS-5, and demonstrated that it is not useful for 
identifying nonadherent use of inhalation medication in patients with COPD. The results of this study 
emphasize the necessity to validate questionnaires in a specific setting before using them as 
instruments within a trial. Moreover, caution is needed when comparing adherence values resulting 
from different measuring methods. We advise authors using MARS-5 in their research to specify the 
goal: to qualify or to quantify adherence. Both types of information on adherence could particularly 
be of interest, depending on the objectives of the study.  
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APPENDIX 3.4.1: ADHERENCE SCORES FOR DIFFERENT TYPES OF INHALERS 
 
 
  Appendix Table 3.4.1: Adherence scores for different types of inhalers 
Evaluated type of inhaler MRA MARS 
Handihaler Mean 82,1% 23,8 
N 255 255 
Std. Deviation 20,6% 2,1 
Pressurized metered dose 
inhaler 
Mean 88,2% 22,9 
N 80 80 
Std. Deviation 27,1% 3,1 
Aerolizer Mean 82,2% 22,7 
N 9 9 
Std. Deviation 31,0% 4,4 
Diskus Mean 83,2% 23,6 
N 158 158 
Std. Deviation 24,6% 2,7 
Turbohaler Mean 83,1% 23,2 
N 111 111 
Std. Deviation 26,0% 2,9 
Total Mean 83,4% 23,5 
N 613 613 
Std. Deviation 23,8% 2,6 
  
Medication counselling for patients with COPD in the community pharmacy – Chapter 3 
 
197 
APPENDIX 3.4.2: ADHERENCE SCORES FOR DIFFERENT TYPES OF MEDICATION 
 
 
Appendix Table 3.4.2: Adherence scores for different types of medication 
Type of medication MRA MARS 
ICS Mean 90,5% 23,1 
N 11 11 
Std. Deviation 20,2% 2,8 
LAAC Mean 82,1% 23,8 
N 254 254 
Std. Deviation 20,6% 2,1 
LABA Mean 87,5% 23,3 
N 16 16 
Std. Deviation 27,9% 3,5 
LABA+ICS Mean 82,8% 23,4 
N 320 320 
Std. Deviation 25,5% 2,8 
Total Mean 82,8% 23,5 
N 601 601 
Std. Deviation 23,5% 2,6 
SABA: Short-Acting Beta2-Agonists, LABA: Long-Acting Beta2-Agonists, SAAC: Short-Acting AntiCholinergics, 
LAAC: Long-Acting AntiCholinergics, ICS: Inhalation CorticoSteroids  
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APPENDIX 3.4.3: DECISION TREE FOR DETERMINING PRINCIPAL MAINTENANCE THERAPY 
 
When a patient is prescribed more than one inhaled drug, we will only calculate a medication 
adherence score for the principal maintenance therapy. This principal therapy can be determined 
based on following scheme. 
Appendix Table 3.4.3 
1. If the patients takes a LAAC or LABA, combined with ICS or not, this is the drug that will 
be chosen for further evaluation, if not, go to 2 
2. If the patients takes a LAAC and a LABA, the drug with the lowest baseline score will be 
chosen for further evaluation, if not, go to 3 
3. If the patient does not take a LAAC or LABA, the ICS monotherapy will be chosen for 
further evaluation, if not, go to 4 
4. If the patient does not take a LAAC, LABA or ICS, the SAAC or SABA will be chosen for 
further evaluation. 
LAAC: long-acting anticholinergs; SAAC: short-acting anticholinergs; LABA: long-acting β2-mimetics; SABA: short-acting β2-
mimetics; ICS: inhaled corticosteroids;  
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APPENDIX 3.4.4: DICHOTOMIZED MEDICATION ADHERENCE REPORT SCALE (MARS-5) (CUT-OFF = VARIABLE) AND 
MEDICATION REFILL ADHERENCE (MRA) (CUT-OFF ≥80%) 
 
 
Appendix Table 3.4.4: Dichotomized Medication Adherence Report Scale (MARS-5) (cut-off = variable) and 
Medication Refill Adherence (MRA) (cut-off ≥80%) 
 
MRA 
<80% ≥80% 
MARS-5 
<25 121 218 
=25 106 168 
MARS-5 
<24 82 284 
≥24 145 102 
MARS-5 
<23 57 58 
≥23 170 328 
MARS-5 
<22 49 42 
≥22 178 344 
MARS-5 
<21 36 29 
≥21 191 357 
MARS-5 
<20 29 22 
≥20 198 364 
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The main goal of this doctoral thesis was to develop and evaluate pharmaceutical care interventions 
in chronic care. Therefore, we focused on A) older patients with polypharmacy and B) on patients with 
chronic obstructive pulmonary disease (COPD) as an example of chronic disease.  
 
A) To optimize pharmaceutical care for older patients with polypharmacy, we first needed to get a 
general image of the problem of potentially inappropriate prescribing (PIP). In a systematic literature 
review, summarizing 82 sample screenings, we determined that the prevalence of PIP in community 
dwelling (CD) older people across Europe is 22.6% (CI: 19.2– 26.7%; Range: 0.0 – 98.0%). Furthermore, 
risk factors most often positively associated with PIP prevalence were polypharmacy, poor functional 
status and depression. Drug classes most often involved in PIP were anxiolytics (ATC-code: N05B), 
antidepressants (N06A) and non-steroidal anti-inflammatory and anti-rheumatic products (M01A).  
Subsequently, we developed a screening tool to systematically detect PIPs in the community 
pharmacy practice. This was achieved through a RAND/UCLA process (11 participants) with a round 
zero meeting, a literature review, a first written evaluation round and a second face-to-face evaluation 
round. An additional round on feasibility in the contemporary community pharmacy resulted in the 
Ghent Older People’s Prescriptions community Pharmacy Screening (GheOP³S-)tool, a list of 83 PIP-
items.  
To validate the newly developed GheOP³S-tool, the medication record of 60 patients (≥70 years and 
≥5 chronic drugs) admitted to the acute geriatric ward at the Sint-Vincentius hospital (Deinze, Belgium) 
was screened. Of all 250 PIP-items detected by the GheOP³S-tool, clinical relevance was scored 
‘serious’ for 182 items (73%) and ‘significant’ for 67 items (26%). Proposed alternative treatment plans 
were accepted for 79% of the PIP-items (n=198). For 9 patients (15%), the hospitalization was 
considered related to a PIP, detected with the GheOP³S-tool. The adapted Medication Appropriateness 
Index detected 536 items, of which 145 were incorporated in 131 PIP-items, detected by the GheOP³S-
tool. One-hundred and nineteen PIP-items were additionally detected by the GheOP³S-tool. 
We executed two observational studies, including 1016 community-dwelling (CD) (i.e. primary care 
setting) and 400 institutionalized (INS) (i.e. long-term care setting) older adults with polypharmacy, 
recruited from 204 community pharmacies and 10 nursing homes, respectively. Evaluating PIP 
prevalence with the GheOP³S-tool detected a median of 3 PIP-items per person (IQR = 2-5) in CD 
patients, compared to a median of 4 (IQR=2-6) for INS patients. Most prevalent PIPs were long-term 
use of benzodiazepines (CD: 50%; INS: 58%), no Ca/VitD suppletion with elevated osteoporotic risk 
(CD: 54%; INS: 54%) and long-term use of antidepressant agents (CD: 21%; INS: 42%). 
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B) In the second part of the thesis, we developed the Pharmaceutical Care for patients with chronic 
Obstructive Pulmonary disease intervention (PHARMACOP-intervention). This intervention focused on 
improving inhalation technique and adherence to maintenance therapy. To evaluate the effectiveness 
of the PHARMACOP-intervention, we conducted a single-blind 3-month RCT in 170 community 
pharmacies in Belgium, enrolling patients prescribed daily COPD medication, aged ≥50 years, and with 
a smoking history ≥10 pack-years. We compared the intervention group to a usual care control group. 
Results showed that at the end of the trial, the inhalation technique score (Mean estimated difference 
[∆], 13.5%; 95% Confidence Interval [CI], 10.8-16.1; P<.0001) and the medication adherence (∆, 8.51%; 
95%CI, 4.63-12.4; P<.0001) of the intervention patients were significantly higher than of patients in the 
control group. Furthermore, a significantly lower hospitalization rate was observed in the intervention 
group, compared to the control group (9 vs. 35; Rate Ratio, 0.28; 95%CI, 0.12-0.64; P=.003). The 
PHARMACOP-study therefore proved to be effective in primary care.  
Nevertheless, the PHARMACOP-intervention protocol is not yet fully implemented in Belgian 
community pharmacies. In >70% of 80 researched pharmacies, 4/7 protocol items for first 
prescriptions and 3/5 protocol items for follow-up prescriptions were already routinely implemented. 
For first and follow-up prescriptions, respectively 39 (49%) and 34 pharmacists (43%) stated they would 
need to spend at least 5 minutes extra to offer optimal patient counselling. Evaluating pharmacists’ 
perspectives on the implementation of this protocol in daily practice, main reported barriers were lack 
of time (80%), no integration in pharmacy software (61%) and too much administrative burden (58%). 
To evaluate a patient’s medication adherence in a straightforward way, an easy but specific tool is 
needed. We showed that the Medication Adherence Report Scale (MARS-5) was not valid as self-report 
measure of adherence to inhalation medication, using the medication refill adherence (MRA) as 
reference. Although the internal consistency of the MARS-5 was high (α=0.77), the scores correlated 
poorly with MRA scores (ρ=0.10; p=.011). When lowering adherence threshold stepwise from 25 to 20, 
MARS-5 did not reach sufficient sensitivity (53% to 13%), specificity (57% to 94%) and positive 
predictive value (42% to 57%) to detect nonadherers, compared to dichotomized MRA. ROC-curve 
plotting resulted in an area under the curve value of only 0.56 (95% CI, [0.521-0.616]; p=.005).  
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1. BROADER INTERNATIONAL CONTEXT 
1.1. Pharmaceutical Care in general 
In Europe, the implementation of pharmaceutical care as a core task of the community pharmacist 
appears to be an evolving, non-parallel process. As discussed in a systematic review quantifying 
provided pharmaceutical care tasks across Europe, it is clear that different aspects of pharmaceutical 
care are implemented to various degrees in different countries1. However, some general conclusions 
can be drawn. On the one hand, community pharmacists scored high on more traditional areas of 
practice, such as verification of patient understanding or patient record screening. On the other hand, 
community pharmacists scored low on the area of direct patient care. This could be explained by the 
fact that these activities tend to be more demanding and time-consuming1.   
In countries outside Europe, e.g. in the United States or Canada, pharmaceutical care services such 
as patient counselling or cognitive services are already well established in daily community pharmacy 
practice2-4. These include for example the provision of in-store education seminars, performance of 
specific disease trainings (e.g. diabetes, asthma etc.), and in-store monitoring and screening. As well, 
a number of these services are remunerated and/or reimbursed2 3 5.  
 
1.2. Medication Review for Older Patients with polypharmacy 
Pharmacist associations from multiple countries have introduced guidelines on medication review6. 
Some of them are rather conceptual, such as the document from the Royal Pharmaceutical Society6, 
describing four guiding principles. Others, such as the guideline ‘Medicatiebeoordeling’ from the Dutch 
Pharmacists Association (KNMP) mention the very specific steps that should be taken to execute a 
medication review (patient interview, pharmacotherapeutical analysis, set-up treatment plan, confirm 
treatment plan and follow-up)7 (Figure 5.1).  
 
   
Figure 5.1: Front covers of medication review guidelines from diverse pharmacy associations. From left to right: Royal 
Pharmacist Association (UK), Koninklijke Nederlandse Maatschappij ter bevordering der Pharmacie (The Netherlands) and 
Pharmaceutical Society of Australia (Australia).  
  207 
Broader International Context, Relevance and Future Perspectives – Chapter 5 
The recently published systematic review of Bulajeva 
et al8 further provides us with detailed data about the 
implementation of medication review in Europe. Thirty-
two countries were asked to provide information, of 
which 25 did. Sixteen reported having established 
medication review procedures in general (Table 5.1), 
and 13 declared having established procedures for the 
community setting in specific. Nine of those 13 countries 
reported having type I procedures (69%) and 11 
reported having a procedure for type II procedures 
(85%). Only 6 countries reported having type III 
medication review procedures (46%)1.  
 
Table 5.1: General information about medication review 
procedures specified by country (Adopted from Bulajeva 
et al.8) 
 
 
These results show that the implementation of medication review procedures that originate from 
the community pharmacy is becoming common in European healthcare. Nevertheless, there is still a 
lot of room for improvement.  
 
1.3. Chronic Disease Counselling in the Community Pharmacy 
Chronic disease counselling has been introduced in community pharmacies across Europe, the USA, 
Canada or Australia4.  
Basic pharmaceutical care includes general medication counselling that is medication centred. This 
includes providing the patient with information about the drug (name, drug class, storage conditions, 
cost), the drug use (indication, expected benefit, directions for use, duration of therapy) and – if 
necessary – non-pharmacologic advice (self-management, self-monitoring)4 9. The proportion of 
patients receiving this counselling varies widely, ranging from 8% to 80%4. Furthermore, studies have 
shown that verbal counselling was far more present for new prescriptions, compared to counselling 
for repeat prescriptions4 10. 
Next to the more general and medication centred counselling in basic pharmaceutical care, there 
also exist advanced counselling services (i.e. cognitive pharmacy services) that are individually adapted 
and patient-centred5 9. For example, the New Medicines Service (NMS) provides support for people 
with long-term conditions that are prescribed a new medicine. The goal of the NMS is to improve 
medicine adherence11. Other services include the Appliance Use Review, the Smoking Cessation 
Service and the Inhaler Technique Assessment Service (Table 5.2)12.  
                                                          
1 For definitions regarding type of medication review: see Chapter 1, Table 1.3 
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Table 5.2: Examples of remunerated advanced counselling services in community pharmacies in other European countries5 11-15 
 Target group Goal Method 
New Medicines 
Service (UK) 
People with long-term 
conditions newly 
prescribed a medicine 
for asthma, COPD, 
diabetes type 2 and 
hypertension or are 
newly prescribed 
antiplatelet/ 
anticoagulant therapy) 
 
To improve medication 
adherence 
Structured patient interview to supplement and 
reinforce information provided by the GP to help 
patients make informed choices about their care. 
Additionally, the pharmacists links the use of 
newly prescribed medicines to lifestyle changes or 
other non-drug interventions to promote well-
being and promote health in people with long 
term conditions.  
Appliance Use 
Review 
(UK) 
Patients with an 
appliance1 
To improve the patient’s 
knowledge and use of their 
appliance 
Structured patient interview to establish the way 
the patient uses the appliance and the patient’s 
experience of such use. Identifying, discussing and 
assisting in the resolution of poor or ineffective 
use of the appliance by the patient. Advising the 
patient on the safe and appropriate storage and 
disposal of the appliance. 
 
Smoking cessation 
service (Scotland) 
Current smokers, older 
than 12 years 
To provide extended access 
to smoking cessation 
support, including the 
provision of patient centred 
behavioural support and 
evidence-based 
pharmacotherapy 
 
Counselling sessions (multiple appointments). In-
depth interviews. Written and verbal counselling 
on nicotine replacement therapy.  
Medicine Use 
Review 
(UK) 
Patients on multiple 
medicines, particularly 
those receiving 
medicines for long term 
conditions 
To improve medication 
adherence  
Structured patient interview in which the patient’s 
actual use, understanding and experience of taking 
their medicines is established. Identifying, 
discussing and resolving poor or ineffective use of 
their medicines. Identifying side effects and drug 
interactions that may affect adherence. Improving 
the clinical and cost effectiveness of prescribed 
medicines and reducing medicine wastage. 
 
Inhaler Technique 
Assessment Service 
(Denmark) 
Patients with asthma or 
chronic obstructive 
pulmonary disease 
To improve inhalation 
technique 
Ten-minute interactive counselling session during 
which pharmacy staff assesses the inhalation 
technique of individual asthma patients at the 
pharmacy counter, and correct any errors. 
 
Polymedication 
Check (Switzerland) 
Patients with 4 or more 
chronic drugs 
To improve medication 
adherence 
A session in which all current problems with the 
pharmacotherapy are discusses, medication 
adherence is assessed and addressed and when 
needed, a pill box up to three months is offered.  
 
Medicatie-
beoordeling (The 
Netherlands) 
Patients with 
polypharmacy 
To improve quality of 
prescribing 
A medication review is performed by the 
pharmacist. This includes a pharmacotherapeutic 
anamnesis with the patient, a 
pharmacotherapeutic analysis by the pharmacist, a 
physician-pharmacist consultation and a 
pharmacist-patient follow-up consultation.  
 
1Appliances include: catheter, laryngectomy or tracheostomy, anal irrigation system, vacuum pump or constrictor ring for erectile 
dysfunction, wound drainage pouch, incontinence appliance or stoma. 
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2. RELEVANCE  
2.1. General 
Scientific research is performed to elucidate how the world is functioning. The acquired knowledge 
can consequently be used to develop or optimize various sectors of society such as industry, education, 
governmental practices, the health system or social cohesion. This potential value of research is called 
‘societal relevance’. Where academic value of research is mainly determined by the impact factor of 
the journal in which it is published or the number of citations, societal relevance finds it value in the 
implementation in (national) guidelines and practice settings as well as in the (cost-)effectiveness of 
the researched interventions16.  
  
2.2. Implementation of cognitive pharmacy services in Belgian guidelines 
In Belgium, the Royal Decree issued in 2009, clearly outlines good pharmaceutical practices of the 
community pharmacists, including pharmaceutical care aspects and cognitive pharmacy services (See 
also General Introduction, section 1.3)9.  
Accordingly, the Belgian Pharmacist Association (APB) defined three action points in their 
guidelines. These would be the action points where the community pharmacist should focus on in the 
future: optimization of chronic medication start-up, optimization of medication adherence and 
medication review. The APB subsequently merges all services serving these three action points under 
the umbrella term ‘Good Medicine Use services’17. 
To achieve these action points, the APB has already established the ‘Counselling New Medication’ 
service. This service is currently remunerated for newly diagnosed asthma patients starting inhaled 
corticosteroids. The service includes a counselling session during first dispensing and a follow-up 
counselling session during first refill. Both counselling sessions comprise of an evaluation of asthma 
control using the Asthma Control Test as well as an elaborate demonstration of and education about 
the inhalation technique. Furthermore, potential issues regarding medication adherence are discussed 
when deemed necessary. Belgian community pharmacists that execute this service receive a 
remuneration of €20 per session.  
Additionally, a ‘Counselling Polypharmacy Patients’ service has been developed and will be piloted 
in 2016. This service includes a medication review by the community pharmacist, comprising of a 
structured patient interview, a pharmacotherapeutic analysis, an adherence improving intervention 
when deemed necessary and a pharmacist-physician consultation to discuss the findings of the review 
process. In collaboration with the APB, researchers of two Belgian Universities will evaluate the 
effectiveness of this new service on both clinical and patient related outcomes.  
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2.3. Implementation of cognitive pharmacy services in Belgian ambulant practice 
According to Belgian research evaluating pharmaceutical care practices of 623 Belgian community 
pharmacists, the extent to which pharmaceutical care is provided in general is sufficient, however with 
a large room for improvement1 18. For example, about one fifth of community pharmacists clearly state 
that they do not check for DRPs. 
Focusing on the ‘Counselling New 
Medication’ service, it appears that the 
implementation of the sessions is limited, 
however slightly increasing. In 2015, 21 262 
first-dispensing counselling sessions were 
declared, compared to 16 913 in 2014. 
Follow-up counselling appears to be more 
difficult to organize, as only for 1593 and 
1491 patients a session was declared, in 2015 
and 2014 respectively (Figure 5.2)19.  
 
Figure 5.2: Monthly declarations of 'Counselling New Medication' services 
In September 2014, the National Institute for Health and Disability Insurance (NIHDI) introduced 
the Collaborative approach to Optimise Medication use for Older people in Nursing homes (COME-ON) 
project. As in Belgium, medication for nursing homes is dispensed through community pharmacies and 
patients withhold their GP while transitioning to a nursing home, this also considers the first-line 
setting. The purpose of this study was to evaluate the effect of a complex, multifaceted intervention, 
including multidisciplinary case conferences on appropriateness use of medicines for older people in 
Belgian nursing homes. Up to now, a multicentre cluster controlled trial has been set up in 63 Belgian 
nursing homes (30 intervention; 33 control). In each of these nursing homes, 35 residents were 
selected for participation. Three-monthly multidisciplinary case conferences between nurse, general 
practitioner and pharmacist were conducted on a resident level. Case conferences facilitated 
structured medication reviews in order to optimize the resident’s medication profile. Education and 
training, through e-learning and on-site sessions, were provided. The primary outcome compared the 
number of PIPs and PPOs per resident between groups. Secondary outcomes included outcomes of 
case conferences, costs and facilitators/barriers for implementation of the intervention20. The results 
of this study are currently being analysed.  
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2.4. Improving implementation in practice: Strategies for patient counselling 
Strategies to improve the implementation of the ‘Counselling New Medication’ service include 
expanding the service to other diseases, e.g. COPD, diabetes, hypertension, etc21. Furthermore, instead 
of only counselling the start-up of chronic therapy, the service could also be expanded to counselling 
chronic therapy on a regular basis21. Indeed, scientific evidence supports counselling of chronic 
therapy. The randomized controlled Pharmaceutical Care for Asthma Control and Improvement 
(PHARMACI)-trial for example, included chronic asthma patient, randomly assigning them to a usual 
pharmacist care control group or to an intervention group. This intervention group received protocol-
based care mainly focusing on inhalation technique and medication adherence. The PHARMACI-trial 
showed an improvement in inhalation technique and medication adherence in the intervention group. 
Additionally, asthma control for uncontrolled patients improved and the use of reliever medication 
and frequency of night-time awakenings diminished22. Another trial, the PHARMaceutical Care for 
patients with COPD (PHARMACOP)-trial, was a single-blind 3-month randomized controlled trial 
researching the effectiveness of pharmaceutical care for patients with COPD (see Chapter 3 Part 2). 
This trial also recruited patients with chronic COPD and demonstrated an improved inhalation 
technique and medication adherence along with a decrease in hospitalization rates for patients with 
COPD23. Moreover, the intervention appeared to have a cost-saving effect24.  
However, community pharmacists can not only play an important role in respiratory diseases. As 
well for patients with diabetes or hypertension, randomized controlled trials showed that long-term 
counselling by community pharmacists can significantly improve disease control25 26. Significant 
reductions in blood glucose, HbA1c and systolic blood pressure in the intervention group as compared 
with control groups were for example found25 26. Therefore, it can be concluded that counselling 
sessions delivered in a community pharmacy setting, in collaboration with patients and physicians can 
improve the achievement of targets. This suggests that redesigning the patient pathway to include 
interventions by community pharmacists may be beneficial. 
 
2.5. Improving implementation in practice: Strategies for medication review 
2.5.1. Developing the medication review process as a complex intervention 
The ultimate goal of medication review is to improve appropriateness of prescribing and to improve 
patient centred outcomes. It is unlikely that one single intervention will be able to achieve this. 
Multiple research indeed confirms that more integrated approaches are needed to effectuate a 
significant change in prescribing behaviour and consequently reduce the burden of PIP27 28. Considering 
medication review, in fact, multiple actors in healthcare are involved. Therefore, the development of 
such a service could be done according to the canvas of a ‘complex intervention’ (Figure 5.3)29.  
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Figure 5.3: Key elements of the development and evaluation process of a complex intervention. Adopted from Craig et a29l. 
 
According to the canvas of complex interventions29, the first issue would be the identification of the 
evidence for a medication review by community pharmacists. This is discussed in the introduction 
section (See section 2.1: ‘Medication review for older patients with polypharmacy’). Subsequently, 
appropriate rationales and theories supporting each part of the intervention should be evaluated to 
yield a first intervention proposal.  
Concerning the performance of a medication review in community pharmacies, our proposed 
intervention consists of a straightforward protocol to execute a multidisciplinary medication review, 
initiated from the community pharmacy. It contains the following steps: (1) a pharmacotherapeutic 
anamnesis combined with a digital screening of the patient’s medication with the GheOP³S-tool, 
yielding a list of potentially inappropriate pharmacotherapy; (2) a multidisciplinary consultation, where 
these potential issues could be discussed and lead to an eventual list of actual inappropriate 
pharmacotherapy; (3) a consultation with the patient, after which a final treatment plan with action 
points for each healthcare provider of the multidisciplinary team could be set up; (4) communication 
of the final action points to all healthcare providers that are part of the multidisciplinary care team 
through a secure electronic platform.  
 
2.5.2. (Dis)advantages of using the GheOP³S-tool as part of the complex intervention 
Using the GheOP³S-tool as a backbone for performing medication reviews has multiple advantages. 
During the developmental process, it was taken into account that clinical or laboratory data are mostly 
not available for community pharmacists. As clinical data are not needed to apply the tool to the 
medication history, the pharmacists can initiate the medication review process based on the 
dispensing data in the community pharmacy. Additionally, the GheOP³S-tool is explicit and therefore 
very straightforward and quick to apply, limiting the time-burden of the process, a much cited barrier30 
31.  
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As well, an extra document with supporting information provides the community pharmacist with 
substantial background information and possible alternative treatment plans which empowers the 
community pharmacists to initiate follow-up interdisciplinary communication. This extended 
document is currently available in Dutch and French via the GheOP³S-tool’s website32.  
There are however also some disadvantages. First, as with all explicit screening tools, there exists a 
risk that community pharmacists will oversimplify prescribing and fall into a black/white vision. 
However, we believe that when educational training sessions expressively emphasize that a lot of 
different factors drive prescribing and there can be a justified reason to deviate from standard 
guidelines, this can be prevented. Second, medication review is an ongoing process. All members of 
the healthcare team must realize that after determination of the final action points, actual 
implementation only gets started. Therefore, counselling the patients in medication changes, 
monitoring them and performing regular follow-up consultations will be necessary.  
 
2.5.3. Piloting and evaluating the complex intervention 
The proposed intervention should first be piloted and the feasibility has to be assessed. To do so, a 
mixture of qualitative and quantitative methods will be necessary to understand barriers to 
participation and to estimate response rates. Depending on the results, a number of studies may be 
required to progressively refine the design before embarking on a full-scale evaluation (Figure 3). The 
effectiveness is preferably assessed through an experimental, randomised design29. 
 
2.5.4. Nationwide implementation in routine practice 
When the effectiveness of the proposed complex intervention is evaluated positively, the 
intervention is to be implemented in routine practice in healthcare. It has been recognized that passive 
strategies to do so are ineffective29. Instead, a number of facilitators should be actively pursued and 
established in different levels in healthcare. We discuss here possibilities for the governmental level, 
the informatics level and the healthcare providers’ level.  
 
2.5.4.1. The governmental level 
Governments could give incentives to perform medication screening in the ambulatory setting by 
providing a remuneration for this service. Adequate remuneration seems to be necessary to allow 
initial investments but appears not to be the only trigger to provide new services30. Moreover, 
pharmacists state that time and resource burdens are not problematic if a remuneration is adequate30 
31. Additionally, a clear legal outline of the specific role of each healthcare provider in the medication 
review process could empower each one of them to take up their tasks33-35.  
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The community pharmacist could act as the initiator of the process after which a consultation in 
local multidisciplinary teams takes place. It is especially this involvement of community pharmacists 
into local multidisciplinary teams that appears to be problematic8 35. For example, of the 16 European 
countries where procedures for medication review in the community are established, communication 
with physicians is only part of the medication review procedure in 5 of them (31%)8. In order to 
enhance interprofessional collaborations, governments could support the organization of local 
interdisciplinary conferences33. Therefore, in Belgium, the NIHDI recently granted financial support to 
the organisation of local small-group multidisciplinary consultations that implement recognized quality 
improving projects36.  
 
2.5.4.2. The informatics level 
Both limited time and difficult communication are often mentioned as barriers to implement 
medication review33 37. These are two issues that informatics or software companies could easily tackle. 
First, informatics and software companies could be of major help in facilitating interprofessional 
communication by developing communication channels that are secure and easy to use33.  
Second, automatizing the screening of medication lists or medication histories, including clinical 
support systems could enhance the implementation of this intervention strategy as this would limit 
the time needed to perform the review. Considering the GheOP³S-tool in specific, this tool could be 
fully automatized in the future, restricting the time spent to the interpretation of the detected PIP’s 
relevance.  
 
2.5.4.3. The healthcare providers’ level 
Healthcare providers should be educated about medication reviews and their potential role in the 
process. This includes recognizing each healthcare provider’s role and responsibility while none 
claiming a position of superiority. In research on medication review however, not all community 
pharmacists consider this an essential part of their job35. On the other hand, physicians are not always 
willing to cede certain responsibilities and therefore do not accept other health care providers as vital 
members of the healthcare team33. It is however important that each healthcare provider feels 
confident providing care for older adults (i.e. prescribing for older adults, evaluating pharmacotherapy 
of older adults, etc.). Therefore, specific courses on geriatric pharmacotherapy should be organized37.  
Indeed, external support helps both community pharmacists and prescribers to improve their 
service-management skills. For pharmacists, educational interventions showed to significantly shorten 
the time spent on the medication review30 while for prescribers, educational interventions showed to 
improve prescribing compentences38. Moreover, pharmacists not receiving external training often 
lacked confidence to submit recommendations to prescribers30.  
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Therefore, the two largest post-academic training institutes for pharmacists in Belgium, IPSA and 
SSPF2, already recognize the value of good external support for performing a medication review using 
the GheOP³S-tool. During the 2016 training cycle, both institutes organize classes to teach community 
pharmacists about the process of a medication review and how to work with the GheOP³S-tool39 40.  
 
2.6. (Cost-)effectiveness of cognitive pharmacy services 
Cognitive pharmacy services in general range in complexity from emergency contraception 
counselling to minor ailments schemes and clinical medication review12. Also, the remunerations for 
these services are highly variable. Systematic reviews consider them however to have a net cost 
benefit, with estimated returns on investment ranging from $1.30 to $26 per dollar spent12 41 42. 
The (cost-)effectiveness of medication reviewing in specific has been evaluated in a both a narrative 
and systematic way43-45. The reviews were however challenging because of variations in the nature of 
the populations studied, the outcome data measured and the evaluation criteria used43. Furthermore, 
performed interventions were often inadequately described or varied widely. There is nevertheless 
some consistency in concluding that falls and hospitalizations might be reduced with modest cost 
savings43-45. Also, significant results favouring pharmacists’ intervention were found for specific health 
outcomes such as blood pressure, blood glucose control, etc45. No studies reported a benefit in terms 
of mortality, mental capacity or activities of daily living43 44. It can be concluded that clinical medication 
review is probably of value and may be cost-effective.  
Evaluating the effect of counselling patients in the community pharmacy appears to have the same 
drawbacks. The interventions and outcomes measured varied broadly42 46. Specifically focusing on 
counselling patients with COPD in the community pharmacy, a cost-effectiveness analysis of the 
PHARMACOP-trial discussed in Chapter 3 Part 2 was executed, showing that the average overall costs 
per patient for the PHARMACOP intervention and usual care were €2,221 and €2,448, respectively 
within the 1-year time horizon. This reflects cost savings of €227 for the PHARMACOP intervention per 
patient with COPD per year24.  
  
                                                          
2 IPSA (Instituut voor Permanente Studie voor Apothekers) is the Flemish post-academic training institute. SSPF (Société Scientifique des 
Pharmaciens Francophones) represents the Wallonian counterpart.  
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3. FUTURE PERSPECTIVES 
3.1. Academic perspectives 
On an academic level, several follow-up studies are planned to be executed. First, the performance 
of a medication screening with the GheOP³S-tool will be tested in a controlled trial including older 
patients with polypharmacy, admitted to the acute geriatric ward of the general hospital in 
Oudenaarde, Belgium. In this controlled trial, a medication screening with the GheOP³S-tool will be 
compared to a medication screening with the STOPP/START-criteria47 and to a control group, receiving 
usual care. The primary outcome of the trial will the appropriateness of prescribing, however also 
patient-related outcomes, such as patient satisfaction and self-rated health, will be assessed.  
Second, an additional screening will be performed on the data from the GheOP³S-tool validation 
study reported in Chapter 2 Part 3. This additional screening will apply the GheOP³S-tool’s addendum 
considering dose adjustments in renal impairment to the medication history of all 60 included patients. 
Subsequently, the study will evaluate whether providing community pharmacists with estimated 
glomerular filtration rates would yield to additional detection of PIP with high clinical relevance. During 
this study, a dose adjustment recommendation for each drug incorporated in the GheOP³S-tool 
addendum will be composed. This recommendation will be based on guidelines about dose adjustment 
in impaired renal function, collected from the ‘Renal Drug Handbook’48, the ‘Doseringsadviezen voor 
geneesmiddelen’ by the KNMP49, and the considered Summaries of Product Characteristics.  
Third, based on the results from studies already performed with the GheOP³S-tool, the content of 
the GheOP³S-tool will be further optimized. Zooming in on the data from the comparison with the 
adapted Medication Appropriateness Index (See Chapter 2 Part 3), we will be able to detect which 
items are systematically missed. These will be consequently be added to the tool. On the contrary, 
items with very low prevalence rates will be omitted. Additionally, new drugs are marketed since the 
development of the tool and new evidence about the use of already marketed drugs in older patients 
is surging. This new information will as well be integrated in the GheOP³S-tool.  
Notwithstanding the fact that already a number of barriers and facilitators to the implementation 
of medication review are known, we want to research whether there exist additional issues specific 
for the Belgian setting. Therefore, we will perform semi-structured interviews with both general 
practitioners and community pharmacists separately regarding their view on medication review 
through multidisciplinary healthcare teams. The interviews will question current practices regarding 
medication review, perceived needs, concerns and prerequisites for medication review, role 
specification in the medication review process and willingness to perform medication review.  
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3.2 Future discussion topics 
3.2.1 Future opportunities for the community pharmacist’s profession 
As the professional tasks of the community pharmacist grow broader, it might be interesting to 
consider pharmacy specialties in line with physician specialities. A number of interesting areas of 
expertise include geriatric pharmacy, paediatric pharmacy or pregnancy/lactation pharmacy (Table 
5.3). This is an interesting strategy as a lot pharmacotherapeutic aspects differ between these patient 
groups, e.g. benefit/risk ratios, preferred administration routes, dosing schedules, evidence, etc. These 
specialized pharmacists can consequently be consulted by other pharmacists but also by other 
healthcare professionals such as physicians when they encounter unsolvable problems with their 
patients. Consultant pharmacists already exist in the UK and their specialties include anticoagulation, 
respiratory medication, mental health, community healthcare, older people’s care etc50.  
On the other hand, pharmacy specialties could exist based on tasks of the community-pharmacist. 
These tasks could for example include pharmacist-reviewers, counselling pharmacists, compounding 
pharmacists and pharmacist specializes in Individual Medication Preparation (IMP) (Table 5.3).  
It is however clear that such specialties need specific training. During the last decades the master’s 
program to become a pharmacist has already changed significantly to better align education and 
practice51-54. Up to the early 21st century, the pharmacy program was centered around classes about 
chemistry and compounding. Since 2010 classes about communication, practical use of drugs and 
(advanced) pharmaceutical care related classes were gradually introduced. Additionally, since January 
2015 post-academic training for pharmacist has become obligatory55. However, there is still some 
room for improvement, as multidisciplinary care becomes more and more important, it is absolutely 
necessary that all courses for healthcare professionals and postacademic trainings introduce 
multidisciplinary classes.  
Table 5.3: Suggestions for pharmacy specialties  
Specialties based on specific target groups 
Pharmacy specialty Target group Specific tasks  
Geriatric pharmacist Geriatric patients Evaluating risk/benefit ratios 
Paediatric pharmacist  Paediatric patients Developing specific dosing schedules and administration routes 
Oncologic pharmacist Patients with cancer Evaluating pharmacotherapeutic treatment of oncologic drugs 
and their side-effects 
Pregnancy/lactation 
pharmacist 
Pregnant or lactating women Evaluating risk/benefit ratios for mother and child  
Specialties based on specific pharmacy tasks 
Pharmacy specialty Target group Specific tasks 
Pharmacist-reviewer Patients with polypharmacy Reviewing the pharmacotherapeutic regimen  
Counselling pharmacist Patients with chronic disease Organizing and performing of specific counselling sessions in 
the community-pharmacy 
Compounding 
pharmacist 
Patients in need of specific 
administration routes or not 
commercially available preparations 
Offer advice about or being responsible for the preparation of 
difficult compounding strategies or administration routes.  
IMP pharmacist Patients with complicated medication 
schemata 
Reviewing the pharmacotherapeutic regimen in the light of 
optimal medication schemes for robotic unit dispensing 
IMP: Individual Medication Preparation  
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3.2.2 Challenges and possibilities for routine implementation of pharmaceutical care 
Large routine implementation of pharmaceutical care remains to date a major challenge and the 
data in this doctoral thesis support this statement (see Chapter 2 Part 4 and Chapter 3 part 3). There 
exist some cultural challenges to face to significantly change mentality. 
 
3.2.2.1 Scale optimization or Organization optimization 
At the beginning of 2015, Belgium had 4,950 pharmacies, or one per 2,150 inhabitants. This is one 
of the densest networks in Europe. In comparison, The Netherlands count 1981 pharmacies, or one 
per 8,481 inhabitants. To ensure adequate, effective and regular supply of medicines in all regions of 
the country, new pharmacies may only be opened based on demographic or geographic criteria 
according to a restrictive law. The introduction of this law slowed down the growth of the number of 
pharmacies, but did not prevent that there exist a large number of small, local pharmacies, often with 
only one pharmacist present. Some actors consider these small, local pharmacies unable to 
qualitatively deliver pharmaceutical care to the patient. However, these local pharmacies could be 
supported in time-management and reorganization of their tasks so they are enabled to deliver high 
quality pharmaceutical care and the accessibility to the patients is retained, which is a major strength 
of Belgian health care.  
 
3.2.2.3 Improved communication between healthcare professionals 
Communication between healthcare professionals is essential to guarantee optimal treatment for 
the patients. From the research in this thesis it is clear that there is a need for enhanced (willingness 
for) communication between community pharmacists and GPs. The Belgian deontological code clearly 
describes an obligation to collaborate, citing that “The community pharmacist loyally exchanges data 
with other health care professionals that are useful of necessary for the patient’s interest” (Article 57, 
Code Farmaceutische Plichtenleer). Furthermore, the NIHDI stimulates better first-line collaboration 
practices by granting financial support to the organisation of local small-group multidisciplinary 
consultations that implement recognized quality improving programss36. However, to achieve optimal 
first-line collaborations, it is as well warranted that all concerned healthcare professions are 
considered as equals. A number of items could be tackled herein, e.g. the fact that only physicians are 
reimbursed by the NIHDI for attending postacademic classes, that some healthcare professionals do 
not recognize shared-decision making and that patients often rely on the advice of only one health 
care professional because of cultural traditions. Raising awareness with both healthcare professionals 
and patients could be a major support to change this mentality.  
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1. SUMMARY 
In Chapter 1, we describe that with an increasing complexity of medication use, the role of the 
community pharmacist as well becomes broader, resulting in more care-related activities. Sound 
pharmaceutical practices subdivides a pharmacist’s tasks into basic and advanced pharmaceutical care. 
Basic pharmaceutical care is rather general and medication-centred, where advanced pharmaceutical 
care is individually-adapted and patient-centred, meant for those patients with special pathologies, 
multi-morbidity or poor medication adherence. However for both types of pharmaceutical care, co-
operation with the patient and co-operation with other healthcare professions is needed.  
During the last decades, extensive research in the community pharmacy field showed that the 
involvement of a community pharmacist in patient care can make a difference. Considering 
pharmaceutical care, multiple programs – both basic and advanced – can be identified across different 
parts of the world. Such programs range in complexity, but are of value and may be cost-effective.  
Optimizing pharmaceutical care in Belgium, especially for chronic care patients and patients with 
difficult medication schemata, has a great potential to improve treatments and overall cost savings as 
these groups consume a disproportionate share of health care expenditures. As the number of chronic 
care patients and patients with difficult medication schemata is increasing, it would be unfortunate 
that the added value of a community pharmacist’s clinical input is not maximally utilized. These 
patients require surely a patient-centered and multidisciplinary care approach. The ultimate goal is to 
ensure that these people derive maximum benefits from their drug therapy. 
In this doctoral thesis, we developed and evaluated advanced pharmaceutical care services (i.e. 
cognitive pharmacy services) for chronic care patients. Therefore, we focused on two patient groups 
that are increasingly present in ambulatory care and are burdensome for both the patient and the 
healthcare system. The first patient group included older patients with polypharmacy, and is addressed 
in Chapter 2. The second group targeted in this doctoral thesis considered patients witch Chronic 
Obstructive Pulmonary Disease (COPD) as an example of chronic disease. This patient group is 
addressed in Chapter 3. 
In Chapter 2 Part 1, we first performed a systematic literature review to get an insight in the overall 
prevalence of Potentially Inappropriate Prescribing (PIP) for older community-dwelling patients in 
Europe. We showed that about one fifth of all community-dwelling older patients had at least one PIP. 
Additionally, reviewing the drugs and drug classes mainly associated with PIP, we observed that 
anxiolytics, antidepressants and non-steroidal anti-inflammatory and anti-rheumatic products were 
mostly involved in PIP. The risk factors most often positively associated with PIP were polypharmacy, 
poor functional status and depression.  
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To tackle this issue from the community pharmacy, in Chapter 2 Part 2, we developed an advanced 
pharmaceutical care service that included a medication screening originating from the community 
pharmacy, based on solely dispensing records. To perform the medication screening, an explicit 
screening tool containing PIP-items with high clinical relevance for primary care was compiled. The 
screening tool was as well checked to be feasible in a typical community pharmacy practice. The 
development of this screening tool resulted in the Ghent Older People’s Prescriptions community 
Pharmacy Screening (GheOP³S-)tool, a list containing 83 PIP-items.  
In Chapter 2 Part 3, the newly developed GheOP³S-tool was validated using the results of an 
observational study, performed on acutely hospitalized older patients with polypharmacy. Almost all 
PIP-items detected with the GheOP³S-tool were considered ‘serious’ or ‘significant’ according to the 
treating geriatrician. Additionally, for 80% of patients, the proposed alternative treatment plan was 
(partially) accepted. Comparing the GheOP³S-tool to a full clinical medication review, about one third 
of PIP-items were detected. These results show that using the GheOP³S-tool to systematically screen 
the medication use of older patients with polypharmacy, could ultimately optimize patient outcomes. 
This way, community pharmacists initiate a process that – in some cases – requires discussion with the 
prescribing physicians. Therefore, performing medication screening with the GheOP³S-tool could also 
further improve interdisciplinary communication and collaboration.  
Subsequently, in Chapter 2 Part 4 and 5, we evaluated PIP-prevalence according to the GheOP³S-
tool, based on two observational studies. The first was executed in about 200 Belgian community 
pharmacies and included about a thousand ambulatory older patients with polypharmacy. 
Analogously, a second observational study, included 400 institutionalized patients with polypharmacy 
from 10 nursing homes in Flanders. PIP prevalence according to the GheOP³S-tool appeared to be high 
in both ambulatory and institutionalized patients, with at least one detected item in more than 95% of 
patients. As well, in almost all patients, more than one PIP-item was detected. Most prevalent PIP-
items appeared to be long-term use of benzodiazepines, no Ca/VitD supplementation with elevated 
osteoporotic risk and long-term use of antidepressant agents. 
In summary, in Chapter 2, we demonstrated that a new tool to screen for PIP in older patients with 
polypharmacy is very effective to detect potential points for prescribing optimization. Additionally, we 
showed that the tool detects items that are clinically relevant and that the room for improvement in 
both ambulatory and institutionalized Belgian older adults with polypharmacy is large. 
 
  
  
226 
Chapter 6 – From ‘Summary’ to ‘About the Author’ 
 
Subsequently, in Chapter 3 Part 1 we describe COPD as a disease and possibilities for COPD 
management optimization. In Belgium, about 2 to 3% of the population has COPD. COPD is irreversible 
and progressive disease. The pathological changes found in COPD result in physiological abnormalities 
such as mucus hypersecretion, progressive airway obstruction, air trapping, gas exchange 
abnormalities, and systemic effects. For patients with COPD however, exacerbations of respiratory 
symptoms put a significant burden on their quality of life. Exacerbations have a characteristic response 
with increased inflammation. There is also increased dyspnoea and possible hypoxaemia. COPD puts a 
significant burden on the patient’s health as it is ranked second for Disability-Adjusted Life Years lost. 
According to the World Health Organization, COPD is the 3th ranked cause of death worldwide. Besides 
the human burden of COPD, as well the economic burden is high. In the European Union both the 
indirect and direct costs for the treatment of COPD approximately count for 6% of the total European 
healthcare budget. 
 Although COPD can be managed well with both non-pharmacological (e.g. smoking cessation, 
pulmonary rehabilitation) and pharmacological options (e.g. bronchodilators), adherence to therapy is 
often suboptimal. Only about half of the COPD population takes his medication as prescribed. 
Additionally, administration through inhalation devices seems to be problematic for many patients 
with COPD. About one fifth of patients with COPD make major inhalation errors. Both inhaler 
mishandling and suboptimal medication adherence are associated with reduced disease control. 
In Chapter 3 Part 2, we evaluated the results of a Randomized Controlled Trial (RCT) including about 
700 patients in Belgium. This RCT researched the effectiveness of a pharmaceutical care intervention, 
provided by the community pharmacist that focuses on inhalation technique and medication 
adherence (the PHARMACOP-protocol). This RCT showed that the PHARMACOP-protocol significantly 
improved inhalation technique and medication adherence. Moreover, the intervention significantly 
decreased the number of hospitalizations in the intervention group, compared to the control group.  
Nevertheless, in Chapter 3 Part 3, we observed that the PHARMACOP-protocol is not yet fully 
implemented in the Belgian community pharmacies. In more than 70% of 80 interviewed pharmacists, 
only about half of the protocol items for both first and follow-up prescriptions were routinely 
implemented. Pharmacists additionally reported significant barriers to implementation of this protocol 
in daily practice, such as lack of time, no integration in pharmacy software and too much administrative 
burden. 
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To address medication adherence in the community pharmacy, in Chapter 3 Part 4, we observed 
that a self-report measure of adherence (the Medication Adherence Report Scale – MARS-5) was not 
valid to identify nonadherent users of inhalation medication among patients with COPD, compared to 
the medication refill adherence (MRA) as a reference.  
In conclusion, in Chapter 3, we demonstrated that a pharmaceutical care intervention improves 
both medication-related (inhalation technique and medication adherence) and patient-related 
(hospitalization) outcomes. Currently, a solid base of pharmaceutical care for patients with COPD is 
already provided by Belgian community pharmacists, however, some additional items (e.g. smoking 
cessation counselling) should be routinely addressed. Implementing facilitators (i.e. simplify 
administrative burden, remuneration, software support) could further optimize the current provision 
of pharmaceutical care for these patients.  
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2. SAMENVATTING 
In Hoofdstuk 1 beschrijven we dat met de stijgende complexiteit van medicatiegebruik, de rol van 
de officina-apotheker breder wordt. Dit resulteert in meer zorggerelateerde activiteiten voor de 
officina-apotheker. De ‘Goede Officinale Praktijken’ verdeelt de taken van een apotheker in basis en 
voortgezette farmaceutische zorg. Basis farmaceutische zorg is eerder algemeen en stelt de medicatie 
centraal in de begeleiding. Voortgezette farmaceutische zorg is daarentegen individueel aangepast en 
stelt de patiënt centraal. Deze laatste is dan ook vooral bedoeld voor patiënten met speciale 
pathologieën, multimorbiditeit of slechte therapietrouw. Voor beide types van farmaceutische is hoe 
dan ook een samenwerking met de patiënt en andere gezondheidszorg medewerkers noodzakelijk.  
Gedurende de laatste tientallen jaren, toonde uitgebreid onderzoek vanuit de officina-apotheek 
aan dat de betrokkenheid van een officina-apotheker in de patiëntzorg een verschil kan betekenen. 
Wat betreft farmaceutische zorg, kunnen wereldwijd zowel basis als voortgezette programma’s 
geïdentificeerd worden. Dergelijke programma’s variëren in complexiteit maar zijn waardevol en 
mogelijks kosteneffectief.  
Het optimaliseren van farmaceutische zorg in België zou veel behandelingen kunnen verbeteren en 
meer kosten besparen. Dit in het bijzonder voor chronische patiënten en patiënten met moeilijke 
medicatieschema’s. Deze patiënten verbruiken immers een disproportioneel aandeel van de uitgaven 
in de gezondheidszorg. Aangezien het aantal dergelijke patiënten blijft stijgen, zou het zonde zijn om 
de meerwaarde van klinische input door de officina-apotheker niet aan te wenden. Deze patiënten 
verdienen immers een patiëntgerichte en multidisciplinaire aanpak met als uiteindelijk doel maximaal 
voordeel uit hun farmacotherapie te halen.  
In deze doctoraatsthesis ontwikkelden en evalueerden we voortgezette farmaceutische zorg 
diensten – ook wel “cognitive pharmacy services” genoemd – voor chronische patiënten. We plaatsten 
onze focus op twee patiëntgroepen die almaar meer aanwezig zijn in de eerstelijnstgezondheidszorg, 
die een significante last betekenen voor de patiënt en druk zetten op de kosten in de gezondheidszorg. 
De eerste groep omvat oudere patiënten met polyfarmacie en wordt behandeld in Hoofdstuk 2. De 
tweede groep omvat patiënten met Chronic Obstructive Pulmonary Disease (COPD) als een voorbeeld 
van een chronische pathologie. Deze groep wordt behandeld in Hoofdstuk 3. 
In Hoofdstuk 2 Deel 1 voerden we een systematische review uit om inzicht te krijgen in de algemene 
prevalentie van mogelijke Geneesmiddel Gebonden Problemen (GGP) voor oudere ambulante 
patiënten in Europa. We toonden aan dat ongeveer één vijfde van de Europese ambulante oudere 
patiënten minstens één GGP had. Daarnaast evalueerden we ook de geneesmiddelen en 
geneesmiddelgroepen die het meest geassocieerd waren met GGPs. Dit bleek vooral om anxiolytica, 
antidepressiva en niet-steroïdale anti-inflammatoire middelen te gaan. De risicofactoren die het meest 
geassocieerd waren met GGPs, betroffen polyfarmacie, slechte functionele status en depressie.  
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Om dit probleem vanuit de officina-apotheek aan te pakken, ontwikkelden we een voortgezette 
farmaceutische zorg dienst in Hoofdstuk 2 Deel 2. Deze dienst omvat een medicatiescreening die 
opgestart wordt vanuit de officina-apotheek en louter gebaseerd is op aflevergegevens. De 
medicatiescreening gebeurt op basis van een expliciete screening tool die GGPs bevat met hoge 
klinische relevantie voor de eerste lijn. Voor alle items die in deze tool opgenomen zijn, werd ook 
nagegaan of het haalbaar is om erop te screenen in de typische Belgische officina-apotheek praktijk. 
De ontwikkeling resulteerde in de Ghent Older People’s Prescriptions community Pharmacy Screening 
(GheOP³S-)tool, een lijst van 83 items.  
In Hoofdstuk 2 Deel 3 valideerden we vervolgens de nieuw ontwikkelde GheOP³S-tool. We 
gebruikten hiervoor de resultaten van een observationele studie, uitgevoerd op 60 acuut 
gehospitaliseerde oudere patiënten met polyfarmacie. Bijna alle GGPs die bij deze patiënten 
gedetecteerd werden met de GheOP³S-tool, bleken ‘ernstig’ of ‘significant’ volgens de behandelende 
geriater. Daarenboven werd voor 80% van de items het alternatieve behandelingsschema dat 
voorgesteld was door de apotheker, (deels) aanvaard.  Wanneer de resultaten van de screening met 
de GheOP³S-tool vergeleken werd met de resultaten van een volledige klinische medicatiereview, 
bleek dat ongeveer één derde van alle mogelijke problemen reeds gedetecteerd werd. Deze resultaten 
tonen aan dat de GheOP³S-tool kan gebruikt worden om systematisch het medicatiegebruik van 
oudere patiënten met polyfarmacie te screenen. Met gebruik van de GheOP³S-tool initiëren officina-
apothekers echter wel een proces dat in sommige gevallen overleg vereist met de voorschrijvende 
arts(en). Op die manier kan het gebruik van de GheOP³S-tool ook nog bijdragen tot interdisciplinaire 
communicatie en samenwerking.  
Vervolgens in Hoofdstuk 2 Deel 4 en 5, evalueerden we via twee observationele studies de 
prevalentie van GGPs in België. De eerste studie werd uitgevoerd in ongeveer 200 Belgische officina-
apotheken en includeerde een duizendtal ambulante oudere patiënten met polyfarmacie. Analoog 
voerden we een tweede observationele studie uit met 400 oudere rusthuisbewoners met 
polyfarmacie, afkomstig uit 10 Vlaamse rusthuizen. De prevalentie van GGPs bleek in beide settingen 
hoog te zijn, met minstens één gedetecteerd item in 95% van de patiënten. De meest prevalente GGPs 
waren het langdurig gebruik van benzodiazepines, geen calcium en vitamine D-supplementen voor 
patiënten met een verhoogd osteoporoserisico en het langdurig gebruik van antidepressiva.  
Samengevat, in Hoofdstuk 2 ontwikkelden we een nieuwe voortgezette farmaceutische zorg dienst, 
en toonden we aan dat de nieuwe GheOP³S-tool om te screenen voor GGPs bij oudere patiënten met 
polyfarmacie zeer effectief is om mogelijke verbeterpunten in het voorschrijfproces te detecteren. 
Daarenboven toonden we aan dat de tool items detecteert die klinisch relevant zijn en dat de ruimte 
voor verbetering in zowel de ambulante als rusthuissetting groot is. 
  
  
230 
Chapter 6 – From ‘Summary’ to ‘About the Author’ 
 
De tweede groep waarop we in deze thesis focussen, betreft patiënten met COPD als voorbeeld 
van een chronische pathologie. In Hoofdstuk 3 Deel 1 beschrijven we COPD als ziekte, naast de 
mogelijkheden voor de optimalisatie van COPD-management. In België lijdt ongeveer 2 à 3% van de 
bevolking aan COPD. COPD is onomkeerbaar en progressief. De pathologische veranderingen die bij 
COPD optreden, resulteren in fysiologische abnormaliteiten zoals oversecretie van mucus, 
progressieve luchtwegobstructie, problemen met gasuitwisseling en andere systemische effecten. 
Voor patiënten met COPD echter, worden vooral de opstoten van hun respiratoire symptomen als een 
grote last ervaren. Dergelijke exacerbaties gaan gepaard met een karakteristieke respons van 
verhoogde inflammatie. Er is ook meer kortademigheid en mogelijke hypoxie. Volgens de World Health 
Organization, is COPD de derde meest voorkomende doodsoorzaak ter wereld. Naast de gevolgen voor 
de patiënt zelf, zet COPD ook een grote druk op de economie. In de Europese Unie, worden de directe 
en indirecte kosten voor de behandeling van COPD geraamd op ongeveer 6% van het totale 
gezondheidszorgbudget.  
Hoewel COPD goed kan behandeld worden met zowel niet-farmacologische als farmacologische 
maatregelen, is de therapietrouw soms suboptimaal. Slechts ongeveer de helft van de patiënten met 
COPD neemt zijn therapie zoals voorgeschreven. Daarbovenop blijkt het toedienen van de medicatie 
via inhalatie voor veel patiënten met COPD problematisch. Zowel het foutief gebruik van de 
inhalatietoestellen als slechte therapietrouw zijn beide geassocieerd met verminderde ziektecontrole.  
In Hoofdstuk 3 Deel 2 evalueerden we de resultaten van een gerandomiseerde gecontroleerde 
studie (RCT) die ongeveer 700 Belgische patiënten met COPD includeerde. Deze RCT onderzocht de 
doeltreffendheid van een voortgezette farmaceutische zorg dienst die focust op inhalatietechniek en 
therapietrouw (het PHARMACOP-protocol) en voorzien wordt door de officina-apotheker. Deze RCT 
toonde aan dat het PHARMACOP-protocol de inhalatietechniek en therapietrouw van de interventie 
patiënten significant verbeterde ten opzichte van de controlegroep. Daarenboven lag het aantal 
hospitalisaties in de interventiegroep significant lager dan in de controlegroep.  
Echter, in Hoofdstuk 3 Deel 3, observeerden we dat het PHARMACOP-protocol nog niet volledig 
geïmplementeerd wordt in Belgische officina-apotheken. Meer dan 70% van de bevraagde apothekers 
bleek slechts de helft van de items van het protocol routinematig in de apotheek te implementeren. 
Officina-apothekers vermeldden daarenboven significante barrières om het protocol in de 
dagdagelijkse praktijk te implementeren zoals tijdsgebrek, geen integratie in de apotheeksoftware en 
te veel administratieve belasting.  
  
  
231 
From ‘Summary’ to ‘About the Author’ – Chapter 6 
Om therapietrouw in de officina-apotheek aan te kaarten, is ook een valide methode om dit te 
evalueren noodzakelijk. In Hoofdstuk 3 Deel 4 toonden we aan dat een zelfrapporteringsmethode voor 
therapietrouw (i.e. de Medication Adherence Report Scale, MARS-5) niet bruikbaar was om niet-
therapietrouwe patiënten met COPD te identificeren. We gebruikten in deze studie de Medication 
Refill Adherence (MRA) als referentie.  
In conclusie, in Hoofdstuk 3, toonden we aan dat voorgezette farmaceutische zorg door officina-
apothekers zowel medicatiegerelateerde uitkomsten (inhalatietechniek, therapietrouw) als 
patiëntgerelateerde uitkomsten (hospitalisaties) verbetert. Momenteel wordt reeds een goede basis 
aan farmaceutische zorg voor patiënten met COPD verstrekt, echter een aantal additionele items zoals 
begeleiding bij rookstop, zouden routinematig moeten geïmplementeerd worden. Het implementeren 
van facilitatoren zou verder de huidige provisie van farmaceutische zorg bij deze patiënten kunnen 
verbeteren. Het betreft dan het versimpelen van de administratieve last, voorzien van remuneratie of 
ondersteuning via de software. 
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